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General introduction
General Introduction
The chronic inflammatory diseases rheumatoid arthritis (RA) and psoriasis affect 1 to 3 
percent of the worldwide population and continue to be subject of investigation, because 
the disabling and destructive processes that are triggered by ongoing inflammation are 
significant and costly. Patients often suffer from physical disability, physical symptoms, 
such as pain, itch, or fatigue, and psychological difficulties that are associated with a 
chronic invalidating or stigmatizing disease. Many factors contribute to the etiology or 
maintenance of chronic inflammatory diseases, one of them being stress. “Stress” is a 
broad concept for a complex process including the exposure to psychological or physical 
triggers (i.e., stress exposure), the evaluation or perception of these stimuli as being 
stressful (i.e., stress evaluation), and the subsequent activation of a psychophysiological 
cascade (i.e., stress response) in the organism in order to re-establish homeostasis. This 
cascade has two main pathways: the autonomic nervous system (ANS), which includes 
the sympathetic-adrenal-medullary (SAM) axis, and the neuroendocrine system, which 
includes the hypothalamus-pituitary-adrenal (HPA) axis. Both pathways are connected 
with the immune system and therefore may influence disease processes (Figure 1). 
 As the relationship between the stress response system and the immune system is 
known to be bidirectional, the ANS and HPA axis may become compromised or altered in 
patients with a chronic inflammatory disease, due to system ‘exhaustion’ of ongoing 
inflammatory input. These alterations may add to the harmful effects of stress on disease 
severity. Furthermore, there is a growing body of evidence that suggests that psychological 
interventions are able to change various psychophysiological parameters of stress and/or 
disease, which indicates that it may be possible to counteract the harmful effects of stress on 
health with an intervention aimed at reducing the psychophysiological response to stress. 
 This thesis aims to provide greater insight into the nature and reactivity of the psycho-
physiological stress response system of patients with different chronic inflammatory 
diseases. The first aim of this thesis is to investigate the psychophysiological stress 
response of patients with the chronic inflammatory diseases RA and psoriasis, with a focus 
on parameters of the main stress response system; the ANS and the HPA axis, and on 
indicators of the immune system. The second aim of this thesis is to investigate whether 
 a short-term stress management intervention for patients with RA is able to alter the 
psycho physiological response to an acute stressor.
Chronic inflammatory diseases 
Chronic inflammatory diseases are defined by long-term inflammatory processes directed 
at a particular pathogen [1]. They include not only (systemic or organ-specific) auto- 
immune diseases, such as systemic lupus erythematosus or type 1 diabetes, but also 
 auto-inflammatory conditions, such as ulcerative colitis, or mixed pattern diseases, such 
as RA, psoriasis or ankylosing spondylitis [2-4]. 
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Chronic inflammation
Inflammation, deduced from the Latin inflammare or ‘to ignite, set on fire’, is a complex 
cascade of biochemical events of the immune system, which are ignited in response to an 
endogenous or exogenous harmful stimulus, such as a pathogen, tissue damage, or 
infection [5]. A wide range of immune cells, such as neutrophils, basophils, mast cells, 
T-cells, and B-cells are sent to the site of injury by a host of extracellular mediators and 
Figure 1   The psychophysiological construct of stress with possible links to disease outcome. 
ACh, acetylcholine; ACTH, adrenocorticotropin hormone; ANS, autonomic 
nervous system; CNS, central nervous system; CRH, corticotropin-releasing 
hormone; EPI, epinephrine; HPA axis, hypothalamus- pituitary-adrenal axis; IL, 
interleukin; NE, norepinephrine; SAM axis, sympathetic-adrenal-medullary axis.
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regulators, including cytokines, growth factors, and peptides, to start a tissue healing 
process and restore homeostasis. Although inflammation is initially a beneficial process, 
the inflammatory response can cause unnecessary tissue damage when it is not 
terminated in time [6]. When a chronic state of inflammation develops, parallel processes 
of tissue healing and cell death occur, underlying a major part of human diseases, including 
RA, psoriasis, asthma, celiac disease, and inflammatory bowel syndrome [7]. In these 
chronic inflammatory states, there is a shift in the type of cells that are present at the site 
of inflammation and inflammation may spread to become systemic. In this thesis, two 
prototypical diseases of chronic inflammation, RA and psoriasis, were subject of research.
Rheumatoid arthritis
Rheumatoid arthritis is a chronic systemic musculoskeletal joint disorder that is characterized 
by persistently inflamed synovial tissues. This persistent synovial inflammation is associated 
with damage to articular cartilage and underlying bone, which can lead to bone 
destruction and loss of function [8]. Synovial inflammation is characterized by the presence 
of many interacting immune cells and various pro-inflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα), interleukin (IL)-1, IL-6, and IL-17 [9]. In some patients, other 
organs apart from the joints, such as the lungs and pericardium, can be affected by the 
systemic inflammatory process [8]. 
 Approximately 1% of the world-wide population is affected by RA, with the age of 
disease onset peaking at 58 years and women being affected twice as much as men 
[10-12]. Frequently, patients suffer from severe pain, fatigue, and disability and decreased 
psychological functioning, especially when they are not treated adequately. The etiology 
of RA contains a complex and multi-factorial framework including genetic, stochastic, 
and environmental factors, which is not yet fully understood. RA has a strong genetic 
component, with a relative contribution of about 50%, and is thought to be associated 
with specific major histocompatibility complex (MHC) HLA antigens; therefore, family 
history is an important risk factor. Furthermore, smoking and being rheumatoid factor (RF) 
positive are amongst some of the risk factors for developing RA [10]. 
 Living with a chronic invalidating disease such as RA is often accompanied by 
adjustment problems with substantially increased levels of distress, such as anxiety and 
depressed mood [13, 14]. Because stress is one of the factors believed to play a role in the 
progression of RA [15-18], the distressing consequences of the disease as well as other 
stress factors can negatively influence disease severity. 
Psoriasis 
Psoriasis, a papulosquamous skin disease, is one of the most common chronic immune- 
mediated disorders [19]. The disease is associated with well-delineated red or pink 
papulosquamous plaques with a white scale, most commonly distributed symmetrically 
on the extensor aspects of elbows and knee, scalp, lumbosacral region, and umbilicus 
14
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[20]. There is strong evidence that cell-mediated adaptive immunity is crucial in psoriasis. 
Pro-inflammatory cytokines of the Th1 pathway, such as interferon gamma (IFNγ), IL-2, IL-12 
and IL-17 dominate plaques [19]. Therefore, psoriasis is typically classified as a Th1-disease, 
just like RA. Debate continues as to whether psoriasis is an autoimmune disorder, with an 
epidermal factor, for example keratin, being the most likely antigen candidate. Psoriasis is 
most common in Caucasian people, with a prevalence of 1.5-3% of the general population 
of Northern Europe, with men and women equally affected. Although psoriasis can 
appear at any time of life, the mean age at which it occurs is estimated at 33 years. Patients 
often suffer from physical symptoms of itch and fatigue and limitations in daily life, 
including stigmatization, which can increase psychological distress and impair quality of 
life [19].
 Despite advances in understanding the pathogenesis of psoriasis, little is known 
about the natural history of the disease. Psoriasis clearly has a genetic component, with 
one pathway that follows the Mendelian pattern, although in general, psoriasis arises 
through multiple genetic risk factors interacting with each other and with environmental 
triggers (e.g., streptococcal infection). In parallel with observations in RA, stress is one of 
the factors involved in aggravation of symptom severity in psoriasis [21, 22].
In sum, patients with RA or psoriasis frequently have to cope with disabling physical and 
psychological limitations. RA and psoriasis represent two prototypic chronic inflammatory 
diseases with, in general, auto-immune processes and systemic inflammation occurring in 
RA, whereas psoriasis mainly has an auto-inflammatory profile with local inflammation of 
the skin. Although the multifactorial etiology of these diseases is a reason that they 
continue to be a subject of investigation, psychological factors, such as stress, have been 
documented to aggravate disease severity in both conditions [16-18]. 
Stress 
In contemporary language, the term ‘stress’ is used abundantly to refer to a wide variety of 
situations and responses. In order to fully include all aspects of this broad construct, the 
term ‘stress’ has gone through some major revisions in scientific literature over the years. 
The psychophysiological construct of stress
Since Selye first identified the concept of stress (the ‘general adaptation syndrome’) in the 
late thirties of the previous century many definitions have been proposed to describe and 
fully comprise this broad construct. In one of his first writings in 1936 Selye spoke about 
stress being ‘the non-specific (neuroendocrine) response of the body’ to an external 
agent, i.e., the ‘stressor’, that could either be physical, chemical, or psychological in nature, 
and the internal bodily changes these stressors produced were called the ‘stress response’ 
[23]. In the mid 1960s, when the focus in stress research shifted to cognitive and behavioral 
factors influencing the stress response, it became widely accepted that psychological 
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processes, such as the interpretation and appraisal of a situation, and our judgments as to 
whether we would be able to cope with a situation successfully, were decisive in making 
a situation a ‘stressor‘. Nowadays, these views are integrated in a psychophysiological 
construct of stress in which it is acknowledged that stress arises from the interaction 
between environmental demands on the one hand and individual resources on the other 
hand, resulting in a physiological response to deal with the stressor. Consequently, 
depending on the focus one chooses, there are different approaches to study the concept 
of stress; a focus on the environmental demands, such as the prevalence of major life 
events, daily hassles, and interpersonal stressors; a focus on individual resources, i.e., how 
does a person appraise a situation, and what coping mechanisms are available; and a 
focus on physiological responses to a stressor, i.e., what happens with the autonomic and 
neuroendocrine systems that are activated when stress is perceived [23-25]. Although 
these three domains are closely linked to each other and cannot be separated when 
trying to fully understanding the concept of stress, this thesis will mainly focus on the 
psychophysiological processes that are activated in response to a stressful stimulus, in our 
attempt to delineate the correlates linking stress and disease in greater depth. 
The physiological stress response and the immune system 
When an organism perceives an external stimulus as stressful, the physiological stress 
response system of the body is activated in order to re-establish homeostasis; a state of 
constant and appropriate internal conditions and functioning in the face of ever changing 
environmental demands [26]. The sensory input in the face of stress is processed by higher 
and limbic brain regions. The hypothalamus responds to stress exposure by activating at 
least two parallel pathways; the first is the fast responding ANS, which consists of the 
sympathetic nervous system (SNS) and includes the SAM axis, and of the parasympathetic 
nervous system (PSNS). Both branches of the ANS connect the organs and tissues with the 
central nervous system (CNS). In response to stimulation of preganglinic (cholinergic) 
sympathetic nerves originating in the spinal cord and receiving their input from the 
hypothalamus, the neurosecretory chromaffin cells of the adrenal medulla synthesize and 
secrete the catecholamines epinephrine and (to a smaller amount) norepinephrine into 
the circulation. The physiological effects of catecholamines are manifold, all more or less 
aimed at preparing for ‘fight or flight’, with actions including increased heart rate, stroke 
volume, blood pressure, dilated bronchi, the mobilization of glucose and stimulated 
lipolysis. All these processes are mediated by β- and α-adrenergic receptors (ARs) found 
on a wide variety of tissues [25, 27]. The second pathway that is activated in response to 
stress is the hypothalamus-pituitary-adrenal (HPA) axis. The neurosecretory cells in the 
paraventricular nucleus of the hypothalamus release corticotropin-releasing hormone 
(CRH) in the portal capillaries that run to the anterior lobe of the pituitary gland, where it 
stimulates the synthesis and secretion of adrenocorticotropic hormone (ACTH), which -in 
turn- stimulates the release of the glucocorticoid cortisol by the adrenal cortex. Cortisol 
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activates intracellular glucocorticoid receptors (GRs), which are present in many tissues of 
the body. Therefore, cortisol has a very wide action range, including on the cardiovascular 
system and the central nervous system. Glucocorticoids are essential steroids to life, not 
only initiating many processes within the body, but also creating a healthy environment 
for these processes to occur by increasing enzyme activity, or augmenting or inhibiting 
the action of other hormones. Homeostasis of the HPA axis occurs by negative feedback 
actions from cortisol on various levels of the HPA axis [25, 27, 28].
 Recent advances in psychoneuroimmunology have provided a more detailed insight 
into how the major stress hormones of the body, catecholamines and cortisol, influence 
inflammatory and immune responses [29-32]. The immune system is highly integrated 
with other physiological systems, including the nervous and endocrine systems. 
Autonomic (sympathetic, parasympathetic, and sensory) nerves innervate organs of the 
immune system, and cells and tissues of the immune system, including spleen, thymus, 
and other lymphoid organs, possess glucocorticoid as well as α- and β-adrenergic 
receptors, which are sensitive to glucocorticoids and catecholamines and other stress 
response mediators [28]. Overall, these mediators affect lymphocyte traffic, circulation, 
and proliferation, and modulate cytokine production and functional activity of various 
lymphoid cells in order to resist infection or challenge and enhance the effectiveness of 
the immune response [33]. In general, glucocorticoids and catecholamines inhibit the 
production of pro-inflammatory prostaglandins and cytokines, such as TNFα, IFNγ, and 
IL-1 [34], whereas they stimulate the production of anti-inflammatory cytokines, such as 
IL-10 and IL-4 [33]. Through inhibition and stimulation of type 1 and type 2 cytokine secretion, 
respectively, they cause selective suppression of Th1-mediated cellular immunity and a 
shift toward Th2-mediated humoral immunity [34]. Stress response mediators can either 
exert immunosuppressive or immunostimulatory effects in a dose-dependent manner, 
with generally, high doses being related to immunoinhibitory effects and low doses to 
immunostimulatory actions [16, 35]. Conversely, the immune system can also communicate 
with the brain and influence the ANS and HPA axis, emphasizing the bidirectional relation- 
ship between autonomic, neuroendocrine, and immune interactions. During an excessive 
immune response, cytokines - particularly those that are pro-inflammatory, such as IL-1 
and IL-6,- stimulate the HPA axis, thereby down-regulating immune and inflammatory 
processes to prevent an “overshoot” of pro-inflammatory cytokines [36]. 
 All in, because stress modulates the body’s physiology, with multifaceted interactions 
between the autonomic, endocrine, and immune system, it seems clear that stress may 
affect the course of immune-mediated diseases.
Stress and chronic inflammatory diseases
Stress has been linked to affect a multitude of somatic diseases, ranging from infectious 
diseases like HIV and Epstein-Barr virus (EBV), to chronic inflammatory diseases, such as RA 
and psoriasis [16, 18, 37-42]. In patients with RA and patients with psoriasis, stressful events 
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have been associated with increases in disease activity, tender joints, pain, physical 
disability, and markers of inflammation [43-56]. This is in line with patients’ reports; with 
45%, stress is the most attributed cause for disease flare-ups by patients with RA [57], while 
37 to 88 percent of patients with psoriasis believe psychological stress to be a factor in the 
manifestations of their condition [21]. Research supports the view that stress can be a 
disease permissive or aggravating factor in these patient groups, but mechanisms 
underlying the influence of stress on inflammatory processes are largely unknown. 
Stress and chronic inflammation
Allostatic responses to stress, which are mainly mediated by glucocorticoids and 
catecholamines, are protective as they try to re-establish homeostasis. However, negative 
consequences can occur when adaptive systems are out of balance, or when responses 
persist (e.g., in case of chronic stress), are terminated inefficiently, or occur inappropriately 
or inadequately (e.g., when the HPA axis is hypoactive) [58]. A general hypocortisolism has 
been documented in various psychiatric disorders, such as clinical depression or social 
anxiety, in stress-related bodily disorders, and incidentally also in chronic inflammatory 
conditions [59, 60]. Low basal cortisol levels and low cortisol responses to stress in patients 
with chronic inflammatory conditions may facilitate or sustain the pro-inflammatory Th1 
shift that is observed in these patients. Moreover, under specific conditions and in certain 
local responses, stress hormones can actually boost immune activity, thereby sustaining 
or stimulating a pro-inflammatory state and influencing the onset and/or course of disease 
[61]. For example, in RA and psoriasis, stress activates the CRH-mast-cell-histamine axis, 
with the peripherally produced corticotropin-releasing hormone (CRH) acting as a local 
pro-inflammatory agent, and stimulating cutaneous and synovial mast cells to release 
histamine and the pro-inflammatory cytokines TNFα and IL-6, which may boost manifestations 
of inflammation. In addition, the pro-inflammatory load of circulating cytokines that is 
associated with chronic inflammation may lead to sustained feedback stimulation of the 
hypothalamus and this may alter ANS or HPA axis function [16]. 
 Therefore, specifically in chronic inflammatory states, stress may increase allostatic 
load and aggravate disease activity through modulation of the systemic or local pro/ 
anti-inflammatory cytokine balance. Moreover, the physiological pathways of the stress 
response system may be altered as a consequence of over-activity due to chronic pro- 
inflammatory load [62]. Indeed, there is evidence that both the ANS and HPA axis may 
be dysfunctional in patients with RA and psoriasis.
The HPA axis
A few decades ago, most knowledge about mechanisms linking stress and RA came from 
experimental work with animals. The HPA axis was one of the main physiological pathways 
identified to be involved. For example, Lewis rats failed to realise an appropriate HPA 
axis response resulting in increased vulnerability to auto-immune and inflammatory 
18
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disturbances such as adjuvant-induced arthritis [62]. Chronic inflammation appeared to be 
associated with a dysfunction of the HPA axis, with altered secretion patterns of CRH, 
ACTH and glucocorticoids that modulated immune functions. In humans, there are 
indications that the diurnal rhythm of plasma cortisol could be absent or at the lower limit 
of normal in patient with long-standing RA, while the diurnal rhythms may still be intact 
in recently diagnosed patients [63-66]. Overall, basal cortisol levels appear to be increased 
in patients with recently diagnosed RA [67, 68] and may decrease during the progression 
of RA, especially during flare-ups [69, 70]. Similarly, a lower daily cortisol output and lower 
basal cortisol levels have been observed in patients with psoriasis [71].
 In order to detect possible alterations on specific levels of the HPA axis in RA and 
incidentally also in psoriasis, pharmacological function tests (e.g., dexamethasone 
suppression test (DST), insulin tolerance tests, or infusions with acetylcholine (ACh), CRH, 
or epinephrine) were set up, with contrasting results. Some studies suggest that patients 
have a relatively hypofunctional axis with defective central (hypothalamic or pituitary) 
and/or peripheral (adrenal) components [37], while other studies hardly found any 
deviations from healthy subjects [72-74]. However, pharmacological function tests do not 
provide information about HPA axis function in response to real-life stressors; this has 
hardly been investigated in patients with chronic inflammatory diseases such as RA and 
psoriasis. Some studies on experimental acute stress reported patients with RA to show 
an impaired stress-induced cortisol increase [49, 75], but others did not find changes in 
cortisol reactivity [76-78] nor in ACTH responses to acute stress [75, 76, 78]. In psoriasis, only 
two studies reported lower cortisol levels after acute stress [79] or diminished cortisol 
increase in a subgroup of patients with psoriasis [80].
 All in, chronic inflammation may be associated with a dysfunction of the HPA axis, 
which could reduce glucocorticoid output and pave the way for other systems, such as 
the immune system, to show elevated activity and increase allostatic load, because of to 
the inability of the HPA axis to contain its activity [62]. Consequently, HPA axis function 
may be too ‘normal’ considering the degree of inflammation present in patients with a 
chronic inflammatory disease, with cortisol levels not being sufficiently high to dampen 
inflammation [81]. Whether this supposed HPA axis hypofunction is primary or secondary 
has not been established yet.
The ANS
Involvement of branches of the ANS, including the sympathetic nervous system (SNS) 
and adrenoceptor-mediated mechanisms, in the chronic inflammatory diseases RA and 
psoriasis have also been first documented in animal research [62]. For example, early 
studies reported that eliminating small afferents through capsaicin administration and 
depleting catecholamines by peripheral sympathectomy attenuates joint injury [82]. 
In contrast to this disease-exacerbating effect of the SNS, later studies also reported 
protecting effects of the SNS, for example, when treatment with β-adrenergic agonists in 
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experimentally induced arthritis in mice significantly reduced disease symptoms [83]. 
These differential effects of the SNS mainly seem to depend on the type of receptor 
stimulation, either α-adrenergic (pro-inflammatory) or β-adrenergic (anti-inflammatory) 
[16]. In humans, histological studies revealed that patients with RA show a functional loss 
of sympathetic nerve fibers in inflamed synovial tissue, while sensory innervation, i.e., 
substance P-positive pro-inflammatory nerve fibers, into the joints is increased, creating 
an imbalance between sensory and sympathetic nerve fibers [84]. This may induce a local 
β- to α-adrenergic shift that could enhance a pro-inflammatory state [16, 85]. Parallel to 
the loss of sympathetic nerve fibers observed in inflamed synovial tissue of patients with 
RA, patients with psoriasis show fewer β-adrenoceptors on keratinocytes in skin lesions 
compared to normal skin, risking insufficient down-regulation of inflammatory and 
immune processes [86]. Because receptor densities often decrease in response to elevated 
ligand levels, this finding may indicate patterns of systemic sympathetic hyperactivity 
(secondary to stressors) [28]. Increased sympathetic tone at rest as well as higher basal 
plasma catecholamines levels have been documented regularly in patients with RA [87]. 
Autonomic function tests have provided some insight into possible ANS alterations in RA 
and -to a lesser extent- in psoriasis [88-92]. They indicate that at least one fifth of patients 
with RA show general hypo- or hyperfunction of the ANS in standardized function tests 
that include the Valsalva maneuver, deep breathing, orthostatic tests, and sustained 
handgrip [91]. The few studies that evaluated the effects of experimental acute physical 
or psychological stress exposure on autonomic responses reveal either hypo- or hyper-
activation of (branches of) the ANS in patients or subgroups of patients with RA [78, 93, 94] 
or psoriasis [52, 95-97].  
 Therefore, although there are indications of systemic or local SNS dysfunction, it has 
not been fully elucidated yet to what extent the ANS or branches of the nervous system 
are dysfunctional in patients with RA or psoriasis when encountering a stressful situation, 
and what the specific consequences are for chronic inflammation.
The immune system
The immune system of patients with the Th1-mediated chronic inflammatory diseases RA 
and psoriasis is obviously affected, evidenced by the high amounts of various inflammatory 
markers, such as IL-1β, TNFα and IL-6, observed both locally, in the joints or skin, as well 
as systemically in some patients  [98-100]. In addition, immune cells of patients with RA 
show changes in the communication pathways with the ANS and HPA axis; alterations in 
corticosteroid receptor densities were observed in circulating lymphocytes (PBMCs), as 
well as changes in β-adrenergic receptors on lymphocytes in the synovial fluid [101-104]. 
Together with indications that receptor sensitivity for G-protein coupled receptors in 
lymphocytes is altered, leading to a disturbed intracellular signaling cascade in 
lymphocytes, these findings suggest that the influence of cortisol and catecholamines on 
lymphocyte function may be compromised [105, 106]. 
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 Therefore, the systemic pro-inflammatory state observed in chronic inflammation 
and possible disturbances in the signaling cascade between stress response mediators 
and immune cells may generate the basis for a disease-specific immune response to stress 
that contributes to the perpetuation of the disease process [37, 62]. The few prospective 
studies that have attempted to shed light on the effects of stress on immune function in 
RA or psoriasis indicate that minor stressful events have been positively associated with an 
overall enhancement of immune function, such as higher B cell numbers [44, 54, 107], 
while major life events have been related to immune suppression, such as lower T-helper/ 
T-suppressor cell ratios [43, 54]. Experimental studies of acute stress showed that short-term 
stressors can lead to acute alterations in leukocyte, lymphocyte, helper T cell, cytotoxic 
T cell, and NK cell numbers and pro-inflammatory cytokine activity and release (e.g., TNFα, 
IL-6) in patients with RA [49-51, 77, 78] or psoriasis [52, 53, 97] compared to healthy controls. 
However, those studies did not investigate the psychophysiological response to experimental 
real-life psychological stress in both patient groups. 
 Because there are only few experimental stress studies investigating short-term 
immune responses, little is known about how psychophysiological stress response 
mediators acutely influence immune function in patients with the chronic inflammatory 
diseases RA and psoriasis.  
Stress exposure
Building on knowledge of how stress affects the ANS, HPA axis and immune response in 
healthy populations, the understanding of how stress influences psychophysiological 
systems in various patient populations, including those suffering from chronic 
inflammation, is still increasing [29, 30, 108, 109]. Possible dysfunctions in the two main 
branches of the stress response system, the ANS and HPA axis, could increase stress-induced 
aggravation of chronic inflammatory conditions, such as RA and psoriasis [36, 87, 91, 92, 
110]. Laboratory studies investigating the psychophysiological effects of short-term 
real-life stressors may be the best way to investigate these mechanisms. Although they do 
not create a natural context, they allow control of key factors in the delivery of stress and 
the observation of its immediate effects. 
 Stress research has a wide variety of experimental real-life stress tests at its disposal, 
ranging from physical exercise to psychological stress tasks, and all applied to evoke a 
general stress response involving central hypothalamic activation and stimulation of both 
the SAM and HPA axis [87]; these types of experimental stressors may give a more 
comprehensive insight into stress physiology than physiological infusion studies that 
inject, for example, epinephrine or autonomic function tests, which are both particularly 
aimed at stimulating and/or measuring specific parts of the stress system. Physical stress 
tests not only include physical exercise, such as treadmill and bicycle training, but also 
sensory stressors, such as exposure to thermal stimuli -either cold or heat- and acoustic 
stimuli [29, 87]. Psychological stressors include tasks with a cognitive component, such as 
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the Stroop task or mental arithmetic, as well as psychosocial tasks with a social-evaluative 
component, such as the Trier Social Stress Test (TSST) [29, 87]. In fact, the TSST is a 
combination of both a psychosocial evaluation and a cognitive challenge, because it 
combines a mock job interview with mental arithmetic in front of a critical audience. The 
TSST is one of the most widely-used psychological stress tasks, which has been applied 
for over two decades, and consistently activates both autonomic and neuroendocrine 
parameters of stress [111, 112], and influences immune system function in healthy 
populations as well as in patients with various psychological or somatic disorders [50, 78, 
113-118]. Therefore, this task may be particularly efficient to elucidate and compare psycho-
physiological stress responses in patients with RA, patients with psoriasis and healthy 
controls, and to investigate how other factors, such as sex, age, medication, menopausal 
status and psychological functioning may influence this response. Until now, the TSST has 
only been used incidentally in these patient groups [50, 52, 53, 78]. 
 Experimental studies of stress may provide valuable information about possible 
alterations in the stress response system, either on the level of the ANS, the HPA axis or the 
immune system, in patients with inflammatory diseases; alterations that may add to 
aggravation of disease severity. Moreover, studies that compare psychophysiological stress 
response patterns of different patient groups with chronic inflammation in order to reveal 
possible disease-specificity in ANS, HPA axis and immune system reactivity are still rare. 
Psychological stress-reducing intervention
In an attempt to alleviate both the physical and psychological burden associated with a 
chronic inflammatory disease such as RA, psychological interventions are frequently used 
adjuncts to pharmacotherapy [119, 120]. Nevertheless, psychological interventions that are 
specifically aimed to alter psychophysiological parameters of stress and disease are still 
scarce.
Psychophysiological effects of psychological intervention
Numerous studies have been investigating the effects of multimodal therapies that are 
usually based on cognitive behavioral principles, such as patient education, cognitive 
training, relaxation therapy, physical exercise, biofeedback, emotional disclosure, and 
stress management training, on psychological and physical functioning in patients with 
RA. Interventions vary in duration, format, and primary outcome, but overall, different 
types of interventions have small but significant effects on physical outcomes, such as 
pain, joint swelling, and functional disability, and on psychological outcomes, such as 
anxiety and depression [119-124]. In line with this, psychological interventions for patients 
with psoriasis have sometimes generated effects on disease severity [125]. In general, 
there has been a growing interest in the ability of intervention studies to specifically alter 
physiological mediators of the stress response system. Stress-reducing interventions 
could eventually lead to decreased anxiety and dampening of the stress response as 
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evidenced by diminished autonomic arousal and neuroendocrine activity. For example, 
basal norepinephrine levels, urinary free cortisol output, serum cortisol levels, and 
dehydro epiandrosterone sulphate (DHEA-S) decrease in patients with HIV and cancer 
after stress management interventions [126-129]. In line with altered ANS and HPA axis 
function, intervention-related changes in immune parameters have also been observed in 
healthy controls and a number of patient groups with immune-related disorders, such as 
patients with HIV, cancer, delayed type hypersensitivity, or EBV or Herpes Simplex virus 
(HSV). For example, psychological interventions, such as stress management or relaxation 
training, can increase total lymphocyte numbers, neutrophil adherence, natural killer cell 
cytotoxicity (NKCC), and total sIgA concentration, and decrease EBV or HSV-2 antibody 
titres and T helper lymphocyte numbers [126, 130-133]. To what extent these types of 
interventions can also alter immune function in patients with RA and psoriasis has not 
been fully investigated. Although some studies with these patients have reported 
improvements in disease activity and/or joint swelling after intervention [134-136], these 
were hardly mirrored by changes in biological parameters of disease status. Studies in 
patients with RA patients that investigate changes in physiological parameters mostly 
focused on circulating levels of the pro-inflammatory C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR) [134, 137-147], with only incidental and temporary 
reports of alterations in those parameters [145]. Only very few studies with RA patients 
reported changes in circulating cytokine levels, such as IL-6 or IFNγ [148, 149]. Therefore, 
until now little research has been conducted to see whether psychological treatments 
can alter specific parameters of disease and immune function in patients with the chronic 
inflammatory conditions RA or psoriasis.  
Psychological intervention and psychophysiological effects after stress exposure
Despite the interest in the effects of psychological interventions on psychophysiological 
parameters and the clear evidence that stress can aggravate symptoms of disease through 
activation of the stress axes, there are hardly any studies designed to specifically investigate 
the effects of psychological interventions on the acute psychophysiological response 
to stress. Whereas basal post-intervention measures of autonomic, neuroendocrine, or 
immune function can be informative, the investigation of the psychophysiological 
response to a natural stressful situation will specifically challenge participants to cope 
with stress; it is only then that the benefits of psychological interventions may in particular 
become evident. To our knowledge only one study previously assessed the effects of a 
psychological intervention for healthy participants on the psychophysiological stress 
response to a laboratory stress task [150, 151]. Subjects attended group-based cognitive- 
behavioral stress management training following the principles of stress inoculation 
training. After the training, treatment and control participants were subjected to the 
previously described TSST [111, 112]. In contrast to the control group, the treatment group 
showed reduced endocrine salivary cortisol responses to the TSST and a lower stress 
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appraisal. Because basal cortisol levels after the training did not differ between groups, it 
seems evident that the effects of the intervention become specifically visible when 
investigating the acute psychophysiological response to stress. This specific approach, 
using a widely-used stress induction paradigm to test the effects of stress management 
training, would be very well-suited to investigate whether similar psychophysiological 
effects as found in healthy participants may be obtained in patients with RA, who may be 
particularly prone to the detrimental effects of stress on health. Psychological treatment 
aimed at decreasing stress levels in patients and reducing the psychophysiological stress 
response may limit the possible detrimental effects of stress on immune and inflammatory 
processes. 
Stress vulnerability
Although psychological interventions for patients with rheumatic and other chronic 
inflammatory diseases have generated moderate improvements in indicators of psychological 
and physical functioning, there is a large individual variability in treatment outcome, 
which is usually attributed to the heterogeneity of the patient population. 
 Specifically for RA research has shown the importance of evaluating psychological 
risk factors for disease progression and treatment outcomes, such as the personality trait 
neuroticism, psychological distress, or other cognitive-behavioral factors [45, 47, 107, 
152-164]. Although a substantial part of patients is relatively well-adjusted, up to 42 percent 
of patients with RA show heightened levels of distress, such as (sub)clinical levels of 
depression or anxiety [165]. In particular these vulnerable patients will probably benefit 
most from psychological interventions, emphasizing the need to customize care to patients 
with psychological risk profiles. In fact, there is increasing evidence that psychological 
treatment tailored to patients with specific risk profiles of heightened levels of distress 
particularly increases treatment effectiveness [15, 166, 167]. The rationale of tailored 
psychological interventions for patients psychologically at risk is also evidenced by 
research in other chronic inflammatory diseases, such as psoriasis, indicating that certain 
patient characteristics, such as patients’ reports that stress influences their disease severity, 
are associated with altered psychophysiological stress responses [80]. 
 Therefore, with the focus shifting to individual differences and tailored or personalized 
care, the largest treatment effects can be expected in patients with a psychological profile 
of heightened levels of distress, which eventually may reduce possible harmful effects of 
stress on disease severity. 
Focus and outline of the thesis
The aim of this thesis is to further elucidate the nature and reactivity of the psychophysio-
logical stress response system of patients with two classical forms of chronic inflammatory 
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diseases, RA and psoriasis. The main objectives of the studies presented in this thesis were 
1) to gain a greater insight into the psychophysiological stress response of patients with 
these different chronic inflammatory diseases, and to compare the psychophysiological 
stress response pattern of these patients with that of a healthy population, and 2) to 
investigate whether a stress management intervention can alter psychophysiological 
responses to stress in patients with RA. 
 Part I concerns the empirical background on and an experimental study of psycho-
physiological stress reactivity in patients with various chronic inflammatory diseases. In 
order to obtain a comprehensive understanding of psychophysiological responses to 
stress in rheumatic patients, Chapter 2 includes a review offering a summary of the 
existing literature on self-reported, autonomic, neuroendocrine, and immune responses 
to various experimental psychological and physical stressors in patients with inflammatory 
rheumatic diseases, such as RA and SLE. Chapter 3 covers an experimental study in which 
we investigate the psychophysiological responses to a psychosocial stress task, the TSST, 
of patients with the chronic inflammatory diseases RA and psoriasis. We compare patients’ 
subjective, autonomic, and neuroendocrine response patterns with the stress response of 
healthy participants. The aim is to investigate whether autonomic and/or neuroendocrine 
stress reactivity is specifically altered in different patient groups with chronic inflammation. 
In Chapter 4 we explore the effects of the TSST on parameters of the immune system, that 
is to say, serum cytokine levels such as IL-6 and TNF-α, in the two patient groups and 
healthy controls, and we examine whether the stress test leads to a specific cytokine 
response in the three groups.
 Part II of this thesis describes the effect of a brief stress management training for 
patients with RA on the psychophysiological response to the TSST. In this randomized 
controlled trial, patients are assigned to the intervention or the control group and 
subjected to the TSST twice, immediately after the intervention and at a follow-up 
assessment 9 weeks later. In Chapter 5, the overall effects of the stress management 
training on psychological and physical functioning are compared between patients in the 
intervention and control groups. We also compare the subjective, autonomic, and 
neuroendocrine response to the TSST post-treatment and at the follow-up between 
intervention and control groups. In addition, we explored whether the effects of the 
training on psychophysiological stress reactivity were particularly observed in patients 
psychologically at risk, i.e, showing heightened levels of distress. In Chapter 6, we examine 
the effects of the stress management training on immune responses to the TSST. We 
explored the effects of the training on circulating cytokine levels, such as IL-6, TNFα, and 
IL-8. In the concluding chapter of this thesis, Chapter 7, the main results of the studies are 
summarized and the theoretical, empirical, and clinical implications of our findings are 
discussed. We give directions for future research based on the existing literature and 
recent developments in stress research. 
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Abstract
Introduction Stressful events are thought to contribute to the etiology, maintenance and 
exacerbation of rheumatic diseases. Given the growing interest in acute stress responses 
and disease, this review investigates the impact of real-life experimental psychosocial, 
cognitive, exercise and sensory stressors on autonomic, neuroendocrine and immune 
function in patients with inflammatory rheumatic diseases. 
Methods Databases Medline, PsychINFO, Embase, Cinahl and Pubmed were screened for 
studies (1985 to 2009) investigating physiological stress responses in inflammatory 
rheumatic diseases. Eighteen articles met the inclusion criteria.
Results Results suggest that immune function may be altered in response to a stressor; 
such alterations could contribute to the maintenance or exacerbation of inflammatory 
rheumatic diseases during stressful events in daily life.
Conclusions This review emphasizes the need for more experimental research in rheumatic 
populations with controlled stress paradigms that include a follow-up with multiple 
evaluation points, simultaneous assessment of different physiological stress systems, and 
studying factors contributing to specific physiological responses, such as stress appraisal.
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Introduction
Stress is widely recognized as an important risk factor in the etiology of inflammatory 
rheumatic diseases [1-5]. An adaptational stress response involves the activation of both 
the hypothalamus-pituitary-adrenal axis (HPA axis) [6] and the autonomic nervous system 
(ANS) [7], and both stress axes are thought to communicate bidirectionally with the 
immune system [7-10]. Because many rheumatic diseases are characterized by im-
mune-mediated joint inflammation, stressful events might contribute to the etiology, 
maintenance and exacerbation of rheumatic diseases [11,12]. Recent advances in psycho-
neuroimmunology have provided insight into the complex mechanisms by which 
stressors might acutely affect the body’s immune system [13-16]. However, little attention 
has been paid to whether and how different short-term experimental stressors influence 
the separate pathways of the physiological stress response system (ANS, HPA axis, immune 
system) in patients with inflammatory rheumatic diseases. 
 Perception of an external stressful stimulus prompts the activation of various 
physiological systems that together define the body’s stress response, which is aimed at 
re-establishing homeostasis. The physiological stress response is mainly coordinated by 
the hypothalamus, with activation of the ANS and the pituitary and adrenal glands (HPA 
axis) resulting in the release of catecholamines and cortisol, respectively [1,9,17]. These 
stress hormones, supposedly acting via β- and α-adrenergic as well as glucocorticoid 
receptors, down-regulate immune and inflammatory processes; however, these processes 
also influence the central nervous system (CNS) [7,18-20]. Circulating cytokines (for 
example, tumor necrosis factor α (TNFα), interleukin (IL)-6 and IL-1) and activated immune 
cells, markers of inflammation, activate both (intermediates of) the HPA axis and the ANS. 
Chronically elevated levels of cytokines, as occur during long-term inflammation, might 
lead to changes in HPA axis and ANS activity [21]. Moreover, the bidirectional relationship 
between the CNS and immune system implies that the physiological response to real-life 
stressors could contribute to the pathophysiology of inflammatory diseases [1-5]. How 
these three systems, the ANS, the HPA axis and the immune system, act in response to a 
stressful event in rheumatic disorders is not well understood.
 Although the laboratory setting is not a natural environment, it allows control of key 
factors in the delivery of stress and observation of its effects and reduces many sources of 
bias and individual differences [16,22]. The literature on acute psychoneuroimmunological 
and psychoendocrinological responses to experimental stress in healthy individuals is still 
increasing. Studies of healthy populations suggest that experimental psychological and 
physical stressors not only activate the ANS [23] and the HPA axis [24], but also influence 
the immune system by activating innate immunity, as reflected by increased numbers of 
natural killer (NK) cells and the production of pro-inflammatory IL-6 [15,16]. Moreover, 
these different physiological systems (ANS, HPA axis and immune system) seem to work in 
an interdependent fashion [25]. 
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Despite the possible detrimental physiological effects of stress in patients with 
inflammatory rheumatic diseases, such as an altered disease course, little is known about 
acute-phase reactants of experimentally induced stress (both autonomic, neuroendocrine 
and immune). Reviews of acute physiological stress responses have either focused on one 
[16,24] or two [2] stress response systems only (for example, ANS and/or neuroendocrine 
system), and included either only patients with rheumatoid arthritis [2] or a heterogeneous 
group of both healthy participants and various patient populations [16]. In addition, 
studies of the relationship between stress and inflammatory rheumatic diseases have 
often used experimental stressors that do not necessarily mimic real-life stressors. Different 
types of time-limited experimental stressors have been identified, namely, physical 
stressors (autonomic function tests, exercise), physiological stressors (corticotropin-releas-
ing hormone (CRH) and (nor)epinephrine infusions, insulin tolerance test and 
dexamethasone suppression test) and psychological stressors (cognitive tests, public 
speaking) [2]. Many studies have investigated the effects of these types of stress on 
components of the stress response system, such as the ANS or the HPA axis, but external 
validity of these studies of stress is questionable. The prevalence of cardiovascular 
dysfunction is high after standard tests of autonomic function [26], such as the Valsalva 
maneuver, deep breathing, orthostatic tests, and sustained handgrip. While these tests 
may trigger autonomic responses, it is not known whether they activate the stress 
response system and alter neuroendocrine or immune function. HPA axis function has 
been investigated extensively by challenging specific parts of the HPA axis by means of 
infusion of CRH, synthetic glucocorticoids, or cytokines [27,28]. Although alterations in 
HPA axis responsiveness at a hypothalamic, pituitary or adrenal level have been reported, 
more subtle changes in HPA functioning have also been suggested to occur [27,28]. While 
injection studies might shed some light on possible altered neuroendocrine responses, 
the anti-inflammatory effects of exogenously administered glucocorticoids are not 
necessarily mirrored by increased secretion of endogenous glucocorticoids in response to 
a real-life stressor. Thus the question remains to what extent different types of experimental 
stressors that mimic real-life stressful events (for example, psychological stressors and 
physical exercise) are able to induce an autonomic, neuroendocrine and immune response 
in patients with inflammatory rheumatic diseases. 
 To the best of our knowledge this is the first review to investigate whether and how 
different experimental stressors mimicking real-life stressful events (psychosocial, 
cognitive, exercise and sensory stressors) influence physiological responses at the three 
levels (ANS, HPA-axis, immune system) in patients with prototypic inflammatory rheumatic 
diseases (for example, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
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Materials and methods
This review is limited to studies involving patients with inflammatory rheumatic diseases 
who were exposed to a time-limited experimental stressor to assess the autonomic, 
neuroendocrine, and/or immune responses to stress.
Search strategy
To identify studies, the electronic bibliographic databases MEDLINE, PsychINFO, Embase, 
Cinahl and Pubmed databases were searched, using the key words rheum*, (idiopathic or 
psoriatic) arthr*, spondylitis, sclerosis and lupus in combination with the terms stress and 
either cortisol or immun* or epinephrine or endocrin* or autonom* or hypothalam* or HPA. 
In addition, reference sections of the articles and review papers were hand-searched for 
relevant articles on psychological and physical stressors and inflammatory rheumatic diseases. 
 Inclusion criteria were studies published after 1985 in English peer-reviewed journals; 
evaluation of an experimental laboratory stress task that induces psychological and/or 
physical (exercise) stress and/or sensory stress (for example, thermoceptive (cold/heat), 
visual (light), auditive (noise)) by means of a time-limited experimental stressor; patients 
diagnosed with systemic inflammatory rheumatic diseases, such as RA, juvenile idiopathic 
arthritis (JIA), ankylosing spondylitis, systemic sclerosis, or SLE; control group consisting of 
either healthy participants or participants without a systemic inflammatory rheumatic 
disease, such as osteoarthritis; use of (neuro)endocrine variables (for example, cortisol 
levels), ANS variables (for example, heart rate, skin conductance, (nor)epinephrine levels), 
or immune variables (for example, number of leucocytes or lymphocytes, subsets of 
lymphocytes, interleukin levels) as outcomes. Exclusion criteria were pharmacological 
studies involving CRH, glucocorticoids, insulin or (nor)epinephrine infusions; studies 
evaluating a battery of standard autonomic function tests, which include deep breathing, 
the Valsalva maneuver, posture changes, and sustained handgrip, unless they were part of 
a paradigm with a psychological and/or exercise and/or sensory stressor [29-33]; 
assessment of anaerobic threshold, peak oxygen consumption, lactate threshold [34,35], 
fibrinogen and prothrombin time [36]. If a research group published more than one article 
on the same experimental study but evaluated different outcome measures, both articles 
were included in the review [29,30,36,37]. 
 Conclusions were based on (uni- or multivariate) statistics for within-group and/or 
between-groups differences. If studies reported significant between-group differences in 
repeated measures ANOVAs, baseline values between groups were assumed to be 
different, unless stated otherwise. If studies did not report significant (within- or between-) 
group differences, it was assumed that none were found. If studies did not provide 
statistical analyses, findings were based on mean (± standard error of the mean (SEM) or 
standard deviation (SD)) or median values. If those values were ambiguous, no conclusions 
were drawn.
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Results
Participants
Patient groups
Sixteen studies (18 articles) met the inclusion criteria. The study sample characteristics are 
summarized in Table 1. Nine studies included patients with RA [29,30,34-42] and seven 
patients with SLE [31,33,35,40,43-45]. Two of these studies involved both types of patients 
[35,40]. In addition, one study included patients with JIA [46] and one study included a 
heterogeneous group of patients with inflammatory arthritis (RA, psoriatic arthritis, 
ankylosing spondylitis and fibrositis) [32]. Fifteen studies included healthy participants 
without systemic inflammatory rheumatic disease as control and one study, patients with 
osteoarthritis [36,37]. In three studies a second control group was added, consisting of 
either patients with myofascial pain [32], patients with sarcoidosis [43], or participants 
taking corticosteroids [44]. Most studies have relatively small sample sizes (N = 10 to 20 per 
group), with even smaller sample sizes (N < 10) in two studies [35,40]. In addition, patient 
samples are probably heterogeneous because, for example, strict exclusion criteria 
regarding comorbidities are lacking in half of all studies [32,33,35,38,42-44,46]. With regard 
to diagnostic criteria, one study even included also patients with non-inflammatory 
arthritis [32]. There is also a high variability in pharmacotherapy profiles, but overall these 
profiles were well-defined for the various classes of drugs (see Table 1), except in two 
studies [32,33]. To control for the effects of pharmacotherapy some studies excluded 
patients using specific medication (for example, corticosteroids [35,38-40,46], opioids 
[39,41], antidepressants [39,40,45], or adrenoceptor antagonists [29,40,45]), or the intake of 
medication was regulated prior to and on the day of testing [39,41]. In addition, two 
studies performed subgroup analyses with patients on different medical regimes [41,45]. 
Stress paradigms 
The stressors included in this review were experimental manipulations of stressful 
experiences, either of a psychological, exercise and/or sensory nature, and lasted between 
one minute and two hours.
Psychological stressors
Ten of 16 studies used a psychological stressor, applied for one minute to two hours 
[29-32,36-38,40,41,43-45].
Cognitive stressors Seven studies used cognitive stressors [29-32,36-38,42,44], namely, 
the Stroop Color-Word Interference test [29,30,38]; a two-minute cognitive discrimination 
task [29,30]; the Attention and Concentration Test, Syndrome Short Test, computer-
ized-controlled Reaction Time Task and three parts of the Hamburg Wechsler Adult 
Intelligence Test (comprehension, digit span, block design) [42,44]; Multiple Choice Word 
Fluency; and the Benton Visual Memory Scale [44]. Mental arithmetic was assessed in 
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two studies, either with a one- or two-minute serial subtraction task [31,32], or with a 
two-minute paced auditory serial addition test performed while patients were tilted to a 
head-up-tilt of 64 degrees [36,37].
Psychosocial stressors Three studies used a psychosocial stressor, namely, a ten-minute 
public speaking task [40]; the Trier Social Stress Test consisting of a five-minute public 
speech and a five-minute public mental subtraction task [41]; or a ten-minute public 
speech (including a five-minute preparation period) on the topic ‘Children in today’s 
society’ [45]. 
Exercise stressors
Three studies used exercise stressors, namely, a bicycle ergometer task, which involved 
cycling at a rate of 50 revolutions per minute against a resistance of 12.5 watt for three 
minutes [38]; or an ergospirometric exercise test on a treadmill to the limit of subject’s 
tolerance for several minutes [34,35].
Sensory stressors
Eight studies assessed sensory stressors, most of which used thermal stimuli, usually 
experienced as painful. Five studies assessed responses to a cold stressor [31,33,38,39,46], 
in which participants either had to put their hand in a bowl filled with (ice) cold water for 
several minutes [38,39,46], or endure an ice-pack on their hand [31]. One study did not 
describe the cold pressor task [33]. Heat pulses [39], an acoustic stress test (several minutes) 
[42,43] and a pupillary light flash test [32] were also used.
Outcome measures
Outcome measures were self-reported distress, autonomous nervous system responses, 
neuroendocrine responses, or immune responses (see Tables 2, 3 and 4). 
Self-reported distress
Stress-induced self-reported distress was assessed in only two of 16 studies [41,45]. 
Subjective distress levels were either measured on a visual analogue scale (VAS) ranging 
from 0 to 100 [41] or on a VAS tension and excitement together with the State Trait Anxiety 
Inventory (STAI) [45].
Measures of the autonomous nervous system
Eleven studies assessed ANS responses (see Table 2) [29,31-33,37,40-43,45,46], namely, 
heart rate [29,31,32,37,41,45], diastolic and/or systolic blood pressure [29,31,33,41,45], mean 
arterial pressure, systemic vascular resistance, plasma volume and cardiac output [36,37], 
and pre-ejection period (PEP) [41]. Furthermore, plasma (nor)epinephrine levels [31,40,42,44-46] 
and skin conductance [29,32] were assessed.
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Table 1   Study sample characteristics
Study Patient sample Control sample Pharmacotherapy of patient sample
N
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er
Pharmacotherapy comments:
Dekkers  
et al., 2001 [38]
N = 29 RA patients;
No exclusion criteria given
N = 30 HC;
Age and sex matched;
Exclusion: chronic disease, chronic pain, 
heart problems, hypertension
+ + - 1 o o 1   patients taking oral prednisone (5-15 mg) or corticosteroid injections 
< 3 months prior to study onset excluded
Edwards  
et al., 2009 [39]
N = 19 RA patients;
Exclusion: history of myocardial infarction or 
cardiovascular disease, peripheral neuropa-
thy, Raynaud syndrome, vasculitis, peripheral 
vascular disease, other autoimmune or rheu-
matic disorders,  current infection, recent 
history of substance abuse or dependence, 
pregnancy, mood or anxiety disorder
N = 21 HC;
No age and sex difference with patients;
Same exclusion criteria as patients;
+2 + - + - 3 2   24h prior to study onset no NSAIDs intake;
3   Opioids, antidepressants excluded;
Stable medication regime of >1 months
Geenen  
et al., 1996/1998 
[29,30]
N = 21 RA patients;
Exclusion: other serious diseases
N = 20 HC;
Age and sex matched; 
Exclusion: chronic pain, cardiovascular 
 complaints, chronic diseases
+ + o o - 4 4   α and β adrenoceptor antagonists excluded (only for autonomic 
response evaluation)
Hinrichsen  
et al., 1989 [43]
N = 14 SLE patients;
No exclusion criteria given 
N = 14 HC, N = 12 sarcoidosis patients;
Age and sex matched;
o o +5 o o 5   24h prior to study onset no corticosteroid therapy;
Hinrichsen  
et al., 1992 [44]
N = 14 SLE patients;
No exclusion criteria given
N = 14 HC, N = 10 HC taking corticosteroids;
Age and sex matched
o o +6 o o 6   4-10 mg; 24h prior to study onset no corticosteroid therapy
Hogarth  
et al., 2002 [31]
N = 23 SLE patients;
Exclusion: diabetes mellitus, hypertension
Remark: some patients have comorbid 
Sjogren syndrome, Raynaud’s phenomenon, 
history of cerebral lupus
N = 23 HC;
Age and sex matched;
Exclusion: diabetes mellitus, hypertension
+ + +7 o - 8 7   1-30 mg;
8   Antihypertensive medication <1 week prior to study excluded
Jacobs  
et al., 2001 [40]
N = 9 RA patients, N = 7 SLE patients;
Exclusion: significant cardiovascular diseases, 
concurrent infections, history of other auto-
immune disorders, drug or alcohol abuse; no 
exacerbation of disease < 4 weeks
N = 15 HC;
Age and sex matched;
Same exclusion criteria as patients
o + - - - 9 9   adrenoceptor antagonists, antidepressants and benzodiazepines 
taken < 4 weeks prior to study onset excluded
Kurtais  
et al., 2006 [34]
N = 19 RA patients;
Exclusion: severe illness, other general con-
traindications for graded exercise test
N = 14 HC;
Age and sex matched;
Inclusion: sedentary 
Exclusion: chronic systemic disease, chronic 
pain, contraindication for exercise test
+ + +10 o o 10  7.5-15 mg;
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o + - - - 9 9   adrenoceptor antagonists, antidepressants and benzodiazepines 
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Table 1   Continued
Study Patient sample Control sample Pharmacotherapy of patient sample
N
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Pharmacotherapy comments:
Motivala  
et al., 2008 [41]
N = 21 RA patients;
Exclusion: cardiovascular disease, endocrine- 
related other immune disorders, acute  
or chronic infections, pregnancy, current 
psychiatric mood or anxiety disorder
N = 20 HC;
Age and sex matched;
Same exclusion criteria as patients
+11 + +12 + - 13 11  24h prior to study onset no NSAIDs taken;
12  < 10 mg  (> 10 mg excluded);
13  Opioids, oral contraception excluded;
Stable medication regime  >2 months
Palm  
et al., 1992 [42]
N = 18 RA patients;
No exclusion criteria given
N = 14 HC;
Age and sex matched;
Half of all controls had been hospitalized 
because of coronary heart disease or  
hypertension
+ + +14 o o 14 2,5-10 mg
Pawlak  
et al., 1999 [45]
N = 15 SLE patients (N < 10 for subanalyses: 
NK cytotoxicity and # β-adrenoceptors);
Exclusion: significant cardiovascular diseases, 
concurrent infections, history of other auto-
immune disorders, drug or alcohol abuse
N = 15 HC (N < 10 for subanalyses:  
NK cytotoxicity and # β-adrenoceptors);
Age and sex matched;
Same exclusion criteria as patients
o + +15 o - 16 15 5-10 mg;
16  Adrenoceptor antagonists, antidepressants, benzodiazepines taken  
< 4 week prior to study onset excluded
Perry  
et al., 1989 [32]
N = 19 heterogeneous group of arthritis 
patients (RA, psoriatic arthritis, ankylosing 
spondylitis, fibrositis);
No exclusion criteria given 
N = 38 HC, 17 patients with myofascial pain;
No exclusion criteria given
+ o o o +17 17  Benzodiazepines, psychotropics, and other medication affecting ANS, 
etc; 12h prior to onset study no medication taken known to affect ANS
Pool  
et al., 2004 [35]
N = 7 RA patients, N = 6 SLE patients;
No exclusion criteria given 
N = 10 HC;
HC recruited from hospital staff;
No exclusion criteria given
+ + - o - 18 18 Phenothiazines (e.o. drugs influencing PRL levels) excluded
Roupe  
et al., 2000 [46]
N = 20 JIA patients (N = 15 for in vivo 
 analyses);
No exclusion criteria given 
N = 20 HC (N = 14 for in vivo analyses);
Age and sex matched;
+ + - o o
Shalimar  
et al., 2006 [33]
N = 51 SLE patients;
No exclusion criteria given
N = 30 HC;
Age and sex matched 
o o o o - 19 19 Medication known to affect HR, BP excluded
Veldhuijzen  
et al., 2005/2008 
[36,37]
N = 21 RA patients;
Exclusion: previously confirmed acute 
 coronary syndrome, DM, serious psychiatric 
diseases
N = 10 OA patients;
Same exclusion criteria as patients
+ + + + +20 20 Analgesics included; no use of oral contraception
RA= rheumatoid arthritis, SLE= systemic lupus erythematosus, HC= healthy controls, JIA= juvenile idiopathic 
arthritis, OA= osteoarthritis, DM = diabetes mellitus.  + = Included;  - = Excluded; o = Not mentioned in article. 
ANS = autonomic nervous system, BP = blood pressure, DMARDs=disease-modifying antirheumatic drugs,  
HR = heart rate, NSAIDs = nonsteroidal anti-inflammatory drugs, PRL = prolactin.
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+ + - o - 18 18 Phenothiazines (e.o. drugs influencing PRL levels) excluded
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N = 20 JIA patients (N = 15 for in vivo 
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N = 20 HC (N = 14 for in vivo analyses);
Age and sex matched;
+ + - o o
Shalimar  
et al., 2006 [33]
N = 51 SLE patients;
No exclusion criteria given
N = 30 HC;
Age and sex matched 
o o o o - 19 19 Medication known to affect HR, BP excluded
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[36,37]
N = 21 RA patients;
Exclusion: previously confirmed acute 
 coronary syndrome, DM, serious psychiatric 
diseases
N = 10 OA patients;
Same exclusion criteria as patients
+ + + + +20 20 Analgesics included; no use of oral contraception
RA= rheumatoid arthritis, SLE= systemic lupus erythematosus, HC= healthy controls, JIA= juvenile idiopathic 
arthritis, OA= osteoarthritis, DM = diabetes mellitus.  + = Included;  - = Excluded; o = Not mentioned in article. 
ANS = autonomic nervous system, BP = blood pressure, DMARDs=disease-modifying antirheumatic drugs,  
HR = heart rate, NSAIDs = nonsteroidal anti-inflammatory drugs, PRL = prolactin.
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Endocrine measures
Eight studies assessed neuroendocrine responses (see Table 3) [30,34,35,38,39,41,42,44], 
namely plasma [30,34,38,41,42,44] or serum [35,39] cortisol levels and plasma ACTH levels 
[34,38,41]. Two studies measured hormones other than those involved in the HPA axis, 
namely, plasma growth hormone (GH) and insulin-like growth factor I (IGF-I) levels [34] 
and serum prolactin levels [35].
Immunological measures
Twelve studies assessed immune responses (see Table 4) [30,35,36,38-46], namely, the 
total number of leucocytes [36,40,42-45], and the number of lymphocytes and/or subsets 
of lymphocytes, including B cells, T cells and NK cells [30,35,40,42-45]. Two studies assessed 
NK cell cytotoxicity [40,45]. Six studies reported on cytokine levels [38-42,46], namely, 
plasma levels of cytokine IL-1β [42], IL-6 [39,41,42] and TNFα [39], ex vivo stimulated 
mononuclear cell production of IL-2 [40], IL-4 [38,40], IL-6 [40,41,46], IL-8 [46], IL-10 [40], 
interferon (IFN) γ [38,40] and TNFα [41], or intracellular concentrations of IL-4, IL-6, IL-10 and 
IFNγ [40]. Other inflammation markers were also assessed, such as C-reactive protein (CRP) 
[36], the number of β-adrenoceptors on monocytes [45], β-adrenoceptor sensitivity [45], 
and plasma soluble IL-2 receptor levels [42].
Time points of outcome measures
All studies reported baseline values for the outcome measures, and all, except two [32,34], 
reported a resting period of 3 to 45 minutes. During administration of the experimental 
stressor, physiological reactivity was either assessed at specific time points (in three 
studies) [35,41,42], or continuously throughout the stress procedure (only for autonomic 
measures such as heart rate, blood pressure and/or skin conductance; in four studies) 
[29,32,37,45]. All studies reported immediate post stress measurements, except two 
studies that only assessed stress reactivity at 30 minutes [34] or 60 minutes [35] after 
cessation of the stressor. Eight of 16 studies have one [29,30,36-38,40,45] or more [39,41,46] 
additional follow-up measurement points, ranging from 5 to 60 minutes after cessation 
of the stressor. 
Baseline characteristics
Autonomic, neuroendocrine, and immune functions were assessed at baseline in patients 
with rheumatic disorders and controls. Results for the separate outcome measures are 
summarized in Tables 2, 3 and 4.
ANS variables
ANS function at baseline was not different between patients with rheumatic disorders and 
controls in most studies. Cardiovascular variables, skin conductance, and catecholamine levels 
did not differ in nine studies [29,31,36,37,40-42,44-46], whereas three studies reported 
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significantly higher levels of autonomic activity at baseline (heart rate and pupil area [32]; 
epinephrine levels [46]) or lower levels ((nor)epinephrine [31]) in patients with rheumatic 
disorders compared with controls (see Table 2).
Neuroendocrine variables
Neuroendocrine function at baseline was not significantly different between patients 
with rheumatic disorders and controls. Five of eight studies reported similar baseline 
levels of cortisol, ACTH, GH, IGF-I, and prolactin [34,35,39,41,42]. Three studies reported 
higher levels of cortisol at baseline (in patients with RA) [30,38] or lower levels (in patients 
with SLE) [44] than in controls (see Table 3). Lower cortisol levels at baseline were also 
observed in one study in which control subjects were taking corticosteroids [44].
Immune variables
Baseline leucocyte counts [36,40,42] were not different between patients with RA and 
controls. However, two of three studies found patients with RA to have lymphopenia at 
baseline [30,42]. Levels of cytokines and other inflammatory factors (IL-2, IL-4, IL-6, IFNγ, 
TNFα, and CRP) were similar in patients with RA and controls in five studies [36,38-41]. 
Three studies reported higher baseline levels of IL-6 [39] and soluble IL-2 receptor [42] and 
lower basal levels of IL-10 and IFNγ [40] in patients with RA compared with controls. 
 Baseline leucocyte counts were not significantly different between patients with SLE 
and controls in most (three of four) studies [43-45]. One study reported baseline leucopenia 
in patients with SLE [40]. All studies reported lower lymphocyte counts (including lower 
subsets of lymphocytes) in patients with SLE than in controls [40,43,45]. Despite this baseline 
lymphopenia, a higher percentage of B cells (from the total lymphocyte count) was found 
once [43]. Only one study reported similar numbers of helper T and cytotoxic T cells in 
patients with SLE and controls [35]. Cytokine (IL-2, IL-4 and IL-6) levels at baseline were not 
significantly different between patients with SLE and controls [40]. However, cytokine levels of 
IL-10 and IFNγ at baseline and the sensitivity of β-adrenoceptors, which are involved in the 
transduction of autonomic signals to immune cells, were lower in patients with SLE than in 
controls [45]. The one study with immunological data on patients with JIA reported higher 
cytokine levels (IL-6 and IL-8) than in controls at baseline [46] (see Table 4). 
 In summary, at baseline autonomic function is similar in patients with RA and SLE and 
controls, with only limited evidence for heightened autonomic function in (a subgroup of) 
patients with rheumatic diseases. Neuroendocrine function at baseline is also comparable 
in patients with RA and SLE and controls, with only three studies reporting altered cortisol 
levels in patient groups. Specific immune variables, mainly (subsets of) lymphocyte 
counts, appear to be lower in patients with SLE than in controls.
Psychophysiological responses to stress
An overview of findings is given in Tables 2, 3 and 4.
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Table 2   Autonomic function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patients vs. controls Stress reactivity within patients Stress reactivity patients vs. controls
Heart rate [29] 21 RA vs. 20 HC
[41] 21 RA vs. 20 HC
[36,37] 21 RA vs. 10 OA
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[32] 19Arthr vs. 38 HC, 17 MFP
RA:
SLE: 
Arthr: 
No difference [29,36,37,41]
No difference [31,45] 
 
Altered ( ) [32]
RA:
SLE:
Arthr: 
Increase [29,36,37,41]                                                                         
Increase [45] 
Not reported [31]                                                                    
Increase [32]                                                                          
RA:        
SLE:      
Arthr: 
No difference [36,37,41]
Altered ( ) [29]
No difference [31] (cogn.) [45]
Altered ( ) (cold) [31]
No difference [32]
Blood pressure  
(diastolic/systolic)
[29] 21 RA vs. 20 HC
[41] 21 RA vs. 20 HC
[36] 21 RA vs. 10 OA
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[33] 51 SLE vs. 30 HC
RA:
SLE: 
No difference [29,36,41] 
No difference [31,45] 
Not reported [33]
RA: 
SLE: 
Increase [29,36,41]
Increase [45] 
Not reported [31,33] 
RA:  
SLE:  
No difference [36,41]
Altered ( ) [29] / ( ) [41]
No difference [31,33,45]          
Mean arterial pressure  
(MAP)
[37] 21 RA vs. 10 OA RA: No difference RA: Increase RA:  No difference
Systemic vascular resistance 
(SVR)
[37] 21 RA vs. 10 OA RA: No difference RA: Increase severe subgroup RA:   Altered ( )  severe subgroup
Plasma volume (PV) [36] 21 RA vs. 10 OA RA: No difference RA: Decrease RA: No difference
Cardiac output (CO) [37] 21 RA vs. 10 OA RA: No difference RA: No response RA:   No difference
Pre-ejection period (PEP) [41] 21 RA vs. 20 HC RA: No difference RA: Decrease RA:  No difference
Plasma catecholamines 
(nor)epinephrine
[42] 18 RA vs. 14 HC 
[40] 9 RA, 7 SLE vs. 15 HC 
[44] 14 SLE vs. 14 HC, 10 HC
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[46] 15 JIA vs. 14 HC
RA:
SLE: 
JIA: 
No difference [40] [42] *
No difference [40,45] 
Altered ( ) [31] 
Not reported [44] 
No difference (NE) [46]
Altered ( ) (EPI) [46]
RA:
SLE: 
JIA: 
Increase [40]
No response [42]
Increase [40,44,45]
Increase (NE)[46]
No response (EPI)[46]
RA:
SLE: 
JIA: 
No difference [40,42]
No difference  [40,45] [44] * 
No difference  [46]
Skin conductance (SC) [29] 21 RA vs. 20 HC
[32] 19 Arthr vs. 38 HC, 17 MFP
RA:
Arthr: 
No difference [29]
No difference [32]
RA:
Arthr: 
Increase [29]
Increase [32]
RA:        
Arthr: 
Altered ( ) [29] 
Altered ( ) [32]
Pupillary constriction [32] 19 Arthr vs. 38 HC, 17 MFP Arthr: Altered ( ) Arthr: Not reported Arthr: Altered ( )
* Findings assumed after inspection of descriptive data. 
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern 
is diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
JIA = juvenile idiopathic arthritis, Arthr= heterogeneous group of arthritis patients, HC= healthy controls,  
OA= osteoarthritis, MFP= patients with myofascial pain, NE= norepinephrine, EPI= epinephrine.
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Table 2   Autonomic function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patients vs. controls Stress reactivity within patients Stress reactivity patients vs. controls
Heart rate [29] 21 RA vs. 20 HC
[41] 21 RA vs. 20 HC
[36,37] 21 RA vs. 10 OA
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[32] 19Arthr vs. 38 HC, 17 MFP
RA:
SLE: 
Arthr: 
No difference [29,36,37,41]
No difference [31,45] 
 
Altered ( ) [32]
RA:
SLE:
Arthr: 
Increase [29,36,37,41]                                                                         
Increase [45] 
Not reported [31]                                                                    
Increase [32]                                                                          
RA:        
SLE:      
Arthr: 
No difference [36,37,41]
Altered ( ) [29]
No difference [31] (cogn.) [45]
Altered ( ) (cold) [31]
No difference [32]
Blood pressure  
(diastolic/systolic)
[29] 21 RA vs. 20 HC
[41] 21 RA vs. 20 HC
[36] 21 RA vs. 10 OA
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[33] 51 SLE vs. 30 HC
RA:
SLE: 
No difference [29,36,41] 
No difference [31,45] 
Not reported [33]
RA: 
SLE: 
Increase [29,36,41]
Increase [45] 
Not reported [31,33] 
RA:  
SLE:  
No difference [36,41]
Altered ( ) [29] / ( ) [41]
No difference [31,33,45]          
Mean arterial pressure  
(MAP)
[37] 21 RA vs. 10 OA RA: No difference RA: Increase RA:  No difference
Systemic vascular resistance 
(SVR)
[37] 21 RA vs. 10 OA RA: No difference RA: Increase severe subgroup RA:   Altered ( )  severe subgroup
Plasma volume (PV) [36] 21 RA vs. 10 OA RA: No difference RA: Decrease RA: No difference
Cardiac output (CO) [37] 21 RA vs. 10 OA RA: No difference RA: No response RA:   No difference
Pre-ejection period (PEP) [41] 21 RA vs. 20 HC RA: No difference RA: Decrease RA:  No difference
Plasma catecholamines 
(nor)epinephrine
[42] 18 RA vs. 14 HC 
[40] 9 RA, 7 SLE vs. 15 HC 
[44] 14 SLE vs. 14 HC, 10 HC
[31] 23 SLE vs. 23 HC
[45] 15 SLE vs. 15 HC
[46] 15 JIA vs. 14 HC
RA:
SLE: 
JIA: 
No difference [40] [42] *
No difference [40,45] 
Altered ( ) [31] 
Not reported [44] 
No difference (NE) [46]
Altered ( ) (EPI) [46]
RA:
SLE: 
JIA: 
Increase [40]
No response [42]
Increase [40,44,45]
Increase (NE)[46]
No response (EPI)[46]
RA:
SLE: 
JIA: 
No difference [40,42]
No difference  [40,45] [44] * 
No difference  [46]
Skin conductance (SC) [29] 21 RA vs. 20 HC
[32] 19 Arthr vs. 38 HC, 17 MFP
RA:
Arthr: 
No difference [29]
No difference [32]
RA:
Arthr: 
Increase [29]
Increase [32]
RA:        
Arthr: 
Altered ( ) [29] 
Altered ( ) [32]
Pupillary constriction [32] 19 Arthr vs. 38 HC, 17 MFP Arthr: Altered ( ) Arthr: Not reported Arthr: Altered ( )
* Findings assumed after inspection of descriptive data. 
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern 
is diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
JIA = juvenile idiopathic arthritis, Arthr= heterogeneous group of arthritis patients, HC= healthy controls,  
OA= osteoarthritis, MFP= patients with myofascial pain, NE= norepinephrine, EPI= epinephrine.
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Table 3   Autonomic function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
ACTH [38] 29 RA vs. 30 HC 
[34] 19 RA vs. 14 HC
[41] 21 RA vs. 20 HC
RA: No difference [34,38,41] RA: 
        
     
Increase [34,41] 
Not reported [38] 
RA: No difference [34,38,41]
Cortisol [30] 21 RA vs. 20 HC 
[38] 29 RA vs. 30 HC 
[39] 19 RA vs. 21 HC
[34] 19 RA vs. 14 HC
[41] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC
[35] 7 RA, 6 SLE vs. 10 HC
[44] 14 SLE vs. 14 HC, 10 HC
RA:  
        
SLE: 
No difference  [34,35,39,41,42]  
Altered ( ) [30,38] 
No difference [35] 
Altered ( ) [44] 
RA:   
SLE:
Decrease [34,35,42]  
Change [30] 
Increase [39,41]
Decrease [35] 
No response [44]
RA:  
  
       
SLE: 
          
No difference [30,34,39,41,42]  
Altered ( ) [35,38] 
No difference [44] 
Altered ( ) [35]
Growth hormone (GH) [34] 19 RA vs. 14 HC RA:  No difference RA: Increase RA: No difference
Insulin-like growth factor 
(IGF-I)
[34] 19 RA vs. 14 HC RA:  No difference RA: No response RA: No difference
Prolactin [35] 7 RA, 6 SLE vs. 10 HC RA: 
SLE: 
No difference
No difference
RA: 
SLE:
No response
No response
RA: 
SLE:
Altered ( )
Altered ( )
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern 
is diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
HC= healthy controls, ACTH= adrenocorticotropin hormone.
Table 4   Immune function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
Leucocytes [42] 18 RA vs. 14 HC
[36] 21 RA vs. 10 OA
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
No difference  [36,40,42] 
No difference [43,45] [44] *
Altered ( ) [40] 
RA:
SLE: 
Increase [36,40,42]
Increase [40,43-45]
RA:    
SLE:  
No difference [36,40] [42] *
Altered ( ) [40,43,45]
No difference [44] *
Total lymphocytes [30] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45] 15 SLE vs. 15 HC
RA:  
SLE: 
Altered ( ) [30,42]
No difference  [40] 
Altered ( ) [40,43,45] 
Not reported [44]
        
RA:   
SLE:  
Increase [30,40]
No response [42]
Increase [40,45]
No response[43,44]
RA:   
           
SLE:  
      
  
No difference [30,40] 
Altered ( ) [42] 
Altered ( ) [43-45] 
No difference  [40]
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Table 3   Autonomic function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
ACTH [38] 29 RA vs. 30 HC 
[34] 19 RA vs. 14 HC
[41] 21 RA vs. 20 HC
RA: No difference [34,38,41] RA: 
        
     
Increase [34,41] 
Not reported [38] 
RA: No difference [34,38,41]
Cortisol [30] 21 RA vs. 20 HC 
[38] 29 RA vs. 30 HC 
[39] 19 RA vs. 21 HC
[34] 19 RA vs. 14 HC
[41] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC
[35] 7 RA, 6 SLE vs. 10 HC
[44] 14 SLE vs. 14 HC, 10 HC
RA:  
        
SLE: 
No difference  [34,35,39,41,42]  
Altered ( ) [30,38] 
No difference [35] 
Altered ( ) [44] 
RA:   
SLE:
Decrease [34,35,42]  
Change [30] 
Increase [39,41]
Decrease [35] 
No response [44]
RA:  
  
       
SLE: 
          
No difference [30,34,39,41,42]  
Altered ( ) [35,38] 
No difference [44] 
Altered ( ) [35]
Growth hormone (GH) [34] 19 RA vs. 14 HC RA:  No difference RA: Increase RA: No difference
Insulin-like growth factor 
(IGF-I)
[34] 19 RA vs. 14 HC RA:  No difference RA: No response RA: No difference
Prolactin [35] 7 RA, 6 SLE vs. 10 HC RA: 
SLE: 
No difference
No difference
RA: 
SLE:
No response
No response
RA: 
SLE:
Altered ( )
Altered ( )
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern 
is diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
HC= healthy controls, ACTH= adrenocorticotropin hormone.
Table 4   Immune function in patients with systemic inflammatory rheumatic diseases
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
Leucocytes [42] 18 RA vs. 14 HC
[36] 21 RA vs. 10 OA
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
No difference  [36,40,42] 
No difference [43,45] [44] *
Altered ( ) [40] 
RA:
SLE: 
Increase [36,40,42]
Increase [40,43-45]
RA:    
SLE:  
No difference [36,40] [42] *
Altered ( ) [40,43,45]
No difference [44] *
Total lymphocytes [30] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45] 15 SLE vs. 15 HC
RA:  
SLE: 
Altered ( ) [30,42]
No difference  [40] 
Altered ( ) [40,43,45] 
Not reported [44]
        
RA:   
SLE:  
Increase [30,40]
No response [42]
Increase [40,45]
No response[43,44]
RA:   
           
SLE:  
      
  
No difference [30,40] 
Altered ( ) [42] 
Altered ( ) [43-45] 
No difference  [40]
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Table 4   Continued
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
Total T cells
(CD3+)
[30] 21 RA vs. 20 HC
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45]15 SLE vs. 15 HC
RA:  
         
SLE: 
No difference [40] 
Altered ( ) [30] 
Altered ( ) [40,45] 
No difference (%) [43] [44] *
RA: 
SLE:             
Increase [40] 
No response [30]
Increase [40,45]
No response (%) [43,44]
RA: 
SLE: 
         
No difference [30,40] 
No difference [40,43] 
Altered ( ) [45] / (%) [44]
Helper T cells
(CD4+)
[40] 9 RA, 7 SLE vs. 15 HC
[35] 7 RA, 6 SLE vs. 10 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
         
No difference [35,40] 
Altered ( ) [40,45] 
No difference [35] / (%) [43]
Not reported [44]
RA:    
SLE:   
Increase [40] 
Decrease [35]
No response [40,45] / (%) [44]
Decrease [35] / (%) [43] 
RA: 
SLE: 
Altered ( ) [35,40]
  
Altered ( ) [45] (%) [43,44]  / (↑) [35]
No difference [40]
Cytotoxic T cells (CD8+) [40] 9 RA, 7SLE vs. 15 HC
[35] 7 RA, 6 SLE vs. 10 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
No difference [35,40] 
Altered ( ) [40,45] 
No difference [35] / (%) [43]
Not reported [44]      
RA:   
SLE:  
Increase [40]
No response [35]
Increase [40,45] /  (%) [43,44]
Decrease [35]
RA: 
SLE:  
No difference [40]
Altered ( ) [35]
No difference [40,45] [44] *
Altered ( ) [35] / (%) [43] 
B cells (CD19+) [30] 21 RA vs. 20 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14HC, 10HC
RA:  
SLE: 
Altered ( ) [30] 
Altered ( ) (%) [43] 
No difference (%) [44] *
RA:    
SLE:  
Increase [30] 
Increase (%) [43] 
No response (%) [44]
RA: 
SLE: 
No difference [30]
Altered ( ) (%) [43,44] 
NK cells (CD56+) [30] 21 RA vs. 20 HC
[40] 9 RA, 7 SLE vs. 15 HC
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA:  
SLE: 
No difference [40] 
Altered ( ) [30] 
Altered ( ) [40,45] 
Not reported [44]
RA:  
SLE: 
Increase [30,40] 
Increase [40,45]
No response [44]
RA: 
SLE: 
No difference [30,40] 
Altered ( ) [40,45]
No difference [44]
NK cell cytotoxicity [40] 9 RA, 7 SLE vs. 15 HC
[45] 4 SLE vs. 8 HC
RA:
SLE:
No difference [40]
No difference [40,45]
RA: 
SLE:
No response [40]
No response [40,45]
RA: 
SLE:
Altered ( ) [40]
Altered ( ) [40,45]
Cytokines
 IL-6 [39] 19 RA vs. 21 HC
[41] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC 
[40] 9 RA, 7 SLE vs. 15 HC
[46] 15 JIA vs. 14 HC
RA: 
SLE: 
JIA: 
No difference  [40,41] 
Altered ( ) [39]
No difference [40] 
Altered ( ) [46]
RA:  
SLE: 
JIA: 
No response [40]
Increase [39]
Decrease (not plasma) [41]
No response [40] 
Increase [46]
RA: 
SLE: 
JIA: 
No difference [39-41]
 
No difference [40] 
Altered ( ) [46]
 IL-2 [40] 9 RA, 7 SLE vs. 15 HC RA:
SLE: 
No difference
No difference
RA:
SLE: 
No response
No response
RA:
SLE: 
No difference
No difference
IL-4 [38] 29 RA vs. 30 HC
[40] 9 RA, 7 SLE vs. 15 HC
RA:   
SLE: 
No difference [38,40] 
No difference [40] 
RA: 
SLE: 
No response [40] 
Increase [40]
RA: 
SLE: 
No difference [40] 
Altered ( ) [40]
IL-8 [46] 15 JIA vs. 14 HC JIA: Altered ( ) JIA: No response JIA: No difference
IL-10 [40] 9 RA, 7 SLE vs. 15 HC RA:
SLE: 
Altered ( ) (not intracell.)
Altered ( ) (not intracell.)
RA
SLE: 
No response
No response
RA: 
SLE:
No difference 
No difference
255
Experimental stress in inflammatory rheumatic diseases
Table 4   Continued
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
Total T cells
(CD3+)
[30] 21 RA vs. 20 HC
[40] 9 RA, 7 SLE vs. 15 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC 
[45]15 SLE vs. 15 HC
RA:  
         
SLE: 
No difference [40] 
Altered ( ) [30] 
Altered ( ) [40,45] 
No difference (%) [43] [44] *
RA: 
SLE:             
Increase [40] 
No response [30]
Increase [40,45]
No response (%) [43,44]
RA: 
SLE: 
         
No difference [30,40] 
No difference [40,43] 
Altered ( ) [45] / (%) [44]
Helper T cells
(CD4+)
[40] 9 RA, 7 SLE vs. 15 HC
[35] 7 RA, 6 SLE vs. 10 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
         
No difference [35,40] 
Altered ( ) [40,45] 
No difference [35] / (%) [43]
Not reported [44]
RA:    
SLE:   
Increase [40] 
Decrease [35]
No response [40,45] / (%) [44]
Decrease [35] / (%) [43] 
RA: 
SLE: 
Altered ( ) [35,40]
  
Altered ( ) [45] (%) [43,44]  / (↑) [35]
No difference [40]
Cytotoxic T cells (CD8+) [40] 9 RA, 7SLE vs. 15 HC
[35] 7 RA, 6 SLE vs. 10 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA: 
SLE: 
No difference [35,40] 
Altered ( ) [40,45] 
No difference [35] / (%) [43]
Not reported [44]      
RA:   
SLE:  
Increase [40]
No response [35]
Increase [40,45] /  (%) [43,44]
Decrease [35]
RA: 
SLE:  
No difference [40]
Altered ( ) [35]
No difference [40,45] [44] *
Altered ( ) [35] / (%) [43] 
B cells (CD19+) [30] 21 RA vs. 20 HC
[43] 14 SLE vs. 14 HC, 12 SD
[44] 14 SLE vs. 14HC, 10HC
RA:  
SLE: 
Altered ( ) [30] 
Altered ( ) (%) [43] 
No difference (%) [44] *
RA:    
SLE:  
Increase [30] 
Increase (%) [43] 
No response (%) [44]
RA: 
SLE: 
No difference [30]
Altered ( ) (%) [43,44] 
NK cells (CD56+) [30] 21 RA vs. 20 HC
[40] 9 RA, 7 SLE vs. 15 HC
[44] 14 SLE vs. 14 HC, 10 HC
[45] 15 SLE vs. 15 HC
RA:  
SLE: 
No difference [40] 
Altered ( ) [30] 
Altered ( ) [40,45] 
Not reported [44]
RA:  
SLE: 
Increase [30,40] 
Increase [40,45]
No response [44]
RA: 
SLE: 
No difference [30,40] 
Altered ( ) [40,45]
No difference [44]
NK cell cytotoxicity [40] 9 RA, 7 SLE vs. 15 HC
[45] 4 SLE vs. 8 HC
RA:
SLE:
No difference [40]
No difference [40,45]
RA: 
SLE:
No response [40]
No response [40,45]
RA: 
SLE:
Altered ( ) [40]
Altered ( ) [40,45]
Cytokines
 IL-6 [39] 19 RA vs. 21 HC
[41] 21 RA vs. 20 HC
[42] 18 RA vs. 14 HC 
[40] 9 RA, 7 SLE vs. 15 HC
[46] 15 JIA vs. 14 HC
RA: 
SLE: 
JIA: 
No difference  [40,41] 
Altered ( ) [39]
No difference [40] 
Altered ( ) [46]
RA:  
SLE: 
JIA: 
No response [40]
Increase [39]
Decrease (not plasma) [41]
No response [40] 
Increase [46]
RA: 
SLE: 
JIA: 
No difference [39-41]
 
No difference [40] 
Altered ( ) [46]
 IL-2 [40] 9 RA, 7 SLE vs. 15 HC RA:
SLE: 
No difference
No difference
RA:
SLE: 
No response
No response
RA:
SLE: 
No difference
No difference
IL-4 [38] 29 RA vs. 30 HC
[40] 9 RA, 7 SLE vs. 15 HC
RA:   
SLE: 
No difference [38,40] 
No difference [40] 
RA: 
SLE: 
No response [40] 
Increase [40]
RA: 
SLE: 
No difference [40] 
Altered ( ) [40]
IL-8 [46] 15 JIA vs. 14 HC JIA: Altered ( ) JIA: No response JIA: No difference
IL-10 [40] 9 RA, 7 SLE vs. 15 HC RA:
SLE: 
Altered ( ) (not intracell.)
Altered ( ) (not intracell.)
RA
SLE: 
No response
No response
RA: 
SLE:
No difference 
No difference
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Self-reported distress
Self-reported distress was increased significantly from baseline by psychosocial stress in 
patients with RA [41] and SLE [45] and in controls. This increase was greater in patients with 
RA [41] than in controls. This was not the case for patients with SLE [45].
ANS variables
The autonomic response to stress was assessed in patients with RA, SLE, JIA and in a 
heterogeneous group of patients with inflammatory arthritis. Results are summarized in 
Table 2. In patients with RA, experimental stress increased autonomic activity (heart rate 
[29,36,37,41], blood pressure [29,37,41], systemic vascular resistance [37], pre-ejection 
period (PEP) [41], plasma volume [36], skin conductance [29], and plasma (nor)epinephrine 
levels [40]), with the increase being similar to that seen in controls in most studies. 
However, three studies reported either diminished [29] or more pronounced [37,41] 
autonomic responses in (a subgroup of) patients. In patients with SLE, experimental stress 
increased autonomic activity (heart rate [45], blood pressure [45], and (nor)epinephrine 
Table 4   Continued
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
IFNγ [38]  29 RA vs. 30 HC
[40]  9 RA, 7 SLE vs. 15 HC
RA:   
SLE: 
        
No difference [38]
Altered ( ) (not intracell.) [40]
Altered ( ) (not intracell.) [40]
RA:
SLE: 
No response [40]
No response [40]
RA: 
SLE: 
Altered ( ) [40]
Altered ( ) [40]
TNFα [39] 19 RA vs. 21 HC
[41] 21 RA vs. 20 HC
RA: No difference [39,41] RA: Increase [39,41] RA: Altered ( ) [39,41]
β-adenoceptors [45] 7 SLE vs. 8 HC SLE: No difference SLE: No response SLE: Altered ( )
β-adrenoceptor sensitivity [45] 7 SLE vs. 8 HC SLE: Altered ( ) Not assessed Not assessed
sIL-2 receptor [42] 18 RA vs. 14 HC RA: Altered ( ) RA: No response RA: No difference
C-reactive protein (CRP) [36] 21 RA vs. 10 OA RA: No difference RA: Increase RA: Altered ( )
* Findings assumed after inspection of descriptive data. 
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern is 
diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
JIA = juvenile idiopathic arthritis, HC= healthy controls, , OA= osteoarthritis, , SD=sarcoidosis patients. IL= interleukin, 
IFNγ= interferon γ, TNFα= tumor necrosis factor  α, sIL-2 receptor=soluble interleukin-2 receptor, intracell. = intra-
cellular interleukin concentration on the single-cell level.
257
Experimental stress in inflammatory rheumatic diseases
levels [40,44,45]), the increase often being similar to that seen in controls [31,33,40,45]. 
Only one study observed a diminished autonomic response (heart rate), but only 
during one specific type of stressor (cold) [31]. The one study involving patients with JIA 
showed experimental stress to increase norepinephrine levels to a similar extent in 
patients and healthy controls [46]. In one study with a heterogeneous group of patients 
with inflammatory arthritis, experimental stress increased autonomic activity (heart rate, 
skin conductance, and pupillary constriction) [32], but this increase was smaller (pupillary 
constriction) or greater (galvanic response) than that of controls. 
 In summary, patients with rheumatic disorders respond to experimental stress with 
increased cardiovascular, galvanic and catecholamine responses. Whereas most autonomic 
responses to stress are similar to those of a control group, there is partial evidence (five 
studies) for altered stress-induced autonomic responses.
Table 4   Continued
Parameter Studies & patients (N) Baseline patient vs. control Stress reactivity within patients Stress reactivity patients vs. controls
IFNγ [38]  29 RA vs. 30 HC
[40]  9 RA, 7 SLE vs. 15 HC
RA:   
SLE: 
        
No difference [38]
Altered ( ) (not intracell.) [40]
Altered ( ) (not intracell.) [40]
RA:
SLE: 
No response [40]
No response [40]
RA: 
SLE: 
Altered ( ) [40]
Altered ( ) [40]
TNFα [39] 19 RA vs. 21 HC
[41] 21 RA vs. 20 HC
RA: No difference [39,41] RA: Increase [39,41] RA: Altered ( ) [39,41]
β-adenoceptors [45] 7 SLE vs. 8 HC SLE: No difference SLE: No response SLE: Altered ( )
β-adrenoceptor sensitivity [45] 7 SLE vs. 8 HC SLE: Altered ( ) Not assessed Not assessed
sIL-2 receptor [42] 18 RA vs. 14 HC RA: Altered ( ) RA: No response RA: No difference
C-reactive protein (CRP) [36] 21 RA vs. 10 OA RA: No difference RA: Increase RA: Altered ( )
* Findings assumed after inspection of descriptive data. 
 = altered response pattern is more pronounced compared to a control group;  = altered response pattern is 
diminished compared to a control group; RA= rheumatoid arthritis, SLE= systemic lupus erythematosus,  
JIA = juvenile idiopathic arthritis, HC= healthy controls, , OA= osteoarthritis, , SD=sarcoidosis patients. IL= interleukin, 
IFNγ= interferon γ, TNFα= tumor necrosis factor  α, sIL-2 receptor=soluble interleukin-2 receptor, intracell. = intra-
cellular interleukin concentration on the single-cell level.
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Neuroendocrine variables
Neuroendocrine reactivity, mainly measured as changes in cortisol levels, was assessed in 
patients with RA and SLE and in controls (see Table 3). Experimental stress elicited both an 
increase [39,41] and (more often) a decrease [34,35,38,42] in cortisol levels in patients with 
RA. ACTH, which is activated upstream of cortisol, increased in response to stress [34,41]. 
In addition to the assessment of HPA axis hormones, one study also reported an increase 
in GH levels in response to a stressor [34]. The neuroendocrine response to stress of 
patients with RA was not significantly different from that of controls in most studies, but 
two studies reported that cortisol responses were diminished in patients with RA compared 
with controls [35,38]. In one study, experimental stress increased prolactin levels in controls 
but not in RA patients [35]. The effect of stress on neuroendocrine function in patients 
with SLE was inconsistent, with stress eliciting a decrease [35] or no change [44] in cortisol 
levels. A lack of responsiveness was also reported in control subjects [35,44]. Experimental 
stress did not increase prolactin levels in patients with SLE [35]. 
 In summary, although cortisol and ACTH levels change in response to experimental 
stress, differences between patients with rheumatic diseases (RA and SLE) and control 
groups have been reported in only two studies. There is preliminary evidence (one study) 
that the prolactin response to stress is different in patients than in controls.
Immune variables
Because several immune variables were used in the various studies to assess the effect of 
experimental stress on immune function, we have classified results on the basis of changes in 
leucocyte and lymphocyte counts and inflammatory markers (see Table 4).
Leucocytes and (subgroups of) lymphocytes In patients with RA, experimental stress 
consistently increased the number of leucocytes [36,40,42], and increased the number of 
lymphocytes [30,40], with increases in the number of B cells [30], total T cells [40] and 
cytotoxic T cells [40] and either an increase [40] or a decrease [35] in helper T cells. The 
stress-induced increase in NK cell numbers [30,40] did not result in an increase in NK cell 
activity [40]. Most studies did not detect a difference in the immune response (leucocyte 
and lymphocyte counts) to stress of patients with RA and controls, but one study reported 
lower lymphocyte counts after stress in patients with RA [42]. Changes compared with 
controls were noted for helper T cells [35,40] and cytotoxic T cells [35]. In patients with SLE, 
stress induced a consistent increase in the number of leucocytes [40,43-45], and a less 
consistent increase in the number of lymphocytes [40,45]. Stress increased the number of 
total T cells [40,45], number [40,45] and percentage [43,44] of cytotoxic T cells, and the 
percentage of B cells [43], and decreased the number of helper T cells [35,43]. Again, 
although NK cell numbers increased after stress [40,45], NK cell activity did not increase 
[40,45]. Comparison showed that the immune response to stress was often smaller in 
patients with SLE than in controls: the increase in total leucocyte counts in patients with 
SLE was smaller than that of controls [40,43,45], as was the increase in total lymphocyte 
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count [43-45]. Moreover, the stress-induced change in subsets of lymphocytes was often 
smaller for B cells [43,44], total T cell numbers [44,45], helper T cells [43-45], cytotoxic T cells 
[35,43], and NK cells [40,45].
 Thus, total leucocyte counts and lymphocyte subsets change in response to stress in 
patients with rheumatic diseases, with patients with SLE having a smaller response (in 
addition to their baseline lymphopenia) than controls; no consistent alterations were 
found for patients with RA. NK cell cytotoxicity is diminished in patients with RA and SLE 
compared with control.
Inflammatory markers In patients with RA, experimental stress did not change levels of 
various inflammatory markers (IL-2, soluble IL-2 receptor, IL-4, IL-10 and IFNγ) [40,42], 
although levels of CRP [36] and TNFα increased after stress [39,41]. Results for IL-6 were 
inconsistent, with stress inducing a decrease [41], an increase [39] or no change [40] in 
levels. Patients differed from controls, having smaller IL-10 and IFNγ responses [40], and 
larger TNFα [39,41] and CRP responses [36]. In patients with SLE, experimental stress did 
not change levels of cytokines and other inflammatory markers (IL-2, IL-6, IL-10, IFNγ, 
 β-adrenoceptors) [40,45], although levels of IL-4 increased after stress [40]. Patients with 
SLE differed from controls in their response to stress, having a larger increase in IL-4, smaller 
IL-10 and IFNγ responses [40], and fewer β-adrenoceptors on monocytes [40,45]. In patients with 
JIA, stress did not affect IL-8 production, but increased IL-6 production [46]. This increase 
was not observed in controls. Thus, although in general experimental stress does not 
seem to influence levels of certain cytokines and inflammatory markers in patients with 
rheumatic diseases (for example, sIL-2, IL-8, IL-10, IFNγ, β-adrenoceptors), it does cause 
specific changes in CRP and TNFα in patients with RA, changes in IL-4 in patients with SLE, 
and changes in IL-6 in patients with JIA. These changes are not observed in controls. 
 In summary, the leucocyte and lymphocyte responses to stress are smaller in patients 
with SLE than in controls but consistent differences with controls are not seen in patients 
with RA. Experimental stress does not seem to affect NK cell cytotoxicity in either patient 
group. However, specific stress-induced changes in inflammatory markers are reported in 
patients with RA (CRP, TNFα), SLE (IL-4) and JIA (IL-6) that are not observed in controls. 
Physiological stress reactivity for specific types of stressors 
As seen above, experimental stress has a distinct effect on the autonomic, neuroendocrine, 
and immune systems. Below, we summarize the effect of the different types of experimental 
stress (cognitive, psychosocial, physical, and sensory), to determine whether different 
types of stress elicit different responses in different patients groups (see Table 5). Studies in 
which more than one type of stressor was used, were not included [38,42] unless outcome 
measures were reported separately for the different types of stressors [31,32].
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Cognitive stressors
Five studies investigated a cognitive stressor in patients with RA, SLE, or inflammatory 
arthritis [29-32,36,37,44]. In all patient groups, cognitive stress consistently increased 
autonomic function: heart rate [29,32,37], blood pressure [29,36,37], skin conductance 
[29,32], cardiac output and systemic vascular resistance [37], plasma volume [36], and 
catecholamines [44]. Patients with RA and SLE had different cortisol responses to cognitive 
stress [30,44] (see Table 5). Cognitive stress elicited changes in leucocyte counts, 
lymphocyte counts, subsets of lymphocytes, and CRP levels in patients with RA [30,36], 
but only changes in leucocyte counts and cytoxic T cell numbers in patients with SLE [44].
Psychosocial stressors
A psychosocial stressor was used in three studies of patients with RA and SLE [40,41,45]. 
Psychosocial stress consistently increased autonomic activity (heart rate [41,45], blood 
pressure [41], pre-ejection period [41] and catecholamine levels [40,45]) in patients with RA 
and SLE and increased neuroendocrine variables (cortisol and ACTH [41]) in patients with 
RA. Some immune responses were similar in the two patient groups (leucocyte counts, 
lymphocyte counts, (cytotoxic) T cells, NK cells and NK cell cytoxicity [40,45]), whereas 
others were different (helper T cells [40], IL-4 [40]) (see Table 5). Cytokine levels were not 
influenced by psychosocial stress, with the exception of an increase in IL-4 in patients with 
SLE, an increase in TNFα in patients with RA, and inconsistent findings for IL-6.
Exercise stressors
The stress of exercise was investigated in two studies with patients with RA and SLE 
[34,35]. These studies did not assess autonomic function; however, cortisol levels 
decreased in both groups of patients [34,35] whereas ACTH levels and GH levels increased 
[34]. Exercise stress elicited a different cytotoxic T cell response in patients with RA and SLE 
[35] (see Table 5).
Sensory stressors
Sensory stressors were used in six studies involving patients with SLE and JIA [31-33,39,43,46]. 
Sensory stress increased catecholamine levels [46] and cortisol levels [39]. It also increased 
leucocyte counts, changed percentages of certain subsets of lymphocytes [43], and 
increased levels of IL-6 [39,46] and TNFα [39] (see Table 5). 
 In summary, although few data are available about the effects of specific types of 
stress, results suggest that psychosocial, cognitive and sensory stress consistently increase 
autonomic activity. Changes in neuroendocrine variables in response to psychosocial, 
cognitive and sensory stressors are observed in patients with RA only. Psychosocial stress 
seems to elicit the strongest immune response in all patient groups studied.
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Discussion
A better understanding of the acute physiological response to stress in patients with 
inflammatory rheumatic diseases might further our knowledge of how stress affects the 
health of these patients. We reviewed the effects of time-limited stressors on autonomic, 
endocrine, and immune variables in patients with chronic inflammatory rheumatic 
diseases. Results suggest that autonomic and neuroendocrine responses to stress are not 
consistently altered in patients with rheumatic disorders compared with controls, although 
patients do appear to show a distinct immune response to stress. Psychosocial stress 
might prove to be the best tool to evaluate these specific immune responses to stress. 
Physiological stress response systems 
ANS
Although previous studies that used regular autonomic function tests showed autonomic 
reactivity to be altered in different populations of patients with rheumatic diseases 
compared with controls [2,47-50], we failed to find consistent evidence for these alterations 
in studies investigating psychological, exercise, or sensory stress. The autonomic function 
of patients with rheumatic disorders was not only similar to that of controls at baseline but 
also after experimental stress, with cardiovascular, galvanic and catecholaminergic 
responses largely comparable to those of controls. Only a minority of studies reported 
autonomic function to be altered in these patients (as compared with controls) 
[29,31,32,37]. Studies have shown that alterations in autonomic function in response to 
stress are correlated with disease severity [36,37,48,51], which suggests that only subgroups 
of patients with severe disease show distinct alterations in autonomic function. Changes 
in autonomic function might also be linked to physical deconditioning, vascular 
inflammation and accelerated atherosclerosis [52], which could explain the inconsisten-
cies in the literature on this subject. It should also be noted that alterations in autonomic 
function might reflect a change in sympathetic or parasympathetic activity or in the 
balance of the two systems [53,54]. Autonomic measures used in experimental stress 
paradigms (for example, the heart rate response) do not always differentiate between 
these systems, in contrast to regular autonomic function tests [55], which specifically aim 
to distinguish between sympathetic dysfunction and parasympathetic neuropathy 
[49,51,56].
HPA axis
The expected increase in neuroendocrine variables in response to a stressor was only 
observed in two studies with patients with RA [39,41]. This increase is consistent with 
previous studies reporting significant and consistent endocrine responses to psychosocial 
stress both in healthy subjects and in various patient populations without rheumatic 
disorders [24,25,41,57-60,60-62]. The change in cortisol levels is consistent with the 
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endocrine response to real-life anticipation stress before hip or knee surgery in patients 
with RA [63,64]. However, most studies evaluated in this review reported a decrease in 
cortisol, levels after stress, both in patients and controls, which might reflect the normal 
diurnal rhythmic decline in cortisol levels instead of a stress response [34,35,38,42]. All 
studies, except the two reporting an increase in cortisol levels, assessed patients in the 
early morning hours, when cortisol levels are known to decrease sharply. 
 Fuelling the ongoing debate on whether or not HPA axis responses are diminished in 
patients with rheumatic disease compared with healthy subjects, we did not find 
consistent changes in HPA axis function in response to psychological and exercise stress 
in patients with rheumatic diseases. Indeed, only two studies showed a different 
neuroendocrine response to stress in patients and controls [35,38]. Previous studies 
involving pharmacological stimulation of the HPA axis reported either similar or slightly 
lower responses in patients with rheumatic diseases compared with controls [27,28]. 
However, results should be interpreted with caution because stress manipulation may 
have been ineffective. Variations across studies in disease duration and activity, age, sex 
and sampling time might contribute to the variability in HPA axis responses in patients 
with rheumatic diseases. Moreover, attention should be paid to the role of pharmacotherapy 
(for example, corticosteroids), which could influence the endocrine response to stress [65].
Immune system
Most studies reported that total leucocyte counts and specific subsets of lymphocytes 
(not total number per se) increased after stress in patients with rheumatic diseases. The 
most consistent finding was an increase in the number of NK cells, as reported in earlier 
studies showing that the most robust effect of acute time-limited stressors in healthy 
subjects is a marked increase in the number of NK cells, which suggest an activation of 
innate immunity [15]. However, NK cell cytotoxicity after stress was lower in patients than 
in controls, possibly due to permanent activation as a consequence of the inflammatory 
disease [40,45]. The change in cytokine levels elicited by stress in patients with rheumatic 
disorders was small or inconsistent, for example, for the most frequently measured 
cytokine IL-6 [40,41,46]. Previous semi-experimental studies with patients with RA reported 
ambiguous results, reporting either significantly increased [63] or decreased levels of IL-6 
[64] during anticipation of planned knee or hip arthroplasty. In addition, in a study 
evaluating responses to cryotherapy, patients with RA not treated with glucocorticoids 
responded with an increase in IL-6 levels [65]. A recent meta-analysis showed IL-6 levels to 
be consistently increased after psychosocial stress in healthy individuals [16]. The 
contradictory findings regarding cytokine responses in patients with rheumatic diseases 
might be due to methodological caveats, such as failed stress manipulation or small 
sample sizes (for example, in Jacobs et al. (2001)). However, it is also possible that cytokines 
do not effectively regulate immune function systemically, but instead near the effector 
site [40]. Future studies involving patients with rheumatic diseases should measure local 
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immune variables in samples obtained from joint tissue or synovial fluid [66,67]. Another 
explanation is that patients or subgroups of patients might have different cytokine 
responses (for example, TNFα) because of differences in disease severity [68] or pharmaco-
therapy [41,65]. In general, as could be expected for immune-mediated diseases, the 
immune response to stress was different in patients and controls, and also differed 
between the various types of inflammatory rheumatic diseases. 
Differences in type of stressor, rheumatic disease and (time points of) 
outcome measures
Findings of this review should be interpreted with caution due to differences in the types 
of stress induced, the various rheumatic diseases evaluated, and the variability in outcome 
measures and assessment times. In addition, the highly variable methodological quality of 
the studies, the small number of studies, and the relatively small patient samples hinder 
an unequivocal interpretation of findings. Future research urgently requires well-designed 
studies with larger numbers of patients. These studies should, for example, systematically 
take into account physiological baseline levels.
Stress paradigms
Only the studies of psychosocial stress evaluated all three physiological stress response 
systems (autonomic, neuroendocrine and immune) and, moreover, consistently reported 
stress-induced increases at all three levels. This is in line with previous studies showing 
significant and consistent autonomic, neuroendocrine, and immune responses to 
psychosocial stress in both healthy subjects and patient groups [25,41,57-60,60-62,69]. In 
contrast, cognitive stressors did not consistently alter neuroendocrine variables, and 
immune responses were small in patients with SLE. The stress of exercise was found not to 
activate the HPA axis in patients with rheumatic diseases, in contrast to what has previously 
been observed in healthy subjects [70], although studies suggest that neuroendocrine 
changes are only observed after exercise of longer duration [71]. Data on immune 
responses were very limited. The studies that assessed sensory stress reported 
stress-induced increases in autonomic, neuroendocrine, and immune function, but data 
were limited. Because most sensory stressors are also frequently applied to induce pain 
[72,73], future studies of stress should take into account whether a stressor is pain-inducing 
in order to unravel the relationship between stressors, pain and physiological responses 
[74]. Overall, more research into the effects of psychosocial stress on physiological function 
is needed, especially because these stress paradigms seem to generate the strongest 
response at all three physiological levels and probably have the greatest ecological 
validity. Importantly, insight in physiological responses to acute stressors cannot 
automatically be translated to the field of daily stressors, major stress events or even 
chronic stressors [5,75]. For example, studies in healthy and other disease populations 
66
Chapter 2
suggest that chronic stress might induce hypocortisolism [6,76] and global immuno-
suppression of both innate and specific immunity [15]. Overall, there is a lack of studies 
examining the association between physiological parameters and chronic stressors in 
rheumatic populations [2]. Studies investigating stressors in daily life reported an association 
between stressors, mainly of an interpersonal nature, and concentrations of cytokines and 
lymphocytes (for example, IL-6, soluble IL-2 receptors and T cell numbers) [77-79]. However, 
results are inconclusive [80] and future studies are needed to elucidate how acute and 
chronic stressors differentially affect inflammatory rheumatic diseases.
Disease and treatment characteristics
In contrast to autonomic and neuroendocrine responses, the immune response elicited 
seemed to be specific to the type of inflammatory rheumatic disorder involved, and this 
was especially evident for psychosocial stress. Patients with SLE often have baseline 
lymphopenia and this review showed that stress led to diminished cell mobilization and 
consequently less pronounced stress-induced changes in lymphocyte (sub)populations 
in these patients compared with controls and patients with RA. In contrast, patients with 
RA did not consistently show these alterations, but only alterations in certain subpopulations 
of lymphocytes. Furthermore, the cytokine response to stress might be distinct for 
different rheumatic populations. The effect of pharmacotherapy (for example, cortico-
steroids and biologics) on neuroendocrine and immune responses to stress in these 
populations is unclear. Only two of 16 studies conducted subgroup analyses to reveal 
possible effects of pharmacotherapy on response patterns. Motivala et al. (2008) found 
significant stress-induced increases in TNFα only in patients with RA not treated with TNFα 
antagonists (and no effect of corticosteroid treatment), and Pawlak et al. (1999) reported 
no significant difference in physiological variables between patients with SLE treated 
with corticosteroids and/or disease-modifying anti-rheumatic drugs (DMARDs) and non- 
treated patients [45]. Four other studies also suggest no effect of pharmacotherapy (more 
specifically, DMARDs [38], nonsteroidal anti-inflammatory drugs (NSAIDs) [34,38], and 
 corticosteroids [34,43,44]) on stress reactivity patterns based on descriptive data. The other 
studies do not mention possible effects of pharmacotherapy [29-33,35-37,39,40,42,46]. 
 Clearly, patient samples are often too small to draw conclusions. More studies comparing 
different inflammatory diseases and healthy participant are needed to address the question 
whether the physiological response to stress is disease-specific, knowledge which might 
facilitate our understanding of factors contributing to the maintenance and exacerbation 
of rheumatic disorders.
Outcome measures
The heterogeneity of outcome measures, especially with regard to immune variables, 
makes it difficult to compare studies of the stress response. Moreover, stressors that activate 
the physiological stress system via the hypothalamus and subsequent down- stream cascades 
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might induce alterations in hormones, peptides and cytokines other than discussed and 
assessed in this review (for examples, dehydroepiandosterone (sulfate) (DHEA-S), neuro - 
peptide Y (NPY), substance P). Previous studies suggest that alterations in the stress 
response in patients with rheumatic disorders might be located in the interaction between 
the two stress axes (HPA and ANS) and the immune system, more specifically in the 
number or signaling capacity of β-adrenoceptors [45,48,66,81] or glucocorticoid receptors 
[82-84] on lymphocytes. 
 Although the HPA axis, ANS, and immune system are thought to function in an 
interdependent fashion, only four of 16 studies in this review investigated outcome variables 
that evaluate all three stress response systems. Cardiovascular reactivity during a mental 
stress task has been shown to be associated with the subsequent cortisol response [25], 
and cardiovascular responses have been associated with post stress levels of cytokines 
such as IL-6 and TNFα [85]. In addition, HPA axis variables are correlated with immune 
responses after stress [53]. Future studies should try to integrate the responses of different 
systems by simultaneously assessing (para)sympathetic responses, neuroendocrine variables, 
and immune factors, to increase our knowledge of the coordination and possible dysregulation 
of these systems [59]. 
Psychological variables
In addition to assessing the physiological response to experimental real-life stressors, it is 
important to consider other key elements of the stress response, such as the individual’s 
appraisal of the threat of the event, perceived distress, coping behavior and personality 
characteristics [4]. As the appraisal of threat might partly determine the biological stress 
response of an individual, self-reported measures of distress appear to be a simple and 
adequate manipulation check in studies of psychosocial stress. Furthermore, acute stress 
responses are known to be correlated with individual differences in psychological factors, 
such as coping styles [86], trait anxiety [87,88], depressed mood [59,89,90], perfectionism 
[91], social inhibition [92] and anticipatory cognitive appraisal [93-96]. However, none of 
the studies, except one [74], assessed individual psychological characteristics. In addition, 
only two studies in this review assessed stress-induced self-reported distress [41,42] and 
only three studies [36,37,39,41] explicitly excluded affective disorders. Although half of all 
studies excluded patients with (severe or chronic) comorbidity, these were mainly physical 
in nature. We cannot rule out the possibility that patients with psychiatric disorders are 
included in these studies, obscuring the major research question whether inflammatory 
rheumatic diseases are related to a specific physiological stress responses profile. Future 
studies of stress responses in patients with rheumatic diseases should include individual 
psychological characteristics (for example, personality, coping styles) and affective responses 
to help identify whether patients differ with regard to psychophysiological responses to 
stress.
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Time points
Some consideration should be given to when outcomes are measured. Almost all the 
studies included at least one immediate post stress measurement, but only half of the 
studies included an additional measurement (mostly 30 or 60 minutes after cessation of 
the stressor), with only two studies including more than two follow-up measurements. 
Cytokine responses may be delayed for minutes or hours relative to ANS and HPA 
responses, because cytokines are produced by activated lymphocytes and macrophages 
[97-99]. This makes it difficult to detect the peak immune response when collecting only 
one or two samples, for example for the increase in IL-6 and IL-1 receptor agonists following 
psychosocial stress [85]. 
 Additionally, in accordance with the allostatic load concept [100] the ability and time 
taken by the activated stress system to return to baseline (recovery period) might be an 
important factor in the link between stress and disease [99,101-103]. Moreover, repeated 
mental stress has been linked to a lack of habituation of the cortisol response [89,104] 
and plasma interleukin-6 [99] in subgroups of individuals. Thus future studies should 
have more frequent evaluation time points and investigate individual differences in the 
return- to-baseline values and in habituation patterns after repeated stress.
Conclusions
In summary, this review shows that there is limited evidence that autonomic and 
neuroendocrine function is altered after physical or psychological stress in patients with 
inflammatory rheumatic diseases compared with healthy subjects. In contrast, there is 
evidence that immune function is altered by stress in a manner specific to different 
rheumatic diseases, and thus real-life stressors could contribute to the maintenance or 
exacerbation of rheumatic diseases.
 Future studies of stress, and particularly psychosocial stress, should have a follow-up 
with multiple measurement points, assess different physiological stress systems, and take 
into account stress appraisal. As individual differences in stress appraisal and stress 
response patterns might be important prognostic factors for disease progression, 
therapies that focus on stress management may be important adjuncts to traditional 
pharmacotherapy in the treatment of inflammatory rheumatic diseases. Stress induction 
studies could prove to be helpful for evaluating the effectiveness of these interventions 
[105,106].
269
Experimental stress in inflammatory rheumatic diseases
References
1. Cutolo M, Straub RH: Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodula-
tion 2006, 13:277-282.
2. Geenen R, Van Middendorp H, Bijlsma JW: The impact of stressors on health status and hypothalamic-pitu-
itary-adrenal axis and autonomic nervous system responsiveness in rheumatoid arthritis. Ann N Y Acad Sci 
2006, 1069:77-97.
3. Straub RH, Dhabhar FS, Bijlsma JW, Cutolo M: How psychological stress via hormones and nerve fibers may 
exacerbate rheumatoid arthritis. Arthritis Rheum 2005, 52:16-26.
4. Walker JG, Littlejohn GO, McMurray NE, Cutolo M: Stress system response and rheumatoid arthritis: a multilevel 
approach. Rheumatology (Oxford) 1999, 38:1050-1057.
5. Zautra AJ, Hamilton NA, Potter P, Smith B: Field research on the relationship between stress and disease 
activity in rheumatoid arthritis. Ann N Y Acad Sci 1999, 876:397-412.
6. Miller GE, Chen E, Zhou ES: If it goes up, must it come down? Chronic stress and the hypothalamic-pitu-
itary-adrenocortical axis in humans. Psychol Bull 2007, 133:25-45.
7. Ader R, Cohen N, Felten D: Psychoneuroimmunology: interactions between the nervous system and the 
immune system. Lancet 1995, 345:99-103.
8. Anisman H, Merali Z: Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003, 35:2-11.
9. Eskandari F, Webster JI, Sternberg EM: Neural immune pathways and their connection to inflammatory 
diseases. Arthritis Res Ther 2003, 5:251-265.
10. Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral 
nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum 
2001, 44:493-507.
11. Calcagni E, Elenkov I: Stress system activity, innate and T helper cytokines, and susceptibility to immune-related 
diseases. Ann N Y Acad Sci 2006, 1069:62-76.
12. Harbuz M: Neuroendocrine function and chronic inflammatory stress. Exp Physiol 2002, 87:519-525.
13. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R: Psychoneuroimmunology and psychosomatic medicine: 
back to the future. Psychosom Med 2002, 64:15-28.
14. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R: Psychoneuroimmunology: psychological influences on 
immune function and health. J Consult Clin Psychol 2002, 70:537-547.
15. Segerstrom SC, Miller GE: Psychological stress and the human immune system: a meta-analytic study of 30 
years of inquiry. Psychol Bull 2004, 130:601-630.
16. Steptoe A, Hamer M, Chida Y: The effects of acute psychological stress on circulating inflammatory factors in 
humans: a review and meta-analysis. Brain Behav Immun 2007, 21:901-912.
17. Steptoe A: Psychophysiological Bases of Disease. In Comprehensive Clinical Psychology. Health Psychology 
Volume 8. Edited by: Johnston DW, Johnston M. Oxford: Pergamon Press; 1998:39-78.
18. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve- an integrative interface between two 
supersystems: the brain and the immune system. Pharmacol Rev 2000, 52:595-638.
19. Maier SF, Watkins LR: Cytokines for psychologists: implications of bidirectional immune-to-brain 
communication for understanding behavior, mood, and cognition. Psychol Rev 1998, 105:83-107.
20. McEwen BS: Protective and damaging effects of stress mediators. N Engl J Med 1998, 338:171-179.
21. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 
1995, 332:1351-1362.
22. Zautra AJ: Comment on “stress-vulnerability factors as long-term predictors of disease activity in early 
rheumatoid arthritis”. J Psychosom Res 2003, 55:303-304.
23. Kamarck TW, Lovallo WR: Cardiovascular reactivity to psychological challenge: conceptual and measurement 
considerations. Psychosom Med 2003, 65:9-21.
24. Dickerson SS, Kemeny ME: Acute stressors and cortisol responses: a theoretical integration and synthesis of 
laboratory research. Psychol Bull 2004, 130:355-391.
25. Kunz-Ebrecht SR, Mohamed-Ali V, Feldman PJ, Kirschbaum C, Steptoe A: Cortisol responses to mild 
psychological stress are inversely associated with proinflammatory cytokines. Brain Behav Immun 2003, 
17:373-383.
70
Chapter 2
26. Straub RH, Baerwald CG, Wahle M, Janig W: Autonomic dysfunction in rheumatic diseases. Rheum Dis Clin 
North Am 2005, 31:61-75. viii
27. Harbuz MS, Jessop DS: Is there a defect in cortisol production in rheumatoid arthritis? Rheumatology (Oxford) 
1999, 38:298-302.
28. Jessop DS, Harbuz MS: A defect in cortisol production in rheumatoid arthritis: why are we still looking? 
Rheumatology (Oxford) 2005, 44:1097-1100.
29. Geenen R, Godaert GL, Jacobs JW, Peters ML, Bijlsma JW: Diminished autonomic nervous system 
responsiveness in rheumatoid arthritis of recent onset. J Rheumatol 1996, 23:258-264.
30. Geenen R, Godaert GL, Heijnen CJ, Vianen ME, Wenting MJ, Nederhoff MG, Bijlsma JW: Experimentally induced 
stress in rheumatoid arthritis of recent onset: effects on peripheral blood lymphocytes. Clin Exp Rheumatol 
1998, 16:553-559.
31. Hogarth MB, Judd L, Mathias CJ, Ritchie J, Stephens D, Rees RG: Cardiovascular autonomic function in systemic 
lupus erythematosus. Lupus 2002, 11:308-312.
32. Perry F, Heller PH, Kamiya J, Levine JD: Altered autonomic function in patients with arthritis or with chronic 
myofascial pain. Pain 1989, 39:77-84.
33. Shalimar , Handa R, Deepak KK, Bhatia M, Aggarwal P, Pandey RM: Autonomic dysfunction in systemic lupus 
erythematosus. Rheumatol Int 2006, 26:837-840.
34. Kurtais Y, Tur BS, Elhan AH, Erdogan MF, Yalcin P: Hypothalamic-pituitary-adrenal hormonal responses to 
exercise stress test in patients with rheumatoid arthritis compared to healthy controls. J Rheumatol 2006, 
33:1530-1537.
35. Pool AJ, Whipp BJ, Skasick AJ, Alavi A, Bland JM, Axford JS: Serum cortisol reduction and abnormal prolactin 
and CD4+/CD8+ T-cell response as a result of controlled exercise in patients with rheumatoid arthritis and 
systemic lupus erythematosus despite unaltered muscle energetics. Rheumatology (Oxford) 2004, 43:43-48.
36. Veldhuijzen van Zanten JJ, Ring C, Carroll D, Kitas GD: Increased C reactive protein in response to acute stress 
in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:1299-1304.
37. Veldhuijzen van Zanten JJ, Kitas GD, Carroll D, Ring C: Increase in systemic vascular resistance during acute 
mental stress in patients with rheumatoid arthritis with high-grade systemic inflammation. Biol Psychol 2008, 
77:106-110.
38. Dekkers JC, Geenen R, Godaert GL, Glaudemans KA, Lafeber FP, van Doornen LJ, Bijlsma JW: Experimentally 
challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed 
rheumatoid arthritis. J Rheumatol 2001, 28:1496-1504.
39. Edwards RR, Wasan AD, Bingham CO III, Bathon J, Haythornthwaite JA, Smith MT, Page GG: Enhanced reactivity 
to pain in patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11:R61.
40. Jacobs R, Pawlak CR, Mikeska E, Meyer-Olson D, Martin M, Heijnen CJ, Schedlowski M, Schmidt RE: Systemic 
lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern 
after stress exposure. Rheumatology (Oxford) 2001, 40:868-875.
41. Motivala SJ, Khanna D, FitzGerald J, Irwin MR: Stress activation of cellular markers of inflammation in 
rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists. Arthritis Rheum 2008, 
58:376-383.
42. Palm S, Hinrichsen H, Barth J, Halabi A, Ferstl R, Tolk J, Kirsten R, Kirch W: Modulation of lymphocyte subsets 
due to psychological stress in patients with rheumatoid arthritis. Eur J Clin Invest 1992, 22(Suppl 1):26-29.
43. Hinrichsen H, Barth J, Ferstl R, Kirch W: Changes of immunoregulatory cells induced by acoustic stress in patients 
with systemic lupus erythematosus, sarcoidosis, and in healthy controls. Eur J Clin Invest 1989, 19:372-377.
44. Hinrichsen H, Barth J, Ruckemann M, Ferstl R, Kirch W: Influence of prolonged neuropsychological testing on 
immunoregulatory cells and hormonal parameters in patients with systemic lupus erythematosus. Rheumatol 
Int 1992, 12:47-51.
45. Pawlak CR, Jacobs R, Mikeska E, Ochsmann S, Lombardi MS, Kavelaars A, Heijnen CJ, Schmidt RE, Schedlowski 
M: Patients with systemic lupus erythematosus differ from healthy controls in their immunological response 
to acute psychological stress. Brain Behav Immun 1999, 13:287-302.
46. Roupe van der Voort C, Heijnen CJ, Wulffraat N, Kuis W, Kavelaars A: Stress induces increases in IL-6 production 
by leucocytes of patients with the chronic inflammatory disease juvenile rheumatoid arthritis: a putative role 
for alpha(1)-adrenergic receptors. J Neuroimmunol 2000, 110:223-229.
271
Experimental stress in inflammatory rheumatic diseases
47. Altomonte L, Mirone L, Zoli A, Magaro M: Autonomic nerve dysfunction in systemic lupus erythematosus: 
evidence for a mild involvement. Lupus 1997, 6:441-444.
48. Kuis W, de Jong-de Vos van Steenwijk C, Sinnema G, Kavelaars A, Prakken B, Helders PJ, Heijnen CJ: The autonomic 
nervous system and the immune system in juvenile rheumatoid arthritis. Brain Behav Immun 1996, 10:387-398.
49. Stojanovich L, Milovanovich B, de Luka SR, Popovich-Kuzmanovich D, Bisenich V, Djukanovich B, Randjelovich 
T, Krotin M: Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjogren 
syndrome and other autoimmune diseases. Lupus 2007, 16:181-185.
50. Toussirot E, Bahjaoui-Bouhaddi M, Poncet JC, Cappelle S, Henriet MT, Wendling D, Regnard J: Abnormal 
autonomic cardiovascular control in ankylosing spondylitis. Ann Rheum Dis 1999, 58:481-487.
51. Leden I, Eriksson A, Lilja B, Sturfelt G, Sundkvist G: Autonomic nerve function in rheumatoid arthritis of varying 
severity. Scand J Rheumatol 1983, 12:166-170.
52. Piha SJ, Voipio-Pulkki LM: Elevated resting heart rate in rheumatoid arthritis: possible role of physical 
deconditioning. Br J Rheumatol 1993, 32:212-215.
53. Cacioppo JT, Berntson GG, Malarkey WB, Kiecolt-Glaser JK, Sheridan JF, Poehlmann KM, Burleson MH, Ernst JM, 
Hawkley LC, Glaser R: Autonomic, neuroendocrine, and immune responses to psychological stress: the 
reactivity hypothesis. Ann N Y Acad Sci 1998, 840:664-673.
54. Cai FZ, Lester S, Lu T, Keen H, Boundy K, Proudman SM, Tonkin A, Rischmueller M: Mild autonomic dysfunction 
in primary Sjogren’s syndrome: a controlled study. Arthritis Res Ther 2008, 10:R31.
55. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 
1982, 285:916-918. 
56. Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W: Cardiovascular autonomic nervous system 
dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM 1999, 92:97-102.
57. Kirschbaum C, Pirke KM, Hellhammer DH: The ‘Trier Social Stress Test’- a tool for investigating psychobiological 
stress responses in a laboratory setting. Neuropsychobiology 1993, 28:76-81.
58. Buske-Kirschbaum A, Geiben A, Hollig H, Morschhauser E, Hellhammer D: Altered responsiveness of the hypo-
thalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic 
dermatitis. J Clin Endocrinol Metab 2002, 87:4245-4251.
59. Schommer NC, Hellhammer DH, Kirschbaum C: Dissociation between reactivity of the hypothalamus-pitu-
itary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress. Psychosom 
Med 2003, 65:450-460.
60. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH: Impact of gender, menstrual cycle phase, 
and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom Med 1999, 
61:154-162.
61. Kudielka BM, Schommer NC, Hellhammer DH, Kirschbaum C: Acute HPA axis responses, heart rate, and mood 
changes to psychosocial stress (TSST) in humans at different times of day. Psychoneuroendocrinology 2004, 
29:983-992.
62. Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C: HPA axis responses to laboratory 
psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psycho-
neuroendocrinology 2004, 29:83-98.
63. Hirano D, Nagashima M, Ogawa R, Yoshino S: Serum levels of interleukin 6 and stress related substances 
indicate mental stress condition in patients with rheumatoid arthritis. J Rheumatol 2001, 28:490-495.
64. Tanno M, Nakajima A, Ishiwata T, Naito Z, Yoshino S: Effect of general anesthesia on the abnormal immune 
response in patients with rheumatoid arthritis. Clin Exp Rheumatol 2004, 22:727-732.
65. Straub RH, Pongratz G, Hirvonen H, Pohjolainen T, Mikkelsson M, Leirisalo- Repo M: Acute cold stress in 
rheumatoid arthritis inadequately activates stress responses and induces an increase of interleukin 6. Ann 
Rheum Dis 2009, 68:572-578.
66. Baerwald CG, Laufenberg M, Specht T, von Wichert P, Burmester GR, Krause A: Impaired sympathetic influence 
on the immune response in patients with rheumatoid arthritis due to lymphocyte subset-specific modulation 
of beta 2-adrenergic receptors. Br J Rheumatol 1997, 36:1262-1269.
67. Miller LE, Justen HP, Scholmerich J, Straub RH: The loss of sympathetic nerve fibers in the synovial tissue of 
patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial 
macrophages. FASEB J 2000, 14:2097-2107.
72
Chapter 2
68. Ishii H, Nagashima M, Tanno M, Nakajima A, Yoshino S: Does being easily moved to tears as a response to 
psychological stress reflect response to treatment and the general prognosis in patients with rheumatoid 
arthritis? Clin Exp Rheumatol 2003, 21:611-616.
69. Schmid-Ott G, Jacobs R, Jager B, Klages S, Wolf J, Werfel T, Kapp A, Schurmeyer T, Lamprecht F, Schmidt RE, 
Schedlowski M: Stress-induced endocrine and immunological changes in psoriasis patients and healthy 
controls. A preliminary study. Psychother Psychosom 1998, 67:37-42.
70. Kraemer WJ, Ratamess NA: Hormonal responses and adaptations to resistance exercise and training. Sports 
Med 2005, 35:339-361.
71. Pedersen BK, Hoffman-Goetz L: Exercise and the immune system: regulation, integration, and adaptation. 
Physiol Rev 2000, 80:1055-1081.
72. Backonja MM, Walk D, Edwards RR, Sehgal N, Moeller-Bertram T, Wasan A, Irving G, Argoff C, Wallace M: 
Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory 
abnormalities. Clin J Pain 2009, 25:641-647.
73. Edwards RR, Sarlani E, Wesselmann U, Fillingim RB: Quantitative assessment of experimental pain perception: 
multiple domains of clinical relevance. Pain 2005, 114:315-319.
74. Edwards RR, Kronfli T, Haythornthwaite JA, Smith MT, McGuire L, Page GG: Association of catastrophizing with 
interleukin-6 responses to acute pain. Pain 2008, 140:135-144.
75. Zautra AJ, Okun MA, Robinson SE, Lee D, Roth SH, Emmanual J: Life stress and lymphocyte alterations among 
patients with rheumatoid arthritis. Health Psychol 1989, 8:1-14.
76. Heim C, Ehlert U, Hellhammer DH: The potential role of hypocortisolism in the pathophysiology of 
stress-related bodily disorders. Psychoneuroendocrinology 2000, 25:1-35.
77. Harrington L, Affleck G, Urrows S, Tennen H, Higgins P, Zautra A, Hoffman S: Temporal covariation of soluble 
interleukin-2 receptor levels, daily stress, and disease activity in rheumatoid arthritis. Arthritis Rheum 1993, 
36:199-203.
78. Zautra AJ, Burleson MH, Matt KS, Roth S, Burrows L: Interpersonal stress, depression, and disease activity in 
rheumatoid arthritis and osteoarthritis patients. Health Psychol 1994, 13:139-148.
79. Zautra AJ, Hoffman JM, Matt KS, Yocum D, Potter PT, Castro WL, Roth S: An examination of individual 
differences in the relationship between interpersonal stress and disease activity among women with 
rheumatoid arthritis. Arthritis Care Res 1998, 11:271-279.
80. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR: Chronic stress and regulation of cellular markers 
of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 2008, 22:24-32.
81. Kavelaars A, de Jong-de Vos van Steenwijk T, Kuis W, Heijnen CJ: The reactivity of the cardiovascular system 
and immunomodulation by catecholamines in juvenile chronic arthritis. Ann N Y Acad Sci 1998, 840:698-704.
82. Eggert M, Kluter A, Rusch D, Schmidt KL, Dotzlaw H, Schulz M, Pabst W, Boke J, Renkawitz R, Neeck G: 
Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from 
patients with rheumatoid arthritis. J Rheumatol 2002, 29:2500-2506.
83. Neeck G, Kluter A, Dotzlaw H, Eggert M: Involvement of the glucocorticoid receptor in the pathogenesis of 
rheumatoid arthritis. Ann N Y Acad Sci 2002, 966:491-495.
84. Schlaghecke R, Kornely E, Wollenhaupt J, Specker C: Glucocorticoid receptors in rheumatoid arthritis. Arthritis 
Rheum 1992, 35:740-744.
85. Steptoe A, Willemsen G, Owen N, Flower L, Mohamed-Ali V: Acute mental stress elicits delayed increases in 
circulating inflammatory cytokine levels. Clin Sci (Lond) 2001, 101:185-192.
86. Bohnen N, Nicolson N, Sulon J, Jolles J: Coping style, trait anxiety and cortisol reactivity during mental stress. J 
Psychosom Res 1991, 35:141-147.
87. Hubert W, de Jong-Meyer R: Saliva cortisol responses to unpleasant film stimuli differ between high and low 
trait anxious subjects. Neuropsychobiology 1992, 25:115-120.
88. Schlotz W, Schulz P, Hellhammer J, Stone AA, Hellhammer DH: Trait anxiety moderates the impact of 
performance pressure on salivary cortisol in everyday life. Psychoneuroendocrinology 2006, 31:459-472.
89. Kirschbaum C, Prussner JC, Stone AA, Federenko I, Gaab J, Lintz D, Schommer N, Hellhammer DH: Persistent 
high cortisol responses to repeated psychological stress in a subpopulation of healthy men. Psychosom Med 
1995, 57:468-474.
273
Experimental stress in inflammatory rheumatic diseases
90. Pruessner JC, Gaab J, Hellhammer DH, Lintz D, Schommer N, Kirschbaum C: Increasing correlations between 
personality traits and cortisol stress responses obtained by data aggregation. Psychoneuroendocrinology 
1997, 22:615-625.
91. Wirtz PH, Elsenbruch S, Emini L, Rudisuli K, Groessbauer S, Ehlert U: Perfectionism and the cortisol response to 
psychosocial stress in men. Psychosom Med 2007, 69:249-255.
92. Habra ME, Linden W, Anderson JC, Weinberg J: Type D personality is related to cardiovascular and 
neuroendocrine reactivity to acute stress. J Psychosom Res 2003, 55:235-245.
93. Gaab J, Rohleder N, Nater UM, Ehlert U: Psychological determinants of the cortisol stress response: the role of 
anticipatory cognitive appraisal. Psychoneuroendocrinology 2005, 30:599-610.
94. Rohrmann S, Hennig J, Netter P: Changing psychobiological stress reactions by manipulating cognitive 
processes. Int J Psychophysiol 1999, 33:149-161.
95. Wirtz PH, Ehlert U, Emini L, Rudisuli K, Groessbauer S, Gaab J, Elsenbruch S, von Känel R: Anticipatory cognitive 
stress appraisal and the acute procoagulant stress response in men. Psychosom Med 2006, 68:851-858.
96. Wirtz PH, von Känel R, Emini L, Suter T, Fontana A, Ehlert U: Variations in anticipatory cognitive stress appraisal 
and differential proinflammatory cytokine expression in response to acute stress. Brain Behav Immun 2007, 
21:851-859.
97. Febbraio MA, Ott P, Nielsen HB, Steensberg A, Keller C, Krustrup P, Secher NH, Pedersen BK: Hepatosplanchnic 
clearance of interleukin-6 in humans during exercise. Am J Physiol Endocrinol Metab 2003, 285:E397-E402.
98. Febbraio MA, Pedersen BK: Muscle-derived interleukin-6: mechanisms for activation and possible biological 
roles. FASEB J 2002, 16:1335-1347. 
99. von Känel R, Kudielka BM, Preckel D, Hanebuth D, Fischer JE: Delayed response and lack of habituation in 
plasma interleukin-6 to acute mental stress in men. Brain Behav Immun 2006, 20:40-48.
100. McEwen BS: Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharma-
cology 2000, 22:108-124.
101. Earle TL, Linden W, Weinberg J: Differential effects of harassment on cardiovascular and salivary cortisol stress 
reactivity and recovery in women and men. J Psychosom Res 1999, 46:125-141.
102. Gerin W, Pickering TG: Association between delayed recovery of blood pressure after acute mental stress and 
parental history of hypertension. J Hypertens 1995, 13:603-610. 
103. Linden W, Earle TL, Gerin W, Christenfeld N: Physiological stress reactivity and recovery: conceptual siblings 
separated at birth? J Psychosom Res 1997, 42:117-135.
104. Kudielka BM, von Känel R, Preckel D, Zgraggen L, Mischler K, Fischer JE: Exhaustion is associated with reduced 
habituation of free cortisol responses to repeated acute psychosocial stress. Biol Psychol 2006, 72:147-153.
105. Gaab J, Blattler N, Menzi T, Pabst B, Stoyer S, Ehlert U: Randomized controlled evaluation of the effects of cog-
nitive-behavioral stress management on cortisol responses to acute stress in healthy subjects. Psychoneuro-
endocrinology 2003, 28:767-779.
106. Hammerfald K, Eberle C, Grau M, Kinsperger A, Zimmermann A, Ehlert U, Gaab J: Persistent effects of cogni-
tive-behavioral stress management on cortisol responses to acute stress in healthy subjects--a randomized 
controlled trial. Psychoneuroendocrinology 2006, 31:333-339.

Published as: De Brouwer SJM, van Middendorp H, Stormink C, Kraaimaat, FW, Sweep FCGJ, 
de Jong EMGJ, Schalkwijk J, Eijsbouts A, Donders ART, van de Kerkhof PCM, van Riel PLCM, Evers AWM. 
The psychophysiological stress response in psoriasis and rheumatoid arthritis. 
British Journal of Dermatology 2013; doi:10.1111/bjd.12697.
Chapter 3
The psychophysiological stress response 
in psoriasis and rheumatoid arthritis
76
Chapter 3
Abstract
Background Psychosocial stress can be a risk factor for the maintenance and exacerbation 
of chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis (RA).
Objectives To gain insight into the specificity of the psychophysiological stress response 
during chronic inflammation, we assessed autonomic and neuroendocrine responses to 
stress in different chronic inflammatory diseases.
Methods Thirty patients with psoriasis (nine women, mean age 58.5 years ± 12.4), 34 
patients with RA (16 women, mean age 60.8 years ± 9.2) and 25 healthy controls (16 
women, mean age 55.6 years ± 8.7) underwent a standardized psychosocial stress task 
(Trier Social Stress Test). Salivary levels of α-amylase and cortisol and self-reported tension 
levels were measured before and after the stress test.
Results The cortisol response to stress was heightened in patients with psoriasis compared 
with patients with RA and healthy controls, whereas there were no differences in the 
autonomic and self-reported measures. 
Conclusions The altered neuroendocrine stress response in patients with psoriasis suggests 
that stressful events might have different physiological consequences for specific patient 
groups with chronic inflammatory conditions, possibly adversely affecting disease status.
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Introduction
Psychosocial stress can be a risk factor for the maintenance and exacerbation of chronic 
inflammation in, for example, patients with psoriasis and rheumatoid arthritis (RA) [1–8]. 
The stress response system, mainly comprising the autonomic nervous system (ANS) and 
the hypothalamus–pituitary–adrenal axis (HPA axis), is activated by stress and induces the 
secretion of (nor)adrenaline and cortisol. Both stress axes interact with the immune system 
[9,10] and are able to influence skin and joint inflammation in patients with psoriasis and 
RA, respectively [11–17]. For example, cortisol activates cutaneous and synovial mast cells, 
which are rich in the proinflammatory cytokines tumor necrosis factor-α and interleukin-6, 
and which might exacerbate disease severity [18,19].
 Moreover, chronic inflammation may compromise the flexibility of the branches of 
the stress response system [20–23], possibly with clinical consequences. With regard to 
autonomic function, patients with psoriasis have fewer ß-adrenoceptors on keratinocytes 
in skin lesions than in normal skin, risking insufficient down regulation of immune and 
inflammatory processes [23]. In addition, the decreased sympathetic (sudomotor) activity 
in patients with psoriasis reduces perspiration and increases skin dryness, which may 
evoke itch and aggravate disease activity [22]. In parallel, patients with RA show a 
functional loss of sympathetic nerve fibres in inflamed synovial tissue and a decrease in 
ß-adrenergic receptors on synovial fluid lymphocytes [24,25]. With regard to 
neuroendocrine function, blunted cortisol suppression after dexamethasone 
administration in patients with psoriasis suggests that the negative feedback action of 
corticosteroids could be attenuated in psoriasis [26]. In RA, subtle alterations in cortisol 
secretion may occur during the diurnal rhythm or in certain disease stages [27]. 
 Studies with real-life experimental stressors might shed light on the extent to which 
stress triggers the ANS and HPA axis in patients with different chronic inflammatory 
diseases, such as psoriasis and RA, and whether autonomic and neuroendocrine function 
is systemically altered in these patients. So far, results have been inconclusive. Although 
some experimental studies have reported changes in autonomic [28–31] and cortisol [30] 
responses to psychological stress in patients with psoriasis, these changes were not 
observed in all autonomic parameters [28,31–34] nor was cortisol reactivity always altered 
[28,29,32,34,35]. Likewise, some studies have shown patients with RA to have altered basal 
or stress-induced autonomic or neuroendocrine function [20,27,36–41], but not all [41].
 In order to gain insight into possible disease-specific changes in HPA axis and ANS 
function during chronic inflammation, we investigated whether the response to experimental 
real-life stress was associated with alterations in autonomic and neuroendocrine reactivity 
in patients with the chronic inflammatory diseases psoriasis and RA. To this end, we 
assessed tension levels and measured α-amylase and cortisol levels in response to an 
acute psychosocial stress task in patients with psoriasis and RA and in healthy subjects.
78
Chapter 3
Materials and methods
Participants
Patients with psoriasis and RA were recruited from the Departments of Dermatology and 
Rheumatology at the Radboud University Medical Center and the Sint Maartens kliniek in 
Nijmegen, The Netherlands. Healthy participants were recruited through a local newspaper 
announcement and on the website of the Radboud University Medical Center. Patients with 
RA were receiving regular care and were in the control group of a trial, the data of which 
have been described elsewhere [42]. Patient inclusion criteria were a diagnosis of psoriasis 
[43] or RA [44], respectively, and a minimum age of 18 years. Exclusion criteria were: severe 
physical comorbidity (e.g. major cardiac problems, psoriatic arthritis, malignancies, severe 
respiratory or renal insufficiency, hepatitis B, HIV and insulin- dependent diabetes mellitus); 
severe psychiatric disturbances that might interfere with the study protocol; pregnancy; 
illiteracy; use of antidepressants, anxiolytics or anti psychotics. The study protocol was 
approved by the regional medical ethics committee and conducted according to the 
Helsinki principles. Written informed consent was obtained from all participants.
Procedure
Stress test sessions were run between 13.00 and 15.30 h at the Radboud University Medical 
Center. All participants were asked to refrain from using caffeine, alcohol, nicotine or 
physical exercise on the test day, and from eating 2 h before the first saliva sample was 
taken. Psychophysiological parameters (tension and saliva) were measured at baseline 
(i.e. after 20 min of rest; t = 0 min), immediately after the stress test (t = 20 min) and 10, 20, 
40 and 60 min after the test (t = 30, 40, 60 and 80 min). During periods of rest participants 
looked at a natural history documentary.
Stress test
The Trier Social Stress Test (TSST) is a 15-min standardized laboratory stress task that 
consists of a public-speaking task and mental arithmetic in front of a critical audience [45]. 
The TSST consistently induces self-reported, neuroendocrine and autonomic nervous 
system responses [46].
Measures
Demographic, psychological and clinical measures
Demographic variables were assessed with a general checklist for age, sex, marital status, 
education and medical history. Psychological functioning was measured with the state 
anxiety and negative and positive mood scales of the Impact of Rheumatic Diseases on 
General Health and Lifestyle (IRGL) questionnaire [47]. Disease severity in patients with 
psoriasis was assessed with the Psoriasis Area and Severity Index (PASI) [48], and disease 
activity in RA patients was measured with the Disease Activity Score 28 (DAS28) [49].
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Self-reported tension
Participants rated how tense they were on a visual analogue scale (VAS; 0–10).
α-Amylase
Saliva samples were collected with salivettes (Sarstedt, Rommelsdorf, Germany) and 
stored at -35°C until analysed. Salivary α-amylase was measured with the Aeroset (Abbott 
Laboratories, Libertyville, IL, U.S.A.). The rate of CPNP (2-chloro-4-nitrophenol) formation 
was detected spectrophotometrically at 404 nm to give a direct measurement of amylase 
in saliva.
Cortisol
Salivary cortisol was measured with a commercial Luminescence Enzyme Immunoassay (IBL, 
Hamburg, Germany). At levels of 3.3 and 27.3 nmol L-1, within-assay coefficients of variation 
were 8.7% and 3.6% respectively, and between-assay coefficients of variation were 12.3% 
and 7.7%. To reduce error variance caused by between-run variation, all samples from one 
participant were analysed in the same run.
Statistical analysis
All outcome parameters were logarithmically transformed to render unskewed data 
distributions. Between-group differences in age, sex and education were tested with 
independent Student’s t-tests and χ2 analyses. Baseline differences in psychophysio logical 
parameters (VAS tension, α-amylase and cortisol at t = 0 min) and total cortisol output 
(area under the curve with respect to ground; AUCG) [50] in the three groups were evaluated 
with analyses of (co)variance [AN(CO)VA]. Psychophysiological responses to the TSST were 
evaluated using a linear mixed model (LMM); the three psychophysiological parameters 
were used as dependent variables, and group (psoriasis, RA, healthy controls), baseline 
measurements of the dependent variable (t = 0 min) and time levels (t = 20, 30, 40, 60 and 
80 min) were used as independent variables. The following factors that are known to 
impact psychophysiological responses [46,51,52] were separately introduced as covariates 
in the ANCOVA and LMM models: medical treatment [i.e. biologics, topical or systemic 
corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and nonsteroidal anti- 
inflammatory drugs (NSAIDs)], medication known to affect the ANS [β-blockers, 
angiotensin- converting enzyme inhibitors, Ca2+-blockers, α1-blockers, thiazides (or 
related),  acetylcholine-receptor antagonists or β2-adrenergics], sex, age, body mass index 
(BMI), smoking status, menopausal status and psychological well-being (state anxiety, 
positive and negative mood). When a significant correlation with the outcome variable 
was found, covariate analyses were reported. Furthermore, analyses were performed with 
and without the participants using contraceptives. Psychophysiological data of the 89 
participants were 93% complete. Analyses were performed using SPSS 16.0 for Windows 
(IBM Corp., Armonk, NY, U.S.A.). The significance level was α = 0.05 (two-tailed).
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Results
Patient characteristics
The baseline demographic characteristics and disease status of 30 patients with psoriasis, 
34 patients with RA and 25 healthy controls are presented in Table 1. Groups did not 
significantly differ in age (F = 1.823, p = 0.168), educational level (χ2 = 1.859, p = 0.162), 
smoking status (χ2 = 4.700, p = 0.319) or psychological functioning (anxiety F = 0.854, 
p = 0.429; positive mood F = 0.732, p = 0.484; trend for negative mood F = 3.109, p = 0.050, 
patients with psoriasis less than patients with RA and healthy controls), but among 
patients with psoriasis, there were more men (χ2 = 6.366, p = 0.041) and the BMI was 
significantly higher than in patients with RA and controls (F = 5.522, p = 0.006) (see Table 1). 
Three patients with psoriasis took biologics (etanercept, adalimumab and ustekinumab) 
vs. 16 patients with RA (etanercept, adalimumab, abatacept and infliximab), and six 
patients with psoriasis received DMARDs [methotrexate (MTX) or sulfasalazine] vs. 23 
patients with RA (MTX, sulfasalazine, hydroxychloroquine, leflunomide and/or azathioprine). 
In addition, four patients with psoriasis and 16 patients with RA received NSAIDs, and five 
patients with RA took glucocorticoids [(methyl-)prednisolone]. Of the 15 patients with psoriasis 
using topical medication, 14 used corticosteroid creams or ointments. Seven patients with 
psoriasis, nine patients with RA and three healthy controls received medication known to 
affect the ANS. One patient with RA and one healthy woman used oral contraceptives, 
and one healthy woman had a hormonal intrauterine device. Three women with psoriasis, 
one woman with RA and four female healthy controls were premenopausal.
Psychophysiological response to stress
Baseline differences in psychophysiological parameters
There were no significant baseline differences between the three groups with regard to 
subjective tension (F = 1.188, P = 0.310) or α-amylase (F = 1.336, p = 0.268) and cortisol 
levels (F = 0.007, p = 0.993) (Table 2). 
 None of the covariates investigated were significantly related to the (baseline) 
outcome variables, except for sex, as men showed higher basal cortisol levels than women 
(p = 0.001), and age, which was negatively associated with basal subjective tension levels 
(p = 0.011) and positively associated with α-amylase levels (p = 0.007); incorporation of these 
confounders as a covariate into the models did not change the results (cortisol F = 0.477, 
p = 0.622; tension F = 1.338, p = 0.268; α-amylase F = 2.148, p = 0.123).
Psychophysiological stress reactivity
The stress test induced significant changes in subjective tension (time effect F1,88 = 
105.969, p < 0.001), α-amylase (time effect F1,146.981 = 24.068, p < 0.001) and cortisol levels 
(time effect F1,86.159 = 43.279, p < 0.001; Fig. 1) across groups, with significant increases in 
the three parameters as measured from baseline (P < 0.001 for all outcomes; Table 2).
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Table 1   Demographic characteristics, disease severity, and medical regimen for patients 
with psoriasis (PS), patients with rheumatoid arthritis (RA) and healthy controls
Patients with PS
(n = 30)
Patients with RA
(n = 34)
Healthy controls
(n = 25)
No. females/males 9/21 16/18 16/9
Age (years), mean ± SD 58.5 ± 12.4
(range 26-76)
 60.8 ± 9.2 
(range 26-80)
 55.6 ± 8.7
(range 39-71)
Education level (%)
Primary
Secondary
Tertiary
0%
70%
30%
3%
71%
27%
0%
52%
48%
BMI, mean ± SD 28.0 ± 5.5  25.7 ± 3.6  23.9 ± 4.6
Smoking status (%)
5-20 per day
1/week to 5/day
No or quitted
17%
7%
77%
24%
3%
74%
4%
4%
92%
PASI, mean ± SD
DAS28, mean ± SD
7.8 ± 5.3 
(range 0.6-19)
-
-
2.6 ± 1.0  
(range 0.8-4.5)
-
-
Disease duration (years), 
mean ± SD
21.2 ± 14.5  
(range 4-53)
12.6 ± 7.6  
(range 3-37)
-
Systemic medication, n
Biologics
DMARDs
NSAIDs
Corticosteroids
Topical medication, n
Corticosteroids
RA/VitD3 analogs
Coal tar
12/30
3
6
4
0
15/30
14
3
1
32/34
16
23
16
5
-
-
-
Medication affecting
 autonomic nervous systema, n
7/30 9/34 3/25
BMI, body mass index; DAS28, Disease Activity Score 28; DMARDs, disease-modifying antirheumatic drugs; 
NSAIDs, nonsteroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; SD, standard deviation; 
VitD3,vitamin D3. ae.g. β-blockers, thiazides.
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 Stress-induced tension responses (group x time F8,86.000 = 1.854, p = 0.078; group 
F2,84.193 = 1.205, p = 0.305) and α-amylase responses (group x time F8,83.550 = 1.328, 
 p = 0.241; group F2,84.429 = 0.022, p = 0.978) did not significantly differ between the three 
groups (Table 2). In contrast, groups significantly differed in their cortisol response over 
time (group x time F8,83.903 = 2.802, p = 0.008; group F2,83.276 = 3.241, p = 0.044), with 
patients with psoriasis showing a larger increase in cortisol levels than healthy controls 
and patients with RA (Table 2 and Fig. 1). The total cortisol output with respect to ground 
(AUCG) did not significantly differ between the groups (F = 1.818, p = 0.169), with patients 
with psoriasis, patients with RA and healthy controls having a mean AUCG (± SD) of 72 
(± 7), 62 (± 11) and 60 (± 9), respectively.
 None of the covariates investigated were significantly related to the (stress-induced) 
outcome variables, except for the use of systemic corticosteroids, which was negatively 
associated with the cortisol response and the AUCG (P = 0.017 and p = 0.019, respectively), 
and sex, for which the AUCG was larger in men (p < 0.001); in addition, the use of biologics 
(p = 0.023) and psychological functioning (positive mood p = 0.055; negative mood 
Table 2   Mean (±SEM) untransformed baseline and stress-induced levels of VAS tension, 
salivary α-amylase and cortisol in patients with psoriasis (PS; n = 30), patients with 
rheumatoid arthritis (RA; n = 34), and healthy controls (HC; n = 25).
t = 0 min t =TSST /
20 min
t = 30 min t = 40 min t = 60 min t = 80 min
VAS tension (0-10) 
PS 
RA
HC
1.0 (0.3)
1.2 (0.2)
1.3 (0.2)
5.8 (0.5)
5.7 (0.4)
5.9 (0.5)
1.4 (0.3)
1.7 (0.3)
1.6 (0.3)
0.6 (0.1)
1.2 (0.3)
1.3 (0.2)
0.6 (0.2)
0.9 (0.3)
1.0 (0.2)
0.6 (0.2)
0.8 (0.2)
1.1 (0.2)
α-Amylase (U mL-1)
PS
RA
HC
241 (37)
221 (37)
271 (47)
373 (45)
323 (46)
375 (56)
259 (29)
244 (43)
249 (36)
241 (29)
240 (39)
305 (52)
237 (28)
264 (43)
294 (47)
258 (30)
291 (48)
295 (39)
Cortisol (nmol L-1)a
PS
RA
HC
5.5 (0.5)
6.7 (1.4)
6.1 (1.0)
8.7 (0.9)
8.5 (1.7)
7.8 (1.3)
12.2 (1.7)
  8.2 (1.6)
  8.4 (1.6)
10.8 (1.4)
  7.3 (1.2)
  7.7 (1.6)
6.8 (0.7)
5.6 (0.9)
5.7 (1.0)
4.9 (0.5)
4.9 (0.8)
4.6 (0.6)
TSST, Trier Social Stress Test; VAS, visual analogue scale. aSignificant group x time and group effects; analyses 
performed on ln-transformed data. 
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p = 0.052; anxiety p = 0.035) were or tended to be positively associated with amylase 
reactivity. Incorporation of these confounders into the models as covariates did not 
change the results (cortisol response: group x time F8,83.872 = 2.806, p = 0.008; group 
F2,84.186 = 2.372, p = 0.100 and AUCG F = 0.439, p = 0.646; amylase response: group x time 
F8,83.585 = 1.326, p = 0.242; group F2,83.029 = 0.565, p = 0.570).
Discussion
Although it is known that stress can maintain or exacerbate chronic inflammatory 
conditions, for example psoriasis and RA, it is still debated whether the response of the 
ANS and HPA axis to stress is altered in these patients [53–55]. Different psychopathologi-
cal (e.g. clinical depression and social anxiety) and somatic diseases (e.g. atopic dermatitis 
and asthma) have been associated with characteristic stress response profiles, which are 
often suggestive of blunted cortisol reactivity, although enhanced cortisol responses 
have also been observed in certain psychopathologies [46,56–58]. We provide preliminary 
evidence that the cortisol response to acute psychosocial stress in patients with psoriasis 
is increased compared with patients with RA and healthy controls, indicating that the 
neuroendocrine stress response system is altered in this population with chronic 
Figure 1   Endocrine response to stress. Mean stress-induced salivary cortisol levels (± SEM) 
in patients with psoriasis (PS), patients with rheumatoid arthritis (RA) and healthy 
controls (HC).
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inflammation. Salivary α-amylase responses, as an indicator of sympathetic reactivity, 
were not different in the three groups. Because general psychological functioning and 
stress-induced tension levels did not significantly differ between groups, the heightened 
cortisol response in patients with psoriasis might not have been caused by underlying 
psychopathology or perceived stressfulness, but could reflect a disease-specific difference 
in neuroendocrine stress reactivity.
 The general hypothesis for chronic inflammatory conditions is that of hypofunctional 
HPA axis activity and reactivity that fuels inflammation through inadequate suppression of 
immune function [6,59]. Our finding of heightened cortisol reactivity in psoriasis does not 
support this idea. Of the limited number of studies available on endocrine responses to 
experimental stressors in patients with psoriasis [28–30,32,34,35], most reported no 
significant difference in cortisol reactivity between patients with psoriasis and controls 
[28,29,32,34,35]. Only one study reported a trend for a larger cortisol response [32]. In line 
with this, dexamethasone-induced cortisol suppression, although still within the normal 
range, was blunted in patients with psoriasis compared with healthy controls [26]. Possibly, 
the negative feedback action of corticosteroids is attenuated in psoriasis, although 
alterations in adrenocorticotropic hormone and cortisol output were not observed in cor-
ticotropin-releasing hormone tests [26]. Nevertheless, pharmacological tests trigger 
specific parts of the HPA axis and are not necessarily comparable with the effects of 
real-life stressors, which activate the stress response system at various psychophysiologi-
cal levels. For example, it is suggested that endocrine activity occurs not only inside the 
classical HPA axis, but also at the peripheral level in the skin; this ‘brain–skin HPA axis’ 
probably coordinates peripheral responses to stress and maintains cutaneous homeostasis 
[60], and may underlie inflammatory skin diseases, such as psoriasis, that are triggered or 
aggravated by stress [18]. However, it is as yet unclear whether this local HPA axis is 
activated after systemic stress induction, and whether and to what extent skin–HPA axis 
mediators are released into the circulation. Furthermore, a distinction should be made 
between the effects of chronic and acute stressors on neuroendocrine function [60]. In 
chronic stress and pain conditions, the HPA axis is thought to be continuously activated, 
which can increase feedback sensitivity of corticosteroids [59,61]. This might lead to 
hypofunction and hyporeactivity of the HPA axis and desensitization of the immune 
system to glucocorticoids, increasing inflammation [59,61]. For example, patients with 
psoriasis persistently experiencing high levels of daily stressors had significantly lower 
basal cortisol levels than patients continuously experiencing low levels of daily stressors 
[11]. During peak levels of stress, daily stressors were significantly associated with an 
increase in disease severity 1 month later, suggesting that stress might exert its negative 
effects on psoriasis severity specifically when stress levels are high [62]. Another study 
reported basal and stress-induced cortisol levels to be lower in patients with psoriasis who 
considered themselves sensitive to stress [34]. In all, stress-related and disease-specific 
mechanisms might be at work at the same time. On the one hand, chronic stress might 
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lead to reduced HPA axis reactivity, while on the other hand, possible disease-specific 
mechanisms that increase cortisol responses might be present. The result of these 
processes – and what this means for stress response patterns in case of acute stress – 
needs further investigation. We did not find patients with RA to have a specific 
neuroendocrine profile, which is in line with literature suggesting that patients with RA 
show no or only subtle alterations in HPA axis function after stress induction [41,54].  
 Our findings do not support there being an altered ANS response to stress in patients 
with psoriasis and RA compared with healthy controls. The few studies investigating 
autonomic function in patients with psoriasis do not equivocally demonstrate sympathetic 
dysfunction [22,63]. Most studies of experimentally induced psychological stress did not 
detect differences in autonomic reactivity between patients with psoriasis and controls 
[28,30–34], although increased [28,29,31] or decreased [30,31] responses have also been 
reported. Our results on autonomic stress reactivity in patients with RA are consistent with 
those of most controlled studies investigating short-term experimental stressors in these 
patients [37,38,54,64–66], although some studies reported diminished [36] or more 
pronounced [37,38] autonomic stress reactivity. However, those alterations were either 
observed in subgroups of patients with severe disease activity [38], in patients using 
biologics [37] or in response to only one type of stress [36]. Our finding supports the idea 
that the autonomic response to acute stress is not altered in patients with psoriasis and 
RA.
 This study has some limitations. Firstly, because patients with relatively mild disease 
activity participated in the study, the study sample might not be representative of patient 
populations and the results cannot be generalized to patients with psoriasis or RA with 
more severe disease activity. Moreover, as we included two different patient groups on 
disease-specific medication regimens, we could not investigate the role of type of phar-
macotherapy on the physiological response to the stress task. However, most pharmaco-
therapy regimens were not related to the psychophysiological outcome measures 
studied, and statistically adjusting for use of systemic corticosteroids and biologics did not 
change the results. Nevertheless, the results of this study should be interpreted with 
caution and replicated in larger groups of patients. Secondly, there was a significant 
difference in sex distribution across the three groups. It is well known that sex [51,67], 
menstrual cycle, menopause and oral contraceptives [52] influence the cortisol response 
to laboratory stress paradigms. Therefore, we explored the possible influence of several 
sex (hormone)-related confounders, but this did not alter our findings. Thirdly, the 
measurement of α-amylase and cortisol may be accompanied by methodological issues 
[68], because, for example, low blood glucose levels [69,70] and smoking [68,71–73] are 
associated with blunted cortisol responses and lower α-amylase activity. We limited the 
effects of these factors by asking patients not to drink alcohol, use caffeine, eat, smoke or 
exercise 2 h before the start of our experiment. Fourthly, although salivary α-amylase is an 
easy-to-use indirect measure of sympathetic stress reactivity and levels correspond with 
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those of cardiovascular measures, its secretion is clearly both sympathetic and parasym-
pathetic in nature and does not give insight into possible peripheral ANS mechanisms 
[74,75]. Future studies should try to unravel the effects of stress on different branches of 
the ANS, including both central and peripheral processes.
 In conclusion, patients with psoriasis showed an increased cortisol response to 
experimental psychosocial stress compared with patients with RA and healthy controls. 
Possibly they have a more pronounced neuroendocrine response to stressful events, 
which could increase their vulnerability to the adverse effects of stress on psoriasis activity. 
Results should be replicated in a larger, more homogeneous cohort of patients with 
chronic inflammatory conditions. This would allow subgroup analyses on medically 
treated and untreated patients, and investigate stress response patterns of stress-sensitive 
patients. It could eventually lead to the development of guidelines for clinical practice to 
make clinicians more alert to the effects of stress in patients with psoriasis and pay special 
attention to those patients who report being sensitive to stress in their daily lives.
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Abstract
Objective Stress is one of the factors that may exacerbate the progression of chronic 
inflammatory diseases such as RA and psoriasis. We exploratively compared the effects of 
acute stress on levels of circulating cytokines involved in disease progression and/or the 
stress response in patients with RA, patients with psoriasis and healthy subjects.
Methods Patients with RA, patients with psoriasis and healthy controls underwent a 
standardized psychosocial stress test (Trier Social Stress Test). Levels of circulating cytokines 
(IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IFNγ and TNFα) were measured before and after the 
stress test.
Results The baseline levels of all cytokines, except IL-8, were significantly higher in 
patients with RA. After correction for baseline levels, patients with RA showed higher 
stress-induced levels of IL-1ß and IL-2 than patients with psoriasis and healthy controls.
Conclusion The results suggest that patients with RA have a different immune response 
to stress than patients with psoriasis or healthy controls. More needs to be learned about 
the complex interaction between stress, immune parameters and chronic inflammation.
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Introduction
The etiology of chronic inflammatory diseases such as RA and psoriasis is complex and 
disease progression may be adversely affected by several factors, including stress [1, 2]. 
The main physiological pathways by which stress exerts its effects on the immune system, 
namely, the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenal-med-
ullary (SAM) axis, are also critically involved in disease progression [3]. In the case of chronic 
inflammation, these axes might be altered [4]. Accompanying local and systemic changes 
in immune function can lead to disease-specific immune responses to stress that differ 
among inflammatory conditions and might increase negative health effects [5]. Various 
prospective studies of stress [6-8] and research with experimental stressors [9-11] or 
psychological interventions [12] have shown a link between stress and measures of 
immune function or disease activity in RA and psoriasis. For example, we previously 
showed that stress management training not only diminished levels of subjective tension 
and cortisol reactivity [13], but also influenced the IL-8 response to acute stress in patients 
with RA [14], indicating that psychological interventions can alter immune function.
 To identify patients with a chronic inflammatory disease who might be especially 
vulnerable to the effects of stress on inflammatory activity and disease progression, we 
explored the effects of an acute real-life laboratory stressor on levels of circulating 
cytokines involved in disease progression and/or the stress response (e.g., IL-6, IL-8 and 
TNFα) in patients with RA, patients with psoriasis and healthy subjects.
Patients and methods
Patient cohort
Patients with RA or psoriasis were recruited from the Departments of Rheumatology 
and Dermatology at the Radboud University Medical Center and Sint Maartenskliniek 
in Nijmegen, the Netherlands. Healthy participants were recruited by means of an 
announcement in a local newspaper and/or on a website. 
 The study was approved by the regional medical ethics committee (CMO Regio 
 Arnhem-Nijmegen) and informed consent was obtained from all participants according 
to the Declaration of Helsinki. As reported previously in the study on autonomic and 
endocrine responses, the study involved 34 RA patients [16 women, mean age 60.8 years 
(S.D. 9.2)], 30 psoriasis patients [9 women, mean age 58.5 years (S.D. 12.4)] and 25 healthy 
controls [HCs, 16 women, mean age 55.6 years (S.D. 8.7)] [11]. The groups differed 
significantly in sex distribution (p = 0.004), with relatively fewer women than men with 
psoriasis. The mean 28-joint DAS (DAS28) and Psoriasis Area and Severity Index scores 
were 2.6 (S.D. 1.0) and 7.8 (S.D. 5.3), respectively. Patients were treated with biologics 
(n = 16 RA, n = 3 psoriasis), DMARDs (n = 23 RA, n = 6 psoriasis), NSAIDs (n = 16 RA, n = 4 
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psoriasis), glucocorticoids (systemic: n = 5 RA; topical: n = 14 psoriasis) and medication 
known to affect the autonomic nervous system (ANS), including β-blockers, angioten-
sin-converting enzyme (ACE) inhibitors, Ca2+blockers, α1-blockers, thiazides or related 
drugs), acetylcholine receptor antagonists or β2-adrenergics (n = 9 RA, n = 7 psoriasis, n = 
3 HCs). Three women used hormonal (oral or intrauterine) contraception (n = 1 RA, n = 2 
HC) and eight women were premenopausal (n = 1 RA, n = 3 psoriasis, n = 4 HCs).
Stress test
Participants underwent the Trier Social Stress Test (TSST), a standardized laboratory stress 
task that consists of a mock job interview and mental arithmetic in front of a critical 
audience [11, 13, 15]. Sessions were run between 1:00 and 3:30 P.M. Blood (for cytokines) 
was collected at baseline (i.e. after 20 min of rest; t = 0 min), immediately after the stress 
test (t = 20 min) and at 20 and 60 min thereafter (t = 40 and t = 80 min). Saliva (for cortisol 
and α-amylase) and self-reported visual analogue scale (VAS) tension scores (0-10) were 
collected at t = 0, t = 20 [tension levels during the TSST (t = TSST) were reported here], 
t = 30, t = 40, t = 60 and t = 80 min.
Cytokine assay
Human IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IFNγ and TNFα were measured in serum using 
human cytokine multiple kits (Invitrogen, Carlsbad, CA, USA). Samples were analysed with 
a Luminex 100 system (Luminex, Austin, TX, USA).
Statistics
Baseline cytokine levels were evaluated with analyses of variance or covariance (ANOVA or 
ANCOVA). Cytokine responses to the TSST were explored using a linear mixed model, 
taking into account the specific design of the study. Lognormal-transformed cytokine 
levels (except skewed IL-5 and IFNγ data, which were excluded from further analyses) were 
used as dependent variables; group (RA, psoriasis, HC), time ( t = 0, t = 20, t = 40, t = 80 min) 
and group x time were used as independent variables. Treatment (i.e. biologics, topical or 
systemic corticosteroids, DMARDs and NSAIDs), use of medication known to affect the 
ANS, sex, age, hormonal contraceptives and menopausal status were tested one by one as 
potential covariates using dummy variables. When a significant correlation with the 
outcome variable was found, covariate analyses were also reported, which happened to 
include at most two covariates per model. In additional analyses, baseline levels of the 
dependent variable (t = 0 min) were used as the covariate. Based on significant 
between-group differences in cytokine responses, Pearson correlation coefficients of 
cytokine parameters [area under the curve with respect to ground (AUCG)] with 
physiological (AUCG of α-amylase and cortisol) and subjective [peak stress-induced 
tension levels (tensiont = TSST)] parameters were explored. Because physiological indices 
showed interindividual variability in the response to the stressor, the AUCG was used to 
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obtain uniform stress-induced output parameters [16]. Blood samples from six psoriasis 
patients and two RA patients were missing. Data from one psoriasis patient and IL-8 levels 
from one control participant were excluded because cytokine levels were more than 4 
S.D. higher than the mean. Consequently, data from 32 RA patients, 23 psoriasis patients 
and 25 healthy controls were analysed. Undetectable cytokine levels were set to zero and 
included in all analyses. The Bonferroni correction for multiple testing was not applied 
due to the high intercorrelation of most cytokines and the explorative nature of this study 
of small sample size [17]. Analyses were performed using SPSS 16.0 for Windows (IBM, 
Armonk, NY, USA). The significance level was α = 0.05 (two-tailed).
Results
Baseline cytokine levels
Baseline levels of all cytokines except IL-8 were significantly different among the three 
groups (p < 0.005 for IL-1ß, IL-2, IL-4, IL-6, IL-7, IL-10 and TNFα), with levels being significantly 
higher in RA patients than in psoriasis patients and HCs (except for IL-10; RA did not 
significantly differ from HCs; p = 0.14) (Table 1). Results remained (non-)significant after 
correction for covariates that were significantly associated with the baseline level of 
specific cytokines (i.e. NSAIDs, biologics, corticosteroids and medication known to affect 
the ANS). 
Stress manipulation check 
As reported in a previous paper, the stress test induced significant increases in tension, 
α-amylase and cortisol levels (p < 0.001 for all). Patients with RA, patients with psoriasis and 
HCs showed mean peak tension levels during stress of 5.7 (S.E.M. 0.4), 5.8 (S.E.M. 0.5) and 
5.9 (S.E.M. 0.5), respectively. Stress-induced tension and α-amylase responses did not differ 
significantly between the three groups, but patients with psoriasis showed a larger 
increase in cortisol levels than HCs and patients with RA [11]. 
Cytokine responses to stress 
The cytokine response to stress did not differ among the three groups (group x time 
interaction; p > 0.14 for all cytokines) (Table 1), also after correction for covariates 
significantly associated with specific cytokine responses (i.e. age, biologics, DMARDs, 
NSAIDs, corticosteroids and medication affecting the ANS). However, after correction for 
baseline differences in cytokine level, stress-induced IL-1ß and IL-2 levels were significantly 
different in the three groups [group effect for IL-1ß, F(2, 76) = 3.323, p = 0.04; group effect 
for IL-2, F(2, 76) = 3.553, p = 0.03], with IL-1ß (Fig. 1A) and IL-2 (Fig. 1B) levels being significantly 
higher in RA patients than in psoriasis patients 5 (p = 0.03 and p = 0.01, respectively) and 
HCs [p = 0.03 and p = 0.10 (trend), respectively]. In addition, the group difference in the IL-7 
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Table 1   Mean untransformed baseline and stress-induced cytokine levels in patients 
with RA, patients with psoriasis and healthy controls
t = 0 min t = 20 min t = 40 min t = 80 min
IL-1β
RA 114.3  (38.6) 130.9  (43.5) 116.6  (37.0) 136.7  (59.0)
PS 8.688  (5.06) 13.66  (8.30) 10.48  (7.52) 11.60  (8.50)
HC 10.20  (6.18) 10.58  (6.38) 12.10  (7.58) 10.60  (6.92)
IL-2
RA 32.60  (14.0) 42.86  (19.2) 38.77  (17.3) 47.51  (27.0)
PS 2.726  (2.20) 4.944  (4.33) 4.243  (3.61) 4.291  (3.76)
HC 4.439  (2.47) 4.910  (2.89) 5.139  (3.01) 4.854  (2.76)
IL-4
RA 60.18  (29.3) 72.79  (30.1) 65.76  (28.4) 65.39  (29.9)
PS 8.354  (2.91) 10.72  (4.14) 9.602  (3.60) 10.13  (3.87)
HC 4.195  (1.97) 4.575  (1.99) 4.339  (1.87) 4.035  (1.76)
IL-5
RA 5.129  (2.17) 7.887  (3.72) 7.006  (2.94) 8.948  (4.51)  
PS 0.112  (0.07) 0.018  (0.01) 0.074  (0.04) 0.142  (0.08)
HC 0.188  (0.07) 0.249  (0.08) 0.253  (0.08) 0.103  (0.04)
IL-6
RA 30.18  (9.36) 41.18  (15.2) 33.54  (10.7) 39.57  (16.2)
PS 4.652  (1.20) 4.344  (1.14) 5.043  (1.21) 5.301  (1.30)
HC 6.340  (2.29) 7.221  (2.78) 6.768  (3.18) 7.076  (2.61)
IL-7
RA 52.69  (16.5) 63.65  (20.5) 55.94  (18.5) 60.73  (21.8)
PS 4.061  (2.55) 3.107  (2.08) 3.440  (2.35) 2.605  (2.24)
HC 2.641  (1.61) 3.561  (1.93) 1.900  (1.21) 1.783  (1.17)
IL-8
RA 29.55  (6.50) 34.04  (7.81) 29.45  (6.75) 28.18  (7.14)
PS 18.95  (4.92) 11.95  (3.20) 11.55  (3.25) 9.236  (2.75)
HC 22.04  (5.51) 20.03  (5.03) 13.74  (4.53) 10.17 (3.87)
IL-10
RA 49.33  (25.9) 57.07  (31.8) 73.55  (48.1) 71.02  (45.9)
PS 0.855  (0.22) 0.898  (0.23) 0.788  (0.20) 0.852  (0.22)
HC 8.407  (4.37) 8.834  (4.63) 8.114  (4.12) 8.500  (4.45)
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response approached statistical significance [group effect, F(2, 76) = 2.883, p = 0.06), with 
levels being higher in RA patients than in psoriasis patients (p = 0.02) and HCs (trend; 
p = 0.08). The other cytokine responses to stress did not differ among the groups (p > 0.23 
for IL-4, IL-6, IL-8, IL-10 and TNFα). Based on significant group differences in the IL-1ß and IL-2 
response to stress, correlations with other physiological and subjective parameters were 
explored. IL-1ß and IL-2 output (AUCG) were not significantly related to peak stress-induced 
tension levels, nor with α-amylase or cortisol output, in the total group and in the RA 
group specifically (p > 0.24 for all tests).
Table 1   Continued
t = 0 min t = 20 min t = 40 min t = 80 min
IFNγ
RA 1.545  (0.45) 8.328  (4.98) 6.623  (4.91) 7.591  (5.70)
PS 0.177  (0.15) 0.000  (0.00) 0.000  (0.00) 0.000  (0.00)
HC 0.082  (0.05)  0.146  (0.10) 0.255  (0.22) 0.184  (0.16)
TNFα
RA 34.56  (12.4) 39.35  (12.7) 36.00  (11.1) 35.45  (11.2)
PS 5.642  (2.94) 6.742  (3.50) 6.688  (3.38) 6.599  (3.56)
HC 0.435  (0.23) 0.680  (0.25) 0.368  (0.18) 0.329  (0.17)
Cytokine levels expressed in pg/ml (S.E.M.). RA, n = 32; PS, n = 23; HCs, n = 25. PS, patients with psoriasis; 
HC, healthy controls.
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Figure 1   Mean lognormal-transformed (A) IL-1β and (B) IL-2 levels [in pg/ml (± S.E.M.)] 
at t = 0 (baseline/pre-TSST), t = 20, t = 40 and t = 80 min (post-TSST) of patients 
with RA (n = 32), patients with psoriasis (PS; n = 23) and healthy controls (HC; 
n = 25).
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Discussion
Basal levels of cytokines were significantly higher in RA patients than in patients with 
psoriasis or HCs, and after correction for baseline levels, patients with RA showed higher 
stress-induced levels of IL-1ß and IL-2 than in patients with psoriasis or HCs. Stress has 
previously been found to have a robust effect on circulating levels of IL-1ß and IL-6 in 
healthy and clinical populations, whereas less consistent results have been found when 
measuring cytokine production after cell stimulation in vitro [18, 19]. While acute 
experimental stress has been found to have an inconsistent (for IL-6) or no (for IL-2, IL-4, IL-8 
and IFNγ) effect on cytokine levels in RA patients, it consistently increased TNFα to a 
greater extent in RA patients than in controls [4]. The only study to investigate the effects 
of stress on cytokine levels in patients with psoriasis found that psychosocial stress 
increased IFNγ and decreased IL-10 and IL-4 levels more in patients than in controls [10]. 
Thus a possible disease-specific immune response to stress is indicated.
 Our results suggest that the immune response to acute stress, and specifically 
circulating IL-1ß and IL-2 levels, might be altered in certain chronic inflammatory conditions. 
It has been postulated that acute stress predominantly up-regulates innate immunity, 
increasing the number of natural killer cells and neutrophils and the production of 
cytokines associated with acute inflammation [18], such as IL-1ß. IL-2, a component of the 
adaptive immune system that mainly activates cellular responses (e.g. T cell activation), 
was specifically elevated in response to stress in RA patients. Since stress-induced acute 
changes in circulating cytokines probably reflect redistribution processes, the response 
may be greater when baseline cytokine levels are already elevated. The effect of stress on 
immune parameters was relatively small, although the study participants reported finding 
the stress test stressful, as was also evidenced by a significant increase in salivary α-amylase 
and cortisol levels [11]. Probably, cytokines do not regulate immune function systemically, 
but instead at the effector site. Functional studies that measure cytokine production by 
local immune cells can test this. Alternatively, patients with different disease activity or on 
different medications, or participants who are specifically sensitive to stress [20], might 
respond differently. This study was limited by the relatively small number of patients with 
RA or psoriasis, the rather heterogeneous groups and patients with mild disease activity, 
which prevented analysis of subgroups of patients on different medications or with 
different disease activity, or a more detailed analysis of possible confounders. Our finding 
that the cytokines IL-1ß and IL-2 seem to increase more in patients with RA than in patients 
with psoriasis and HCs could indicate that stress might specifically have altered effects on 
immune function in those patients and possibly increases negative effects on disease 
severity. Nevertheless, the clinical significance of stress-induced changes in circulating 
cytokine levels and their possible association with disease exacerbation remain to be 
investigated.
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 In conclusion, basal levels of cytokines were significantly higher in patients with RA 
than in patients with psoriasis or controls, and stress-induced levels of IL-1ß and IL-2 were 
higher in patients with RA than in patients with psoriasis or controls after correction for 
baseline differences in cytokine levels. The results suggest that there is a complex 
interaction between stress, immune parameters and chronic inflammation that should be 
investigated further.
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Abstract
Background Stress management interventions may prove useful in preventing the 
detrimental effects of stress on health. This study assessed the effects of a stress 
management intervention on the psychophysiological response to stress in patients with 
rheumatoid arthritis (RA). 
Methods Seventy-four patients with RA, who were randomly assigned to either a control 
group or a group that received short-term stress management training, performed a 
standardized psychosocial stress task (Trier Social Stress Test; TSST) 1 week after the stress 
management training and at a 9-week follow-up. Psychological and physical functioning 
and the acute psychophysiological response to the stress test were assessed. 
Results Patients in the intervention group showed significantly lower psychological 
distress levels of anxiety after the training than did the controls. While there were no 
between-group differences in stress-induced tension levels, and autonomic (α-amylase) 
or endocrine (cortisol) responses to the stress test 1 week after the intervention, levels of 
stress induced tension and cortisol were significantly lower in the intervention group at 
the 9-week follow-up. Overall, the response to the intervention was particularly evident in 
a subgroup of patients with a psychological risk profile.
Conclusion A relatively short stress management intervention can improve psychological 
functioning and influences the psychophysiological response to stress in patients with 
RA, particularly those psychologically at risk. These findings might help understand how 
stress can affect health and the role of individual differences in stress responsiveness.
 
Trail registration The Netherlands National Trial Register (NTR1193)
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Introduction
The etiology of rheumatoid arthritis (RA), a chronic inflammatory systemic disease that 
affects 1% of the general population [1,2], remains poorly understood. Despite the 
growing spectrum of pharmacological therapies aimed at reducing disease activity [3], 
many patients continue to suffer from pain, fatigue, functional disability, and an overall 
poor quality of life [4]. One of the factors believed to play a role in the initiation, 
maintenance, and exacerbation of RA is psychological stress [5,6]. Evidence is accumulating 
that stress-evoked physiological changes, brought about by activation of the two main 
branches of the stress response system, the autonomic nervous system (ANS) and the 
hypothalamus-pituitary-adrenal (HPA) axis, might have detrimental effects on disease 
activity and health [7–10]. This has led to growing interest into the effects of stress 
management interventions on physiological outcomes. Stress-reducing psychological 
interventions aimed at modifying stress appraisal and decreasing subjective anxiety 
might alter autonomic arousal (e.g., decrease heart rate and galvanic responses, and 
increase tonic vasodilation) and influence neuroendocrine activity (e.g., lower cortisol 
levels) [11–14]. Alleviating the physiological response to a stressor could be particularly 
relevant in clinical populations, specifically in patients with immune-mediated diseases, 
such as RA. Although evidence is limited, there are indications that stress management 
interventions might affect basal autonomic or endocrine parameters, such as norepinephrine 
levels, urinary free cortisol output, serum dehydroepiandrosterone sulphate, or testosterone 
levels in patients with HIV and cancer [15–21]. 
 Psychological interventions, such as multimodal cognitive-behavioral therapy (CBT), 
biofeedback, stress management training, or emotional disclosure, have generally led to 
modest improvements in psychological and physical functioning in patients with RA, 
with similar effects for the different types of interventions [4,22–25]. Only incidental effects 
have been found on biological measures of disease, such as C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR) [26–28]. Medical and methodological explanations 
have been searched for this lack of uniform effects of psychological interventions on 
biological measures, such as disease status, medication regimen, and used time frame to 
assess physiological stress measures. However, there is also relatively consistent support 
that inter-individual variation in psychological risk factors also play a role [29,30]. Specifically, 
previous research increasingly indicates the importance of evaluating psychological risk 
factors when investigating treatment outcome, such as the experience of interpersonal 
stress and levels of depression [29,31]. For instance, there is increasing evidence that 
patients at risk, for example those who report being sensitive to stress or who have 
heightened levels of distress (e.g., heightened anxiety and depression), are especially 
prone to the detrimental effects of stress on disease activity and accompanying physical 
symptoms [32,33]. Moreover, stress-induced changes in physiological function are 
particularly observed in these groups of patients psychologically at risk [29,31,34]. 
110
Chapter 5
Although there is preliminary evidence that stress management interventions can 
influence the acute psychophysiological response to stress in healthy individuals [35,36], it 
is not known whether such interventions alter the acute-phase psychophysiological 
response to a stressful event in immune-comprised patients with chronic inflammatory 
diseases, such as RA. 
 In this study, we examined the effects of a short-term individual stress management 
intervention on the self-reported, sympathetic, and neuroendocrine response to a 
validated psychosocial stress test (Trier Social Stress Test, TSST) in patients with RA and in 
a subsample of patients at risk of heightened anxiety and depression. We hypothesized 
that patients in the intervention group, particularly those at risk, would show reduced 
levels of distress and a diminished psychophysiological response to acute psychosocial 
stress compared with controls both after the intervention and at the 9-week follow-up 
after prolonged use of the stress management techniques.
Materials and Methods
Ethics statement
The protocol for this trial and supporting CONSORT checklist are available as supporting 
information; see Checklist S1 and Protocol S1. The study protocol was approved by the 
regional medical ethics committee (CMO Regio Arnhem-Nijmegen) and registered in The 
Netherlands National Trial Register (NTR 1193). Written informed consent was obtained 
from all participants.
Participants
Patients with RA were recruited from the Department of Rheumatology at the Radboud 
University Nijmegen Medical Centre and the St Maartenskliniek in Nijmegen, the Netherlands. 
Inclusion criteria were a diagnosis of RA according to the American Rheumatism 
Association 1987 classification criteria [37] and a minimum age of 18. Exclusion criteria 
were severe physical comorbidity (e.g., major cardiac problems, psoriasis, malignancies, 
severe respiratory or renal insufficiency, hepatitis B, HIV, and insulin-dependent diabetes 
mellitus); severe psychiatric disturbances that might interfere with the study protocol; 
pregnancy; illiteracy; use of antidepressants, anxiolytics, or antipsychotics; and psychological 
treatment.
Procedure
Ninety-six eligible patients were enrolled (see Figure 1) and randomized through simple 
randomization with an equal allocation ratio to one of two parallel groups, the control 
or the treatment condition, in accordance with the fixed therapist’s time schedule and 
using a computerized random generator scheme made by an independent researcher. 
5111
Psychophysiological stress responses after stress management training in RA
Allocation was concealed for the participant enroller until the moment that participants 
were scheduled into the treatment program. After randomization, 19 participants (n = 8 
intervention, n = 11 control) withdrew from the study prematurely (prior to the first stress 
test), because of physical comorbidity (n = 3 intervention, n = 6 control), severe illness or 
death of a significant other (n = 3 intervention, n = 1 control), a change in pharmacotherapy 
(n = 1 control), or lack of motivation (n = 2 intervention, n = 3 control). In addition, 3 
participants (n = 1 intervention, n = 2 control) reported taking antidepressants or 
anxiolytics after randomization and were excluded based on our predefined exclusion 
criteria. Seven of 74 participants withdrew from the second stress test (n = 4 intervention, 
n = 3 control) because of physical comorbidity (n = 2 intervention), death of a significant 
other (n = 1 intervention), and lack of motivation (n = 1 intervention, n = 3 control). There 
were no differences in sociodemographic variables (sex, age, education level) and 
Figure 1   Flow chart showing participant selection and drop-out.
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psychological and physical functioning at baseline (anxiety, negative mood, positive 
mood, Disease Activity Score 28 (DAS28)) between the drop-outs and the completers.
 Participants were post hoc divided into 2 subgroups based on the participant’s risk 
status by means of a median split on a composite score of baseline anxiety and negative 
mood assessed with the IRGL (see Measures) [30,32]. 
Study design
At the first assessment, the medical history and current disease activity of all participants 
were evaluated at the University Medical Centre, and in the subsequent two weeks half of 
the participants started the individual stress management training program. All participants 
performed a stress test three weeks after the first assessment (i.e., second assessment) and 
9 weeks thereafter (i.e., third assessment). Stress test sessions were run between 13.00 and 
15.30 hours. Participants were asked to refrain from using caffeine, alcohol, nicotine, or 
physical exercise on the test day, and from eating 2 hours before the first blood sample 
was drawn. Forty minutes before the stress test, a venous catheter was inserted into the 
non-dominant arm (immunological data presented elsewhere) and participants were 
asked to rest for 20 minutes. They then performed the stress test. During periods of rest, 
participants looked at a natural history documentary. Psychophysiological parameters 
(tension, saliva, and blood) were measured at baseline (i.e., after 20 minutes of rest), 
immediately after the stress test, and 10, 20, 40, and 60 minutes after cessation of the test.
Stress task
The Trier Social Stress Test (TSST) is a standardized laboratory stress task that consists of a 
mock job interview and mental arithmetic in front of an audience. The persons conducting 
the TSST were unaware of group allocation of the participants. The TSST lasts 15 minutes, 
including introduction to the job interview and a 5-minute preparation phase, and has 
repeatedly been found to induce self-reported, neuroendocrine, and autonomic nervous 
system responses [38].
Stress management training
Participants in the intervention group received individual stress management training 
with a focus on psycho-education and the principles of applied relaxation, including 
progressive, cue controlled, and differential relaxation [30,39–42]. In addition, patients 
were taught breathing and visualization exercises. Participants attended 4 individual 
1-hour sessions with a trained therapist over 2 consecutive weeks. Patients received an 
MP3-player with relaxation exercises and, at the end of each session, a training manual 
containing a summary of the information and stress-reducing techniques introduced in 
that session. As consolidating homework, participants assessed stress-relevant situations 
and behaviors in their daily life and used relaxation exercises for 1 hour at least twice a day 
during the 2 weeks of the stress management intervention. Subsequently, patients were 
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encouraged to continue the homework assignments, to use the relaxation exercises, to 
focus on long-term goals, and to stick to a relapse-prevention checklist during the 
2-month follow-up period.
Measures
Demographic, clinical, and self-report measures at baseline, post-treatment,  
and follow-up
Demographic variables were assessed with a general checklist for age, sex, marital status, 
education, and medical history. Educational level was measured using seven categories 
that can be classified as primary, secondary, and tertiary education, representing on 
average 7, 12, and 17 years of education, respectively. 
Physical functioning was assessed in terms of disease activity. Disease activity of patients 
was measured with the DAS28, which is a validated composite score for swelling and 
tenderness of 28 joints, a Visual Analogue Scale (VAS) of the patients’ general health, and 
the ESR (mm/h) [43]. 
Psychological functioning was measured with the state anxiety and negative and positive 
mood scales of the IRGL [44,45]. The IRGL is derived from the Arthritis Impact Measurement 
Scales (AIMS) [46]. The 10-item anxiety scale is a shortened version of the Dutch State 
Anxiety Scale [47,48] and assesses anxiety over the last 2 weeks (sample item: ‘‘I worry too 
much about unimportant matters.’’); the 6-item negative mood scale assesses various 
negative mood states over the previous 2 weeks (sample item: ‘‘How depressed were you 
during the past 2 weeks?’’); and the 6- item positive mood scale assesses various positive 
mood states over the previous 2 weeks (sample item: ‘‘How cheerful were you during the 
past 2 weeks?’’). 
Patients’ evaluation of stress management training
After training ended, patients were asked to indicate their satisfaction with the training 
and its usefulness (score range 0–10, ranging from ‘‘not at all’’ to ‘‘very’’), and to what 
extent their distress and tension had improved (score range 1–4, ranging from ‘‘not’’ to 
‘‘very’’).
Psychophysiological measures during the stress test at post-treatment  
and follow-up
VAS tension Participants rated how tense they were on a VAS at baseline (after 20 minutes 
of rest), during the stress test (retrospectively), and 10, 20, 40, and 60 minutes after cessation 
of the stress test. 
α-Amylase as a measure of autonomic reactivity. Saliva samples were collected with 
salivettes (Sarstedt, Rommelsdorf, Germany) and stored at -35°C until further biochemical 
analyses. After saliva samples were thawed, centrifuged, and diluted, α-amylase (AA) was 
measured with the Aeroset (Abbott). According to the procedure, α-amylase hydrolyses 
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the reagent CNPG3 (2-chloro-4-nitrophenyl-α-D-maltotrioside) to CPNP (2-chloro-4-nitro-
phenol), CNPG2 (2-chloro-4-nitrophenyl-α-D-maltoside), maltotriose, and glucose. The 
rate of CPNP formation was detected spectrophotometrically at 404 nm to give a direct 
measurement of amylase in saliva.
Cortisol as a measure of endocrine reactivity. Salivary cortisol was measured with a 
commercial Luminescence Enzyme Immunoassay (IBL, Hamburg, Germany). After samples 
were thawed and centrifuged, 20 μl aliquots of the supernatant were pipette into 
anti-cortisol (rabbit-) antibody-coated microtitre plate wells, followed by 100 μl of enzyme 
conjugate (horseradish peroxydase). After 3-hour incubation at room temperature, the 
plate was washed and luminescence reagent (luminol/peroxide) was added to each well, 
with subsequent reading of the signal in a luminometer. At levels of 3.3 and 27.3 nmol/l, 
within-assay coefficients of variation (CV) were 8.7 and 3.6% respectively, and between- 
assay CVs were 12.3 and 7.7%. To reduce error variance caused by between-run variation, 
all samples from one participant were analyzed in the same run.
Statistics
Analyses were performed on the 74 participants completing the study protocol. Skewed 
data (i.e., negative mood and all physiological parameters) were logarithmically transformed to 
render unskewed data distributions before statistical analysis. Between-group differences in 
age, sex, education, and psychological measures at baseline were tested with independent 
Student’s t–tests and Chi-square analyses. For cortisol, the area under the curve (AUCG) was 
calculated using the trapezoid formula [49]. Baseline differences in psychophysiological 
outcome parameters (VAS tension, cortisol, and α-amylase) (t = 0 minutes) and AUCG in the 
intervention and control groups were evaluated with analyses of covariance (ANCOVA). 
Effects of the stress management training (i.e., psychological/physical functioning and 
psychophysiological responses to the stress test) were evaluated using a linear mixed 
model taking into account the specific design features of the study. The primary outcome 
measure was state anxiety as a measure of psychological distress. The effects on secondary 
outcomes of psychological and physical functioning (positive and negative mood, and 
DAS28) and psychophysiological stress parameters (tension, cortisol, and α-amylase 
measured during the stress test) at the post-treatment and follow-up assessments were 
also assessed. In analyses of the effects of the stress management training on psychological 
and physical functioning, measures of psychological and physical functioning were used 
as dependent variables, and group, baseline measurement of the dependent variable 
(pretreatment), and time levels (post-treatment and follow-up) were used as independent 
variables. With regard to the psychophysiological response to the stress test, the three 
psychophysiological outcome measures (tension, cortisol, and α-amylase) were used as 
dependent variables, and group, baseline measurement of the dependent variable (t = 0 
minutes), and time levels (t = 20; t = 30; t = 40; t = 60; and t = 80 minutes) were used as 
independent variables. Explorative subgroup analyses were performed to test whether 
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effects were stronger or only held in patients at risk as compared to patients not at risk 
(also see Procedure) by incorporating risk group and risk group by treatment interactions 
into the analysis models. A significant interaction was interpreted as an indication of 
subgroup differences with respect to the effect of the treatment. Stratified analyses were 
performed to gain a better understanding of the nature of the responses in the subgroups 
of patients. 
 For every outcome measure, an unstructured covariance matrix was used to model 
the dependence between repeated measurements of the dependent variable. Owing to 
a slightly unequal distribution of sex across the two groups (p = 0.08) and a trend towards 
higher anxiety scores at baseline in the intervention group (p = 0.09) (see Results section, 
Patient characteristics), all analyses were performed with the covariates sex and baseline 
(pretreatment) anxiety. In addition, cortisol analyses were also performed with the additional 
covariate hormonal contraceptives [36] (see Results section, Patient characteristics). 
 A priori power calculation resulted in an optimal sample size of N = 64 (expected 
adjusted effect size of f = 0.45 of the primary outcome measure psychological distress 
(state anxiety), a power of 0.90, and α = 0.05). However, because there were missing blood 
samples (a venous catheter could not be inserted in n = 15 patients during one or two 
stress tests) and the high drop-out rate before the start of the first stress test was high 
(n = 22; see procedure), we increased the earlier estimate of 64 patients to 96. In total, data 
of the 74 patients included in the analyses were 95% complete regarding psychological 
and physical outcomes at baseline, post-treatment, and follow-up, and 97% complete 
regarding psychophysiological parameters at post-treatment and follow-up. Physiological 
data for three participants at one of the assessment moments (cortisol levels in two 
participants and amylase levels in one participant) were excluded from analyses because 
levels were four standard deviations higher than the mean for at least one of the six time 
points during the stress test. All analyses were performed using SPSS 16.0 for Windows. 
For all analyses, the significance level was α = 0.05 (two-sided). Unless indicated, all results 
are means ± standard deviation (SD).
Results
Patient characteristics
Baseline demographic and disease-related characteristics of the 74 participants are 
presented in Table 1. The two groups did not differ significantly regarding age, education 
level, mean disease activity, and mean disease duration. However, there tended to be 
more women in the intervention group (χ2 = 3.155, p = 0.08). Thirty-three of 74 patients 
were taking  biologics (including etanercept, adalimumab, abatacept, and infliximab), 
54 patients were taking DMARDS (including methotrexate (MTX), sulfasalazine, hydroxy-
chloroquine, leflunomide, and/or azathioprine), 47 patients were taking NSAIDs, and 14 
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patients were taking prednisone (<10 mg/day). Twenty-four patients received medication 
known to affect the ANS (including β-blockers, ACE-inhibitors, Ca2+-blockers, α1-blockers, 
thiazides (or –related), ACh-receptor antagonists, β2-adrenergics, and anti-histamines), 
and 7 patients used hormonal contraceptives (6 intervention, 1 control; χ2 = 3.120, p = 0.08). 
There were no significant group differences in the use of biologics, DMARDs, steroids, and 
medication known to influence the ANS, except for the use of NSAIDs, which was 
significantly higher in the intervention group (χ2 = 7.349, p = 0.01). There were no significant 
group differences in pretreatment measures of negative and positive mood, and disease 
activity, but anxiety scores tended to be higher in the intervention group than in the 
control group (t(67.835) = 21.715, p = 0.09) (Table 2). Consequently, all further analyses 
were performed with covariates sex and baseline anxiety, with the additional covariate 
hormonal contraceptives for endocrine analyses. 
Table 1   Demographic characteristics, disease severity, and medical regime of patients 
with rheumatoid arthritis in the intervention and control groups a
Intervention
(n = 40)
Control
(n = 34)
p-value
No. females/males 27/13 16/18 .08
Age (years ± SD)  57.2 ± 11.8 
(range 24-75)
 60.7 ± 9.2 
(range 26-80)
.17
Education level (%)
Primary
Secondary
Tertiary
  7.5%
60.0%
32.5%
  2.9%
70.6%
26.5%
.56
Disease Activity (DAS28) 2.6 ± 1.0 
(range 0.8-4.5)
2.6 ± 1.1 
(range 0.5-5.1)
.81
Disease duration (years ± SD) 15.7 ± 10.9 
(range 5-51)
12.4 ± 7.6 
(range 3-37)
.15
No. of patients currently 
under treatment for RA 
Biologics
DMARDS
NSAIDs
Steroids (< 10mg/day)
38
17
31
31
9
32
16
23
16
5
.69
.43
.007
.39
a Values are means ± SD. RA, rheumatoid arthritis; DMARDs, disease-modifying anti-rheumatic drugs;  
NSAIDs = nonsteroidal anti-inflammatory drugs.
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Psychological and physical functioning
Satisfaction and usefulness of the training
Patients rated their satisfaction with the intervention with a score of 8.1 ± SD 1.2 and its 
usefulness with a score of 7.6 ± SD 2.0. Approximately 87% of patients in the intervention 
group reported an improvement in stress and tension after the training (little improvement 
by 42%, moderate improvement by 32%, and strong improvement by 13%).
Psychological functioning in intervention and control condition
Means and estimated marginal means (EMM; i.e., means corrected for the covariates) 
(± SEM) of the psychological and physical outcomes are presented in Table 2. A significant 
group effect was found for anxiety (F(1,69.887) = 5.579, p = 0.02); the intervention group 
had a significantly lower anxiety score than the control group after the intervention. 
Furthermore, patients in the intervention group had significantly higher levels of positive 
mood after the intervention than did patients in the control group (group effect, F(1,67.436) 
= 4.851, p = 0.03). No overall group effect was observed for negative mood (F(1,68.389) = 
0.028 p = 0.87). Subgroup analyses showed a significant interaction effect between 
condition (intervention/control) and risk group (high/low) for anxiety (F(1,68.002) = 7.820, 
p < 0.01) and negative mood (F(1,66.893) = 11.509, p <0.01), but not for positive mood 
(F(1,65.985) = 0.205, p = 0.65), indicating that high-risk patients responded differently to 
the stress management training with regard to anxiety and negative mood than did 
low-risk patients. Inspection of the data by post hoc tests revealed that lower anxiety 
scores (group effect, F(1,32.725) = 8.128, p < 0.01) and lower negative mood scores 
(F(1,31.473) = 4.021, p = 0.05) were present in the subgroup of high-risk patients in the 
intervention group compared to high-risk controls, but not in low-risk patients (group 
effect anxiety, F(1,33.898) = 0.019, p = 0.89; reverse group effect negative mood, F(1,31.677) 
= 8.644, p < 0.01). In addition, a trend towards higher positive mood scores was observed 
in high-risk patients in the intervention group compared to controls (F(1,31.578) = 3.548, 
p = 0.07), but not in low-risk patients (F(1,31.256) = 0.691, p =0.41). 
Physical functioning in intervention and control condition
There were no differences in disease activity (DAS28) between control and intervention 
groups after the stress management intervention (F(1,61.610) = 0.004, p = 0.95). Subgroup 
analyses showed no interaction effect between condition (intervention/control) and risk 
group (high/low) (F(1,59.864) = 0.051, p = 0.82).
Psychophysiological stress reactivity
Stress manipulation check
Both after treatment and at follow-up, the stress test induced a significant increase in 
tension (time effect, F(1,73) = 304,899; p < 0.001, and F(1,66) = 182.031, p < 0.001, respectively; 
Figure 2), α-amylase (time effect, F(1,69.211) = 46.003; p < 0.001, and F(1,65) = 21.404, 
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Figure 2   Self-reported response to stress. Mean stress-induced VAS tension levels (± SEM) in 
the intervention (IC) and control (CC) conditions post-treatment (A; IC, n = 40; 
CC, n = 34) and at follow-up (B; IC, n = 36; CC, n = 31).
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p < 0.001, respectively; Figure 3), and cortisol levels (time effect, F(1,69.041) = 29.566; 
p < 0.001, and F(1,63.003) = 9.688, p < 0.01, respectively; Figure 4) in all patients. 
Baseline differences between intervention and control condition
Both after treatment and at follow-up, there were no significant differences between the 
intervention and control groups in baseline levels (t = 0 minutes) of tension (F = 0.230, 
p = 0.63 and F = 0.444, p = 0.51, respectively), α-amylase (F = 0.007, p = 0.93 and F = 0.326, 
p = 0.57, respectively) and cortisol (F = 1.530, p = 0.22 and F = 1.729, p = 0.19, respectively).
Post-treatment psychophysiological stress reactivity
After treatment, levels of self-reported tension in response to the stress task were similar in 
the intervention and control groups (group effect, F(1,69.000) = 0.340, p = 0.56, Figure 2), 
as was autonomic reactivity (group effect α-amylase, F(1,66.359) = 0.068, p = 0.80, Figure 3), 
and endocrine reactivity (group effect cortisol, F(1,64.287) = 0.315, p = 0.58, Figure 4; and 
AUCG: F(1,66) = 0.734, p = 0.40, Table 3), indicating that patients in the intervention group 
did not have an altered psychophysiological response to stress compared to patients in 
the control group after the intervention. Subgroup analyses also showed no interaction 
effect between condition (intervention/control) and risk group (high/low) for psycho-
physiological measures of stress, indicating that high-risk and low-risk patients did not 
respond differently to the stress management training with regard to stress-induced 
levels of tension, α-amylase, and cortisol. 
Follow-up psychophysiological stress reactivity
At the follow-up assessment, self-reported tension elicited by the stress test was 
significantly lower in patients in the intervention group than in patients in the control 
group (group effect, F(1,62.000) = 6.092, p = 0.02, Figure 2). In addition, there was a 
significantly diminished cortisol response (group effect, F(1,59.010) = 4.877, p = 0.03, Figure 
4) and a trend towards a lower total cortisol output (AUCG) in the intervention group 
compared with the control group (AUCG, F(1,60) = 3.689, p = 0.06, Table 3). The autonomic 
response was similar in the two groups (group effect α-amylase, F(1,61.085) = 0.301, 
p = 0.59, Figure 3). Subgroup analyses showed no interaction effect between condition 
(intervention/control) and risk group (high/low) for tension (F(1,60.000) = 1.919, p = 0.17), 
but a trend towards an interaction effect for α-amylase (F(1,58.996) = 2.752, p = 0.10) and 
cortisol (F1,57.100) = 3.682, p = 0.06), indicating that high-risk patients tended to respond 
differently to the stress management training with regard to physiological measures of 
stress than did low-risk patients. Inspection of the data by post hoc tests revealed that 
high-risk patients in the intervention group had or tended to have lower overall levels of 
tension, α-amylase, and cortisol than did high-risk patients in the control group (group 
effect tension, F(1,28.000) = 6.768, p = 0.02; group effect α-amylase, F(1,28.052) = 3.495, 
p = 0.07; group effect cortisol, F(1,25.384) = 7.450, p = 0.01; and AUCG F(1,27) = 5.264, 
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Figure 3   Autonomic response to stress. Mean stress-induced α-amylase levels (± SEM) in 
the intervention (IC) and control (CC) conditions post-treatment (A; IC, n = 39; 
CC, n = 33) and at follow-up (B; IC, n = 35; CC, n = 31).
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Figure 4   Endocrine response to stress. Mean stress-induced cortisol levels (± SEM) in the 
intervention (IC) and control (CC) conditions post-treatment (A; IC, n = 39; CC, 
n = 32) and at follow-up (B; IC, n = 34; CC, n = 31).
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p = 0.03); this was not the case for the low-risk patients (group effect tension, F(1,29.000) = 
1.965, p = 0.17; group effect α-amylase, F(1,28.000) = 1.277, p = 0.27; group effect cortisol, 
F(1,27.000) = 0.818, p = 0.37; and AUCG (F(1,28) = 0.548, p = 0.47).
Discussion
This is the first study to assess psychological functioning and psychophysiological 
responsiveness (subjective, autonomic, and neuroendocrine) to a psychosocial stress task 
in patients with RA who had received training in stress management. Results indicated 
high satisfaction and perceived usefulness of the training, and a lower anxiety and higher 
positive mood after the training in the stress management than in the control group. No 
effect on disease activity or post-treatment psychophysiological stress responsiveness 
was found, but at follow-up (9 weeks after the training) the stress management group 
showed a lower tension and cortisol response to stress than the control group. These 
results were particularly evident in a subgroup of patients psychologically at risk, 
supporting previous findings of increased treatment effects in at-risk patients [32,50]. 
Results of this study suggest that short-term individual stress management training is not 
only able to improve psychological functioning by the level of tension, but may also alter 
psychophysiological responses to stress by reducing levels of cortisol.
 Stress might have detrimental effects on health, particularly in clinical populations. 
Over the last decade, there has been an increasing interest in the physiological effects of 
stress management interventions for patient groups [15–21]. Studies of various forms of 
stress management or cognitive-behavioral therapy in patients with RA have only 
incidentally reported changes in overall disease activity or biological indicators of disease 
after the intervention, such as a decrease in overall disease activity [51,52], self-reported 
disease flare-ups [24], and joint tenderness [53] in the intervention group compared with 
the control group. Changes in cortisol values [54], cytokine INF-c [54], C-reactive protein 
[28], and ESR [51] have also been reported. In a response to the aforementioned studies, 
the current study uniquely investigated the effects of a stress management intervention 
on the acute-phase physiological response to stress. It seems apparent that alterations on 
Table 3   Area under the curve (AUCG) for cortisol (means ± SEM) in the intervention 
(IC) and control (CC) conditions post-treatment and at follow-up
Post-treatment Follow-up
Intervention condition
Control condition
42.59 (4.50)
54.04 (7.30)
33.46 (2.73)
47.05 (6.96)
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the physiological level might particularly occur when interventions are successful in 
changing the appraisal or perception of stressors [55]. We found that anxiety was 
significantly, but modestly, reduced after 2 weeks of individual stress management 
training. After an interval of 9 weeks, during which participants practiced the stress 
management exercises at home, focusing on long-term stress management and relapse 
prevention, stress-induced tension was slightly lower and there was a lower stress-evoked 
cortisol response in the intervention group compared with patients in the control group. 
The effect of stress management training on psychophysiological stress responsiveness 
appears to be delayed, possibly because repeated exercise during two months might 
have stronger effects than exercise of two weeks; it takes time to integrate the learned 
exercises into the daily lives of participants and to help them cope with stress-provoking 
situations. Results are in line with preliminary evidence suggesting that intervention-relat-
ed physiological changes, particularly those related to the immune system, might become 
more pronounced with time [52,56].
 To our knowledge, only two other studies assessed the acute-phase physiological 
response to a laboratory stressor after stress management [35,36]. Healthy males 
participating in a group-based cognitive-behavioral stress management training showed 
a significantly diminished cortisol response to the TSST 2 weeks after the intervention [35], 
and this pattern, although less pronounced, was also observed 4 months after a similar 
training in male and female subjects [36]. Our results provide preliminary evidence that, in 
line with recent findings in healthy populations, stress management might also alter 
endocrine responsiveness to a stress task in a clinically comprised population of patients 
with RA. Our findings on endocrine responsiveness extend recent results suggesting that 
basal cortisol levels and stress-induced cortisol reactivity in patients with RA might not be 
significantly different from those of healthy participants [8,57]. This implies that the 
endocrine stress response system could be a target for stress management interventions 
not only in healthy subjects, but also in patients with immune-mediated diseases such as 
RA. These interventions might prevent the possible negative physiological consequences 
of stress on health. Although a reduced psychophysiological stress reaction was found at 
the follow-up in the stress management group as compared to the control group, this was 
not accompanied by a simultaneous decrease in disease activity. Because the psycho-
physiological results were only found at the longer term, this could imply that the effects 
on disease activity may have occurred even later. Theoretically, a lowered cortisol response 
might reflect a decreased psychological stress level and/or an improvement in the 
functioning of all physiological regulatory systems [e.g., 54]. However, no studies have yet 
reliably shown the consequences of non-pharmacological cortisol changes in rheumatoid 
arthritis and future studies with a longer-term follow-up are needed to provide insight 
into this question.
 In contrast to altered responses on self-reported tension and cortisol, autonomic 
reactivity to stress was similar in the two patient groups, as evidenced by the similar levels 
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of α-amylase levels in saliva, an indicator of sympathetic activity [58,59]. The stress 
management intervention included principles and techniques that are mainly aimed at 
reducing tension and negative emotion by inducing a generalized relaxation response 
[60], which is hypothesized to dampen sympathetic activity [61]. Several studies 
investigating the effects of relaxation on autonomic changes at baseline or in stress-pro-
voking situations have reported reduced galvanic and cardiovascular reactivity, but 
evidence of altered autonomic responsiveness is not unequivocal [11–13,62–64]. Our 
results suggest that the responses of the ANS and HPA axis to (repeated) stress are not 
necessarily synchronous; a phenomenon that has also been documented after recurrent 
exposure to the same stressful stimulus, both in animal and human research [65]. Whereas 
(social-evaluative) threat and uncontrollability might be the most important components 
contributing to an endocrine response to a laboratory stressor [66], autonomic reactivity 
could be an a-specific response to more generalized arousal, such as the effort to do well 
[67,68]. As the cortisol response to a stressor is sensitive to emotions and appraisals that are 
associated with threats of the social self, such as rumination and submissiveness [69], we 
hypothesize that the training specifically influenced the endocrine response to stress due 
to changes in specific emotions.
 Overall, subgroup analyses showed that the effects of the stress management 
training on specific psychological outcomes and physiological stress responses (anxiety 
and cortisol levels) were particularly evident in a subgroup of patients at risk. Previous 
studies have shown that particularly patients with RA with heightened levels of anxiety 
and depression benefit from cognitive-behavioral therapy, not only after treatment but 
also at follow-up assessments [32]. The importance of subgroup analyses has also been 
acknowledged in other patient populations [70–72]. The lower anxiety and cortisol levels 
that were observed in the intervention group at follow-up might be attributed to the 
subgroup of high-risk patients. Additional subgroup effects were found for negative 
mood and α-amylase levels at follow-up in the subgroup of high-risk patients only. The 
latter findings support the idea that beneficial effects of treatment might be particularly 
observed in dysfunctional groups of patients and highlights the importance of identifying 
subgroups of patients most likely to benefit from a specific intervention in future studies 
of stress.
 This study has several limitations. First, exclusion criteria with regard to physical and 
psychological comorbidity may have resulted in a homogenous sample of patients 
showing relatively mild disease activity at baseline. In addition, the sample size was 
relatively small for the subgroup analyses, particularly when considering multiple testing. 
Therefore, the results of this study, particularly those regarding subgroups of patients, 
should be interpreted with caution and should be replicated in larger groups of patients. 
Secondly, there were marginal baseline differences between the intervention and control 
groups, with a trend towards a higher female-to-male ratio in the intervention group and 
higher anxiety scores. We statistically controlled for differences by adding these 
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confounders as a covariate in all analyses, in addition to the use of oral contraceptives for 
endocrine analyses. It is well-documented that not only has a person’s sex differential 
effects on physiological stress response patterns [73,74], but also the menstrual cycle, 
menopause, and the use of oral contraceptives of females influence the cortisol response 
to laboratory stress paradigms [75], which makes it difficult to control for these effects in a 
heterogeneous group of patients with arthritis. Thirdly, due to the character of the study, 
which included a no-treatment control condition, it was impossible to blind patients and 
researchers for the treatment status of the participants. However, by blinding the persons 
conducting the Trier Social Stress Test for the treatment status of participants, we tried to 
limit possible bias on the psychophysiological stress response as much as possible. Lastly, 
we decided against pre- and post-treatment assessment of psychophysiological stress 
reactivity, because repeated exposure to the stress test has been found to elicit small 
habituation effects [76,77]. In addition, the small effects found on psychophysiological 
measures at the follow-up assessment might have been larger if the stress test would have 
been performed only once, at the follow-up assessment.
 This is the first study to provide preliminary evidence that a relatively short stress 
management intervention not only improves psychological functioning, but may also 
influence the psychophysiological response to stress (self-reported tension and cortisol 
reactivity) in patients with RA, particularly those psychologically at risk. Our study 
highlights the need to look at individual differences in stress responsiveness and 
psychological factors that are able to influence stress response patterns. Interventions 
such as the current stress management training, alone or as a part of a more comprehensive 
treatment programme, may prove useful in preventing the detrimental effects of stress on 
patients with systemic inflammatory diseases, such as RA.
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Abstract
Introduction Psychological stress may alter immune function by activating physiological 
stress pathways. Building on our previous study, in which we report that stress management 
training led to an altered self-reported and cortisol response to psychological stress in 
patients with rheumatoid arthritis (RA), we explored the effects of this stress management 
intervention on the immune response to a psychological stress task in patients with RA.
Methods In this study, 74 patients with RA, who were randomly assigned to either a 
control group or a group that received short stress management training, performed the 
Trier Social Stress Test (TSST) 1 week after the intervention and at a 9-week follow-up. 
Stress-induced changes in levels of key cytokines involved in stress and inflammatory 
processes (for example, interleukin (IL)-6 and IL-8) were assessed.
Results Basal and stress-induced cytokine levels were not significantly different in patients 
in the intervention and control groups one week after treatment, but stress-induced IL-8 
levels were lower in patients in the intervention group than in the control group at the 
follow-up assessment.
Conclusion In line with our previous findings of lower stress-induced cortisol levels at the 
follow-up of stress management intervention, this is the first study to show that relatively 
short stress management training might also alter stress-induced IL-8 levels in patients 
with RA. These results might help to determine the role of immunological mediators in 
stress and disease.
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Introduction
Psychological stress may alter immune function by activating physiological pathways of 
stress, such as the autonomic nervous system and the hypothalamus–pituitary–adrenal 
axis, which in turn interact with the immune system [1-4]. Consequently, stress could have 
negative effects on health, particularly in populations with immune dysfunction, such as 
patients with rheumatoid arthritis (RA). The pathophysiological mechanisms involved in 
stress and disease exacerbation have not yet been elucidated.
 Psychological responses to stress that might lead to immune dysregulation can be 
altered by interventions aimed at reducing psychological stress [1,5]. As yet there is no 
consensus about whether and to what extent stress management interventions are able 
to alter immune function. In an extensive meta-analysis by Miller and Cohen there was 
only modest evidence that different types of stress management interventions change 
basal immune function in healthy and clinical populations, with most consistent changes 
being found in basal total leukocyte counts and secretory immunoglobulin A levels [6]. 
More recent studies reported that psychological interventions for patients with HIV or 
cancer changed basal lymphocyte proliferation and basal levels of proinflammatory 
cytokines [7-10]. Even though the effects of psychological interventions in patients with 
RA have been extensively studied and reviewed [11-16], there are only incidental reports 
of immune changes after psychological interventions in patients with RA, such as changes 
in interleukin (IL)-6 or interferon-gamma (IFNγ) [17,18], or in immune measures indicative of 
disease status, such as C-reactive protein and erythrocyte sedimentation rate [19-24]. 
Potentially, previous effects in RA might be limited because changes in immune function 
in response to a real-life stressor have not yet been investigated combining both a stress 
management intervention and a stress induction paradigm. Particularly then, the benefits 
of stress management training can become evident because patients are challenged to 
cope with a stressful situation. 
 We previously showed that a short course of stress management training decreased 
the subjective distress response and stress-induced cortisol levels in patients with RA at a 
follow-up assessment, and especially in those patients psychologically at risk [5]. In the 
present study, we explored the effects of the intervention on stress-induced levels of key 
cytokines involved in disease progression (for example, IL-6 and IL-8) in patients with RA, 
with stress being elicited by the Trier Social Stress Test. Building on our previous findings 
[5], we expected that patients in the intervention group would show an altered cytokine 
response to acute psychosocial stress compared with controls at the 9-week follow-up 
assessment. We also explored immune effects specifically in patients psychologically at risk.
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Materials and methods
This study was part of a larger trial for which the methods and CONSORT statement have 
been described extensively elsewhere [5]. The study protocol was approved by the 
regional medical ethics committee (CMO Region Arnhem-Nijmegen) and was registered 
in The Netherlands National Trial Register (NTR 1193). Written informed consent was 
obtained from all participants.
Participants and procedure
Participants
Ninety-six eligible patients with RA [25] were randomized to one of two parallel groups: 
the control or the intervention condition. After randomization, 19 participants withdrew 
before the first stress test and three participants were excluded based on our predefined 
exclusion criteria (that is, use of psychiatric medication). In addition, seven out of 74 
participants withdrew before the second stress test. Reasons for withdrawal were physical 
comorbidity, severe illness or death of a significant other, a change in pharmacotherapy, 
or lack of motivation (for more information on completers and dropouts, see the flowchart 
in [5]). There were no differences in sociodemographic variables and psychological and 
physical functioning at baseline between the dropouts and the completers. For explorative 
subgroup analyses of patients psychologically at risk, participants were post hoc divided 
into two subgroups using a median split of a composite score for baseline anxiety and 
negative mood [5].
Study design
Participants performed a stress test 3 weeks after the first assessment (post treatment) 
and 9 weeks thereafter (follow-up). One-half of the participants had participated in an 
individual stress management training program between the first and second assessments. 
The control group received care as usual. Stress test sessions were run between 13:00 and 
15:30 hours. Participants refrained from using caffeine, alcohol, nicotine, or physical 
exercise on the test day, and from eating 2 hours before the first blood sample was drawn. 
Forty minutes before the stress test, a venous catheter was inserted into the nondominant 
arm and participants rested for 20 minutes. Blood samples were taken at baseline (that is, 
after 20 minutes of rest), immediately after the stress test, and 20 and 60 minutes later (t = 
0, t = 20, t = 40, and t = 80 minutes, respectively).
Stress task
The Trier Social Stress Test is a standardized laboratory stress task consisting of a mock job 
interview and mental arithmetic, and induces self-reported, neuroendocrine, and autonomic 
nervous system responses [26,27].
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Stress management training
Participants in the intervention group received individual stress management training as 
described previously [5]. The program consisted of four individual 1-hour sessions of stress 
management with a trained therapist over 2 consecutive weeks and included applied, 
progressive, cue-controlled, and differential relaxation techniques, as well as psycho-edu-
cation, breathing and visualization exercises. After the training, patients were encouraged 
to stick to a relapse-prevention checklist during the 9-week follow-up period.
Measures
This study builds on a previous study [5], in which general psychological (for example, 
anxiety), physical (28-joint Disease Activity Score), autonomic (α-amylase) and 
neuroendocrine (cortisol) outcomes are reported, by further exploring immune responses 
to stress through measurement of various circulating cytokines.
Cytokine assay
The blood samples that were collected during the two stress tests (post treatment and 
follow-up) were stored at –35°C until analysis. Based on the literature of psychophysiolog-
ical stress reactivity in healthy populations and chronic inflammatory diseases, such as RA 
[1,28-30], human IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IFNγ and tumor necrosis factor alpha 
(TNFα) were measured in serum using human cytokine multiple kits (Invitrogen 
Corporation, Camarillo, CA, USA) according to the manufacturer’s instructions. Samples 
were analyzed with a Luminex® 100 TM instrument (Luminex Corporation, Austin, TX, 
USA). The sensitivity of the cytokine assay was <5 pg/ml for all cytokines measured. To 
reduce error variance caused by between-run variation, all samples from one participant 
were analyzed in the same run.
Statistical analysis
Data for the 74 participants who completed the study protocol were analyzed. Skewed 
data were logarithmically transformed to generate unskewed data distributions before 
statistical analysis. Normal distributions and residuals were not obtained after logarithmic 
transformation of data for IL-5 and IFNγ levels. Between-group differences in age, sex, 
education, and psychological measures at baseline were tested with independent 
Student’s t tests and chi-square analyses. Baseline cytokine levels (t = 0 minutes) were 
compared between intervention and control groups with analyses of covariance. Cytokine 
responses to the Trier Social Stress Test (post treatment and follow-up) were evaluated 
using a linear mixed model taking into account the specific design features of the study. 
Cytokine levels (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IFNγ, and TNFα) were used as 
dependent variables; and group, baseline measurement of the dependent variable (t = 0 
minutes), and time (t = 20 minutes, t = 40, minutes, and t = 80 minutes) were used as 
independent variables. As group by time interactions were not observed, the final model 
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contained only main effects. Explorative subgroup analyses were performed to test 
whether effects were particularly detected in patients psychologically at risk as compared 
with patients not at risk [5] by incorporating risk group and risk group by treatment 
interactions into the models. A significant interaction was interpreted as indicating that 
there were subgroup differences in the effect of the treatment. Stratified analyses were 
performed to gain a better understanding of the nature of the responses in the patient 
subgroups. For each outcome measure, an unstructured covariance matrix was used to 
model the dependence between repeated measurements of the dependent variable. 
Owing to (a tendency towards) an unequal sex distribution, use of hormonal contraceptives, 
baseline anxiety scores, and the use of nonsteroidal anti-inflammatory drugs across the 
two groups [5], all analyses were performed with these four covariates.
 Because participants dropped out mostly prior to the first stress test (see previous 
section and [5]), and consequently no stress test data were available for these participants 
1 week after treatment and at follow-up, intention-to-treat analyses were not performed 
[31]. In total, the data for the 74 patients (post treatment) and 67 patients (follow-up) 
included in the analyses were 85% complete, mainly because a venous catheter could not 
be inserted in a number of patients during one or both stress tests. Cytokines were 
significantly intercorrelated with at least five to nine of the other cytokines, and significant 
correlations ranged from 0.20 to 0.80. Undetectable levels (in percentage of available 
samples) of IL-1β (33%), IL-2 (41%), IL-4 (37%), IL-5 (43%), IL-6 (27%), IL-7 (41%), IL-8 (13%), IL-10 
(25%), IFNγ (70%) and TNFα (16%) were set to zero and included in all analyses. The 
Bonferroni correction for multiple testing was not applied due to the explorative nature of 
this study, the small sample size, and the high intercorrelation of most cytokines, which 
makes the method even more conservative than in other applications [32]. Analyses were 
performed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL, USA). For all analyses, the 
significance level was α = 0.05 (two-sided).
Results
Psychophysiological stress reactivity
Cytokine levels at baseline
Both after the intervention and at follow-up there were no significant differences between 
the intervention and control groups in baseline levels (t = 0 minutes) of all cytokines 
(p >0.05) (Table 1 and Additional file 1).
Post-treatment stress-induced cytokine levels
Immediately after the intervention, stress-induced cytokine levels were similar in the 
intervention and control groups (group effect, p > 0.10 for all cytokines), indicating 
that patients in the intervention group did not have an altered immune response to 
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Table 1   Baseline and stress-induced cytokine levels (pg/ml) in the intervention and 
control conditions post-treatment and at follow-up
t = 0 min t = 20 min t = 40 min t = 80 min
IL-1β
Post-treatment IC 92.39 (33.6) 106.7 (41.4) 111.3 (46.4) 111.6 (45.4)
CC 114.3 (38.6) 130.9 (43.5) 116.6 (37.0) 136.7 (59.0)
Follow-up IC 66.48 (18.8) 77.43 (23.7) 69.49 (20.1) 70.89 (19.9)
CC 119.0 (43.0) 100.7 (32.5) 98.13 (34.1) 117.6 (41.2)
IL-2
Post-treatment IC 28.11 (11.1) 30.85 (11.9) 34.83 (15.6) 31.58 (13.4)
CC 32.60 (14.0) 42.86 (19.2) 38.77 (17.3) 47.51 (27.0)
Follow-up IC 20.28 (7.20) 25.27 (10.3) 17.37 (7.23) 19.32 (7.15)
CC 35.89 (18.4) 27.82 (14.1) 28.12 (14.0) 32.24 (15.4)
IL-4
Post-treatment IC 48.22 (24.9) 48.30 (21.0) 48.98 (20.3) 52.90 (25.7)
CC 60.18 (29.3) 72.79 (30.1) 65.76 (28.4) 65.39 (29.9)
Follow-up IC 33.22 (13.9) 35.16 (14.9) 33.62 (12.6) 33.08 (13.6)
CC 56.48 (23.2) 51.79 (20.0) 50.91 (21.5) 56.99 (24.8)
IL-5
Post-treatment IC 20.94 (15.2) 21.89 (15.3) 23.24 (16.5) 21.49 (15.6)
CC 5.129 (2.17) 7.887 (3.72) 7.006 (2.94) 8.948 (4.51)
Follow-up IC 16.23 (12.8) 15.89 (12.1) 15.14 (12.1) 17.60 (14.5)
CC 7.368 (3.48) 6.048 (2.95) 5.929 (2.60) 6.969 (3.11)
IL-6
Post-treatment IC 36.46 (11.2) 34.94 (9.69) 38.80 (11.1) 40.36 (11.2)
CC 30.18 (9.36) 41.18 (15.2) 33.54 (10.7) 39.57 (16.2)
Follow-up IC 25.79 (7.51) 23.39 (7.90) 23.63 (6.41) 23.18 (6.68)
CC 31.20 (14.1) 30.18 (12.0) 29.22 (11.3) 30.43 (11.6)
IL-7
Post-treatment IC 70.11 (26.0) 70.27 (24.8) 73.62 (24.7) 69.51 (27.2)
CC 52.69 (16.5) 63.65 (20.5) 55.94 (18.5) 60.73 (21.8)
Follow-up IC 52.54 (23.4) 54.54 (23.5) 49.13 (19.6) 53.32 (22.2)
CC 52.80 (18.4) 53.69 (18.0) 48.64 (18.2) 52.89 (19.1)
IL-8
Post-treatment IC 22.14 (3.67) 16.19 (3.70) 17.02 (3.53) 14.47 (3.41)
CC 29.55 (6.50) 34.04 (7.81) 29.45 (6.75) 28.18 (7.14)
Follow-up IC 19.51 (4.28) 13.97 (4.67) 12.53 (4.00) 10.37 (3.38) a
CC 33.63 (6.68) 33.46 (8.33) 29.31 (7.83) 23.64 (5.72)
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stress compared with patients in the control group. Subgroup analyses also showed no 
interaction between condition (intervention/control) and psychological risk group (high/
low) (p > 0.20 for all cytokines) (Table 1 and Additional file 1).
Follow-up stress-induced cytokine levels
At the follow-up assessment, stress-induced IL-8 levels were significantly lower in patients 
in the intervention group than in patients in the control group (group effect, F(1, 54.273) = 
5.421, p = 0.02) (Figure 1). Exploration of IL-8 responses in subgroups of patients psycho-
logically at risk and not at risk showed a tendency towards an interaction effect between 
condition (intervention/control) and risk group (high/low) (interaction effect, F(1, 51.990) = 
3.244, p = 0.08), indicating that high-risk patients tended to respond differently to stress 
management training than low-risk patients. Post hoc tests revealed that IL-8 levels were 
more decreased in high-risk patients in the intervention group than in the low-risk 
intervention group. Omission of the data for patients with undetectable IL-8 levels from 
analyses did not change the main result (group effect, F(1, 48.178) = 8.226, p = 0.01), and 
Table 1   Continued
t = 0 min t = 20 min t = 40 min t = 80 min
IL-10
Post-treatment IC 172.0 (75.2) 183.7 (81.0) 175.5 (80.0) 164.7 (75.8)
CC 49.33 (25.9) 57.07 (31.8) 73.55 (48.1) 71.02 (45.9)
Follow-up IC 72.67 (35.6) 115.6 (54.6) 85.90 (41.9) 78.49 (37.4)
CC 46.83 (26.8) 43.63 (24.2) 39.90 (20.9) 50.27 (28.0)
IFNγ
Post-treatment IC 1.063 (0.39) 1.070 (0.43) 0.821 (0.33) 0.706 (0.31)
CC 1.545 (0.45) 8.328 (4.98) 6.623 (4.91) 7.591 (5.70)
Follow-up IC 0.857 (0.39) 0.772 (0.32) 0.925 (0.36) 1.062 (0.38)
CC 4.389 (2.87) 8.535 (6.37) 6.597 (4.98) 7.377 (5,94)
TNFα
Post-treatment IC 31.40 (8.54) 34.98 (8.95) 34.82 (8.35) 35.60 (10.7)
CC 34.56 (12.4) 39.35 (12.7) 36.00 (11.1) 35.45 (11.2)
Follow-up IC 23.90 (5.75) 26.44 (6.94) 24.74 (5.89) 25.19 (6.44)
CC 26.26 (8.74) 23.84 (7.17) 25.04 (9.44) 25.93 (8.92)
Data presented as mean (± standard error of the mean). CC, control condition; IC, intervention condition; 
IFNγ, interferon gamma; IL, interleukin; TNFα, tumor necrosis factor alpha. aSignificant between-group effect 
(p ≤ 0.05). Means at the 4 time points. Statistical analyses performed on ln-transformed data.
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Figure 1   Interleukin-8 response to stress. Mean ± standard error of the mean interleukin 
(IL)-8 levels (pg/ml) at t = 0 minutes (baseline/pre-Trier Social Stress Test (TSST)), 
t = 20 minutes, t = 40 minutes, and t = 80 minutes (post TSST) of patients in the 
intervention conditions (IC) and control conditions (CC) immediately after the 
intervention (A: IC, n = 35; CC, n = 32) and at follow-up (B: IC, n = 33; CC, n = 28).
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high-risk patients still showed a (significantly) different response to the training than 
low-risk patients (interaction effect condition and risk status, F(1, 46.212) = 4.472, p = 0.04). 
For all other cytokines, there were no significant differences in levels after stress induction 
between the intervention and control groups at follow-up (p >0.10) (Table 1 and Additional 
file 1).
Discussion
This is the first study to explore the response of circulating cytokines to a psychosocial 
stress test after stress management training in patients with RA. Although no differences 
in basal and stress-induced levels of key cytokines were observed immediately after the 
intervention, patients in the intervention group had lower stress-induced IL-8 levels than 
patients in the control group at the follow-up assessment. Results suggest that a short 
individual training in stress management might alter immune parameters after a 
psychosocial stress task in a population with immune dysfunction; namely, patients with 
RA. This finding is in line with our previous report indicating that the stress management 
training improves psychological functioning and influences subjective and endocrine 
parameters of stress (that is, distress and cortisol levels) at the follow-up assessment [5].
 Stress-induced immune effects after a stress management intervention have not so 
far been investigated in rheumatic patients, including patients with RA. Stress induction 
paradigms using only a single stress exposure have yielded relatively robust effects on 
IL-6, IL-1β, and IFNγ levels in various healthy and patient populations [28,29]. Stress exposure 
also changes levels of these and other cytokines in rheumatic patients, but results are 
much less consistent [2]. For example, IL-6 levels increased in response to a cold pressor 
task in patients with RA and juvenile idiopathic arthritis [33,34], but IL-6 and IFNγ levels 
remained unchanged after psychological stress was induced in patients with RA and 
systemic lupus erythematosus [35-37]. Differences in stress induction paradigms and 
detection methods used and differences in the heterogeneity of patient samples might 
explain the inconsistent findings. Immune function after stress management training has 
only been measured incidentally in patients with RA and, moreover, has not been 
investigated in combination with stress exposure. One study reported altered basal IFNγ 
levels after emotional disclosure therapy for patients with RA [17], while lower basal IL-6 
levels were observed after cognitive behavioral therapy compared with meditation and 
education groups [18]. Several other studies also reported other types of biological 
markers, mostly erythrocyte sedimentation rate and/or C-reactive protein, often as part of 
assessing overall disease activity, but did not find intervention-related changes [21,22,24,38-
46]. In our study, the stress management intervention did not change basal or 
stress-induced cytokine levels, except for a decrease in stress-induced IL-8 levels at 
follow-up.
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 Chemotactic IL-8 is a key player in the acute exacerbation of inflammatory conditions, 
directing neutrophils and other cell types (for example, monocytes and lymphocytes) to 
sites of inflammation when homeostasis is disrupted [47]. Blocking the actions of IL-8 has 
been shown to prevent acute inflammation in animal models [48]. The lipopolysaccha-
ride-stimulated production of IL-8 has been found to be positively correlated with 
perceived stress in healthy adults, and this could be primarily attributed to negative affect 
[49,50]. However, IL-8 levels did not change after the induction of stress with the cold 
pressor task in patients with juvenile idiopathic arthritis and healthy controls [34]. Whether 
IL-8 acts as a more general marker of stress or whether it is specifically involved in the 
physiological stress response of patients with RA is not yet clear. Consequently, future 
studies should compare IL-8 responses to stress and stress management training in both 
healthy and clinical populations. Interestingly, the effect of the stress management 
training on stress-induced IL-8 levels tended to be particularly evident in patients with 
heightened levels of anxiety and negative mood. We found comparable effects for 
self-reported levels of tension and cortisol levels in our previous report [5], but these 
measures were not related to IL-8 levels in this study. In addition, the effectiveness of 
psychological treatment for RA patients at risk was reported previously [51], which 
warrants further research into the benefits of stress management on different types of 
psychophysiological parameters in high-risk patients.
 This study had several limitations. The relatively homogeneous and small sample of 
patients with mild RA prevents generalization of our findings. The normal range for many 
immune parameters is very broad and psychological interventions, especially of short 
duration, might not induce physiological changes of sufficient magnitude or duration to 
move cytokine levels beyond this range [6]. Nevertheless, intervention studies have 
demonstrated that immune alterations occur when people display a change in cognition 
[52] and emotion [7]. Moreover, intervention-related immune changes could have been 
masked by biological forces, such as disease flare-ups and biological treatments that 
affect the patients’ immune system [6]. Although we tried to limit effects of disease 
flare-ups by monitoring the patients’ disease status and ruled out that treatment effects 
were caused by differences in biological treatment protocols through covariate analyses, 
we cannot preclude that this problem might have influenced our results. Prompted by 
earlier unequivocal findings of stress-induced changes to immune function in rheumatic 
patients [2], the high intercorrelation of most cytokines, and the small sample size, 
Bonferroni correction for multiple testing was not applied in this explorative study. Future 
research should try to replicate our findings and, if possible, apply the Bonferroni correction 
to data with large sample sizes. Moreover, the direction of other cytokine responses 
observed in this study (for example, IFNγ) seems consistent with the stress literature and 
tentatively suggests a broader effect of stress management training on immune function, 
but larger studies are needed to validate this effect. Furthermore, no statements can be 
made about the clinical relevance of our results, especially since the intervention was of 
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short duration (four 1-hour sessions over 2 weeks) and disease activity did not improve 
over the course of our study [5]. A longer intervention that may produce more pronounced 
effects might overcome these problems. Another general problem concerning immune 
markers in stress research, particularly circulating cytokines, is the ambiguity regarding the 
interpretation of findings. Circulating levels of cytokines are thought to reflect levels of 
systemic inflammation and are correlated with disease activity and radiographic 
progression [53]; however, changes in cytokine concentrations from baseline might not 
indicate de novo cytokine production or clearance, but a redistribution of existing 
cytokines from or into the periphery [54]. To what extent these alterations represent 
adaptive or maladaptive immune processes is not well understood and needs further 
investigation.
Conclusions
Patients with RA who received training in stress management not only show changes in 
the subjective and cortisol response to stress [5], but might also be characterized by an 
altered immune response to stress; that is, lower IL-8 levels. Although results of this and 
our previous study need validation in larger studies, they provide preliminary evidence 
that a short psychological intervention is not only able to improve psychological 
functioning, but also acts on the neuroendocrine and immune systems and therefore 
might have the potential to ameliorate the possible harmful effects of stress on health in 
patients with RA. Stress management training might prove to be beneficial as an adjunct 
to standard therapy to control arthritis symptoms.
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Appendix
Additional file 1
Additional file 1 the mean response to stress of (A) IL-1β, (B) IL-2, (C) IL-4, (D) IL-5, (E) IL-6, 
(F) IL-7, (G) IL-8, (H) IL-10, (I) IFNγ, and (J) TNFα (in pg/ml ± standard error of the mean) at 
t = 0 minutes (baseline/pre TSST), t = 20 minutes, t = 40 minutes, and t = 80 minutes (post 
TSST) for patients in the intervention condition (IC) and control condition (CC) immediately 
after the intervention (post; red) and at follow-up (FU; blue).
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Summary
Stress is one of the factors believed to play a role in the maintenance or exacerbation 
of chronic inflammatory diseases, such as rheumatoid arthritis (RA) and psoriasis. The 
physiological stress response system, that is, the ANS and HPA axis, is activated when a 
stressful situation is encountered. Its bidirectional relationship with the immune system 
mediates an important link between stress and chronic inflammatory diseases. How stress 
activates these physiological pathways in patients with inflammatory conditions and to 
what extent they are altered in the light of chronic inflammation is not yet fully understood. 
The overall goal of this thesis was to further elucidate the nature of the psychophysiological 
stress response system of patients with chronic inflammatory diseases. Furthermore, this 
thesis adds insight into the psychophysiological effects of stress-reducing interventions 
that are aimed at counteracting the possible detrimental effects of stress on health. This 
chapter will summarize the main findings of the experimental studies that were conducted.
The first part of this thesis aimed to give a greater insight into the psychophysiological 
stress response of patients with chronic inflammatory conditions, such as RA and psoriasis, 
and to investigate whether and how the stress response system might be altered in these 
patients. We investigated whether patients with different chronic inflammatory conditions 
differ in their physiological response to stress, and whether patient groups differed in their 
response to stress from healthy individuals without chronic inflammatory condition. 
 In Chapter 2, we reviewed the literature on psychophysiological stress reactivity 
in patients with various inflammatory rheumatic diseases. We extensively summarized 
and discussed autonomic, neuroendocrine, and immune responses to different types of 
short-term experimental physical and psychological stress tasks in patients with RA, 
systemic lupus erythematosus (SLE) and juvenile ideopathic arthritis (JIA). Sixteen studies 
published between 1985 and 2009 complied with the inclusion criteria and were 
evaluated. These studies assessed a wide variety of stress induction paradigms, including 
cognitive stress tasks (e.g., Stroop, arithmetic, memory test), psychosocial stressors (e.g., 
Trier Social Stress Test), physical exercise (ergometer or treadmill test), or sensory stressors 
(e.g., cold pressor, heat pulses, acoustic test, or pupillary light flash) in patients and control 
subjects without inflammatory condition. Overall, there was hardly any evidence that 
autonomic and neuroendocrine basal function and stress-induced responses were altered 
in patients compared to control subjects. However, patients showed disease-specific 
alterations in the immune response to stress compared to control subjects. Clearly, 
the large heterogeneity of studies with regard to outcome parameters, stress tests, 
measurement points and patient characteristics thwarted the interpretation of findings 
and an adequate comparison of studies. In particular, the role of pharmacotherapy, age, 
sex, and disease severity should be taken into account when evaluating psychophysiological 
stress responses in future studies. 
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In Chapter 3 and 4, psychophysiological responses to stress were investigated in patients 
with two prototypic chronic inflammatory diseases, RA and psoriasis, and in healthy 
controls. Participants were subjected to a psychosocial stress task (Trier Social Stress Test) 
and self-reported tension levels, indices of SAM and HPA axis function (salivary α-amylase 
and cortisol levels, respectively), and immune system parameters (circulating cytokine 
levels) were measured at baseline and up to 1 hour after cessation of the stress test. In 
Chapter 3, we found that the salivary cortisol response to stress was significantly increased 
in patients with psoriasis compared to patients with RA and healthy controls. There were 
no differences in subjective tension and α-amylase responses to stress among the three 
groups. Covariate analyses with possible confounders, such as various pharmacotherapies 
(e.g., biologics, topical or systemic corticosteroids, DMARDs, and NSAIDs), age, sex, BMI, 
smoking status, menopausal status, and psychological well-being, did not yield different 
results. In Chapter 4, we reported that all basal cytokine levels, except IL-8, were significantly 
elevated in patients with RA compared to patients with psoriasis and controls. When 
controlling for baseline differences in cytokine levels, the IL-1β and IL-2 response to stress 
was significantly heightened in patients with RA compared to the other groups. Again, 
statistically controlling for pharmacotherapies, age, sex, hormonal contraceptives or 
menopausal status did not change the results. The results of Chapters 3 and 4 suggest a 
distinct cortisol response to stress in psoriasis and a distinct cytokine response to stress in 
RA compared to the other groups, but results should be interpreted with caution due to 
the explorative nature of this study.
The second aim of this thesis was to investigate whether a stress management intervention was 
able to alter the psychophysiological response to stress in patients with RA. In Chapter 5 
and 6, the effects of individual short-term stress management training for patients with RA 
on overall psychological and physical functioning and on the psychophysiological response 
to a psychosocial stress task (Trier Social Stress Test) were evaluated. Patients with RA were 
randomized to either the intervention or the control group, and subjected to the TSST 
immediately after the intervention and at a 9-weeks follow-up. Measures of psychological 
and physical functioning were assessed before and after the stress management training 
and indices of sympathetic, neuroendocrine and immune function (salivary α-amylase, 
salivary cortisol, and circulating cytokine levels) were measured during and after the two 
stress tests. After the baseline assessment half of the participants enrolled in the training 
program. Patients in the intervention group received four individual training sessions in 
stress management over two consecutive weeks. The sessions were based on psycho- 
education and the principles of applied relaxation, including progressive, cue controlled, and 
differential relaxation. In addition, patients were taught breathing and visualization exercises. 
During the training, participants were encouraged to make homework assignments on 
a daily basis. After the training, participants were encouraged to continue this practice, 
as well as to stick to a relapse-prevention program during the time of the study. 
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 In Chapter 5, we showed that the short-term stress management training overall 
improved psychological functioning (anxiety and positive mood) in patients in the 
intervention group compared to the control group (post-treatment and follow-up 
combined). In addition, the training decreased subjective tension and cortisol levels in 
response to the stress test at the follow-up assessment, but not immediately after the 
intervention. The effect of the intervention on psychophysiological stress reactivity (e.g., 
cortisol levels) was particularly evident in patients psychologically at risk (i.e., with 
heightened levels of psychological distress). In Chapter 6, lower stress-induced IL-8 levels 
at the follow-up assessment (not immediately after treatment) were reported in patients 
in the intervention group compared to patient controls, in line with our results on tension 
and cortisol in Chapter 5. Again, the effect of the training tended to be more pronounced 
in patients psychologically at risk compared to low-risk patients. When combined, the 
results of this study indicate that a brief training in stress management is able to improve 
psychological functioning and alter the neuroendocrine and immune response to acute 
stress in patients with RA.
 To conclude, the results of the studies in this thesis suggest that patients with different 
chronic inflammatory diseases show a disease-specific psychophysiological response to 
stress and that brief training in stress management can alter this psychophysiological 
stress response in patients with RA.

Chapter 8
General Discussion
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General discussion
A growing body of evidence shows a link between stress factors and exacerbation of 
disease severity in a multitude of conditions, including infectious diseases and chronic 
inflammatory diseases [1-8]. Patients with chronic inflammatory conditions, such as rheumatoid 
arthritis (RA) or psoriasis, are in danger of slipping into a vicious disease- distress cycle; 
the pain or itch and limitations of living with a chronic inflammatory disease can result in 
substantial psychological distress, which may in turn enhance inflammatory activity 
through activation of the stress response system. This may result in even greater levels 
of psychological distress with the above-mentioned consequences. An understanding of 
the mechanisms linking stress and disease and knowledge on how to intervene in this 
process may eventually help limit the psychophysiological consequences of stressful 
experiences on health. In the following paragraphs, we will elaborate on the findings 
presented in this thesis. Methodological considerations will be discussed and directions 
for future research will be given.
Stress exposure and chronic inflammatory diseases
Chronic inflammation has been suggested to compromise the flexibility of the branches 
of the stress response system, that is, the autonomic nervous system (ANS) with its 
 sympathetic-adrenal-medullary (SAM) axis and the neuroendocrine system with its 
 hypothalamic-pituitary-adrenal (HPA) axis [2, 9]. As yet, there is no consensus about whether 
the physiological response to stress is altered in patients with chronic inflammatory 
diseases compared to healthy controls, and to what extent these potential alterations may 
be specific for a certain chronic inflammatory condition. 
Psychophysiological effects of stress exposure 
In this thesis, we report that a brief psychosocial stress task alters the physiological stress 
response in patients with RA, patients with psoriasis, and a control group of participants 
without chronic inflammatory condition. Not only did we find an increase in salivary 
α-amylase levels (an indicator of ANS activation) in the three groups, we also reported a 
significant rise in salivary cortisol levels (an indicator of HPA axis activation) with a higher 
increase in patients with psoriasis than in patients with RA and controls (Chapter 3). The 
stress task was perceived as being stressful, evidenced by significantly increased tension 
levels, and it activated both the ANS and the HPA axis. Although the stress response 
system is known to interact with the immune system, circulating cytokine levels were not 
significantly affected by the stress task. Only when controlling for baseline differences in 
cytokine levels, we found that patients with RA had heightened stress-induced levels of 
interleukin (IL)-1β and IL-2 compared to patients with psoriasis and controls (Chapter 4). 
Our results suggest that specific markers of the physiological response to stress are altered 
in chronic inflammatory diseases, which may adversely affect disease status. In our review 
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in Chapter 2, a consistent increase in cardiovascular and galvanic activity and a rise in 
catecholamines after stress induction in patients with inflammatory rheumatic diseases 
was not necessarily followed by changes in immune parameters. Nevertheless, changes in 
leukocyte and (subsets of) lymphocyte counts, and inflammatory markers C-reactive 
protein (CRP), tumor necrosis factor (TNF) α, IL-4 and IL-6 were sometimes reported after 
stress induction (Chapter 2). Apart from these unequivocal effects of stress on immune 
function in rheumatic populations, little is known about immune effects of acute stress in 
other chronic inflammatory conditions, such as psoriasis or atopic dermatitis (AD); studies 
have reported changes in subsets of lymphocytes, immunoglobulin, Th1 cytokines 
(interferon gamma [IFNγ], IL-2) and Th2 cytokines (IL-4, IL-10) [10-13]. In a meta-analysis 
combing data of both patient and healthy populations, general effects of acute stress 
suggest some activation of natural immunity and suppression of specific immunity. In 
general, the most consistent changes across groups were an increase in natural killer cells 
and large granular lymphocytes in the circulation, decreased proliferative responses, and 
increases in pro-inflammatory cytokines IL-6 and IFNγ [14]. How these stress-induced 
changes in immune function eventually affect disease severity is a question that is 
complex to answer in studies investigating acute experimental stress, such as ours. Due to 
ethical reasons, stressors are generally mild in nature and of short duration, and the time 
that it takes to see alterations in disease severity is usually longer than the time span of the 
study protocol. Although prospective studies of stress are very well-suited to show a 
possible association between stress and exacerbation of disease severity [15], controlled 
experimental studies can infer causal relations between stress exposure and markers of 
disease progression, but not disease progression itself. 
Stress paradigms
When investigating the physiological effects of acute stress in controlled experimental 
studies, an important decision is which stress paradigm should be applied. The degree of 
external validity of the stress test, as well its ability to consistently activate the physiological 
stress response system, should be an important criterion in this decision. For example, in 
our review covering all controlled experimental studies of acute stress in inflammatory 
rheumatic diseases, we included 16 studies that applied different types of stressors, 
including psychological tests (e.g., cognitive tasks), exercise stress (e.g., treadmill), and 
sensory stressors (e.g., thermal, acoustic or visual stimuli). Psychosocial stress was mostly 
induced by the short-term Trier Social Stress Test (TSST) or a derivative of this test. We 
demonstrated that not all stress paradigms necessarily activate the HPA axis in the same 
way and increase cortisol levels (Chapter 2). Instead, especially stress paradigms containing 
both uncontrollable and social-evaluative elements have previously been associated with 
the largest cortisol changes [16]. In our review, psychosocial stress paradigms such as the 
TSST most consistently activated different levels of the stress response system in rheumatic 
patients; in our experimental studies, the TSST was also able to effectively activate both 
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the ANS and HPA axis (Chapter 3), in line with previous reports [17]. With regard to 
immunological reactivity to acute stress, the effects of different types of stress paradigms 
on immune function in rheumatic patients were more inconsistent, possibly due to the 
high heterogeneity in stress induction paradigms, outcome measures, and time points of 
measurements. However, the paradigms were usually able to generate at least some 
changes in immune function in rheumatic patients, either in leukocyte or lymphocyte 
(subset) counts, or specific cytokine levels. These findings are in line with previous reviews 
suggesting that acute stressors can elicit similar patterns of immune change across a wide 
spectrum of durations ranging from 5 through 100 minutes, and irrespective of whether 
they involved social (e.g., public speaking), cognitive (e.g., mental arithmetic), or 
experiential (e.g., sky diving) forms of stressful experiences across populations [14].  Future 
studies may further explore possible specificity in the psychophysiological stress response 
of various stress designs.  
Markers of stress and temporal kinetics
When investigating physiological intermediates of stress and disease, there is a wide array 
of stress markers to choose from. In this thesis, we selected widely-used markers of 
activation of the ANS and HPA axis, namely, salivary α-amylase and salivary cortisol, 
respectively. These markers are non-invasive and easily assessed, and possible confounders 
could be controlled for by asking participants to refrain from using alcohol or caffeine, and 
from eating, smoking and exercising prior to the experimental session. Nevertheless, 
these two markers have their weaknesses; even though α-amylase is mainly sympathetic 
in nature and correlates with cardiovascular measures, it also receives parasympathetic 
input [18]. In order to differentiate between the parasympathetic and sympathetic 
branches of the ANS different and separate measures will be required, such as the sympa-
thetically mediated pre-ejection period (PEP) and the parasympathetically mediated 
high-frequency heart rate variability (HF-HRV) [19, 20]. Moreover, salivary cortisol does not 
necessarily correlate with plasma cortisol levels [21]. With regard to immunological 
measures, we measured circulating cytokine levels that are known to be associated with 
stress and/or disease severity in chronic inflammatory diseases, namely IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IFNγ and TNFα. Other cytokine studies of acute stress have measured 
either similar well-known cytokines in the circulation, or focused on in vitro stimulation of 
immune cells and their cytokine production, or measured activity or numbers of local 
(e.g., synovial or skin) immune cells [14, 22]. Our choice to explore circulating levels was in 
part based on the idea that systemic changes may be a general measure of the overall 
response of the immune system. 
 Associated with the choice of a specific marker of stress are the temporal kinetics 
of the chosen parameter; these will determine the time frame of the response and 
 return-to-baseline and are a guideline for the choice of measurement points after stress 
exposure. While ANS responses, especially cardiovascular or galvanic in nature, will happen 
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within seconds after perception of the stressor, neuroendocrine changes in HPA axis 
activity usually take about 20 minutes. In our study, both α-amylase and cortisol showed 
peak levels 20 minutes (first measurement point after the TSST) to 30 minutes after 
initiating the stress task. Previous studies are less conclusive about the time frame for 
immunological parameters, such as circulating cytokines, to respond to stress; a rise in 
circulating levels of interleukins has been reported to occur within minutes to hours after 
cessation of a stressor [22]. Overall, cytokine levels in our study usually did not show a 
clearly defined peak increase or decrease in response to the stress task during our 
measurement period of up to 1 hour after stress induction. Future studies may examine 
the response profile of sensitive markers of acute stress in more detail.
Disease-specific effects of stress
Both disease-specific and generic effects of stress on health may aggravate disease 
severity in patients with a chronic inflammatory disease. In this thesis, we have reported 
some disease-specific differences in physiological stress reactivity across chronic 
inflammatory diseases. These could either represent differences in the stress response 
between patients and controls, or differences between patient groups. In our review, we 
were not able to delineate consistent disease-specific differences in autonomic or 
neuroendocrine markers of stress in patients with various rheumatic disorders, but 
immune reactivity to stress seemed to be specific in these populations; patients with 
systemic lupus erythematosus (SLE) showed less pronounced changes in lymphocyte 
(sub)populations compared to controls, and patients with RA, SLE and juvenile idiopathic 
arthritis (JIA) had increases in CRP and TNFα (RA), IL-4 (SLE) and IL-6 (JIA), that were not 
observed in control subjects. In contrast, patients with RA or SLE lacked the stress-induced 
increase in IFNγ and IL-10 observed in controls. Nevertheless, most studies did not compare 
patient groups, but only included a control group. Only once it was suggested that 
patients with RA and SLE may differ in their IL-4 response to stress. In our stress exposure 
study, the cortisol response to stress was heightened in patients with psoriasis compared 
to RA and controls, while patients with RA showed heightened immune reactivity (IL-1β 
and IL-2) compared to the other two groups, but only when controlling for baseline 
differences in cytokine levels. These and other studies with patients with chronic 
inflammatory diseases, such as psoriasis and atopic dermatitis (AD) [10-13] support the 
hypothesis of possible disease-specific physiological stress reactivity patterns, which may 
in turn affect the course of chronic inflammation. However, a lack of consistency in study 
designs, patient samples, outcome measures, and measurement points thwarts 
generalization of the findings. 
 To our knowledge, our study was the first to report a heightened cortisol response to 
a stress task in psoriasis. Usually, chronic inflammatory or psychopathological conditions 
have been associated with blunted neuroendocrine stress response profiles. In chronic 
stress and pain conditions, the HPA axis is thought to be activated continuously, which 
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may increase feedback sensitivity of corticosteroids. This could lead to hypo-function and 
-reactivity of the HPA axis and desensitization of the immune system to glucocorticoids, 
increasing inflammation. It is complex to determine the exact immune effects of hypo- or 
hyperactivity of the stress response system, because they may differ as a function of 
location (local versus systemic) and type of immune measure. For example, although 
cortisol is known to be immunosuppressive, a rise in cortisol in response to stress may lead 
to local activation of the immune system; activation of the corticotropin-releasing-hor-
mone (CRH)-mast-cell-histamine axis leads to heightened levels of peripherally produced 
CRH. CRH can act as a local pro-inflammatory agent and stimulate mast cells to release 
histamine and the pro-inflammatory cytokines TNFα and IL-6, which can boost 
inflammation [23]. When cortisol reactivity to stress is heightened compared to the 
response of healthy controls, as we observed in our psoriasis sample, this may result in 
heightened local activation of the CRH-mast-cell-histamine axis, a more pronounced local 
pro-inflammatory state, and a larger release of pro-inflammatory cytokines TNFα and IL-6. 
However, differences in stress-induced TNFα and IL-6 levels were not found in our study, 
which suggest that other mediators and/or pathways may be involved in the link between 
stress and disease. 
 In contrast, patients with RA did not show altered cortisol reactivity, but disease-spe-
cific alterations in certain inflammatory markers after stress when controlling for basal 
cytokine levels; i.e., heightened levels of IL-1β, involved in innate immune responses, and 
IL-2, a cytokine of the adaptive immune system. Results suggest that a stress-induced rise 
in cortisol may be accompanied by a relatively bigger increase in specific immune markers 
in RA than in controls and patients with psoriasis; an increase that may further fuel the 
chronic inflammatory state observed in RA. A possible explanation could be that part of 
the signaling cascade from cortisol to the immune system, for example corticosteroid 
receptor sensitivity or density, may be altered in patients with RA [24-26]. The significance 
of alterations in these cytokine responses to stress and their possible clinical value still 
remains to be elucidated. Acute stress-induced changes in cytokine levels probably do 
not only reflect de novo protein synthesis or clearance, especially when responses occur 
within minutes after stress exposure, but may also indicate a redistribution process of 
immune cells releasing these cytokines from or into the periphery, with fluctuations being 
either adaptive or maladaptive [22].
 In sum, preliminary data show disease-specific changes in the acute psychophysio-
logical response to stress in patients with RA and patients with psoriasis; changes that may 
augment the possible damaging effects of stress on health. The significance of (dis-
ease-specific) alterations in stress physiology and their link to aggravating disease severity 
clearly requires further elucidation, but interventions that decrease psychological distress 
in patients may be fruitful to moderate these effects. 
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Psychological stress-reducing intervention and stress exposure 
Although a substantial part of patients with a chronic inflammatory condition face 
psychological and physical problems, such as physical disability, pain and fatigue, 
intervention studies have proven to be modestly successful in improving psychological 
and physical functioning in these patients as adjunct to pharmacotherapy [27-31]. 
As stress factors have been related to disease flare-ups, specific interventions aimed at 
reducing stress reactions may prove an adjunct therapy in relieving symptoms of disease. 
Several studies in healthy participants showed that interventions aimed at decreasing 
levels of distress, such as muscle relaxation and guided imagery, can also alter autonomic 
and neuroendocrine activity [32, 33]. The effect of psychological interventions on 
autonomic, neuroendocrine, and immune function was also evidenced in several clinical 
populations, such as in patients with HIV and cancer [34-40]. In addition, there have been 
reports of changes in basal physiological parameters after psychological interventions in 
patients with RA, such as in cortisol, levels of interleukin (IL)-6 or IFNγ, or immune measures 
indicative of disease status, such as C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR)  [41-44]. To our knowledge, the study in this thesis is the first to investigate stress- 
induced autonomic, neuroendocrine, and immune responses after stress management 
training in patients with RA.
Psychophysiological effects of a stress management intervention
After a brief stress management training, patients with RA showed a significant overall 
reduction in levels of distress (specifically anxiety) and higher levels of positive mood 
compared to the control group (Chapter 5). Moreover, after stress exposure, stress-induced 
subjective tension, and cortisol and IL-8 levels were significantly lower in the intervention 
than in the control group, but only at the follow-up assessment 9 weeks after the 
intervention (Chapter 5 and 6). These results suggest that a brief psychological intervention 
is able to influence the psychophysiological response to stress and may help prevent the 
possible detrimental effects of stress on health.
 Stress arises when the environmental demands outsource individual resources, 
resulting in the activation of the stress response system in order to deal with the stressor 
and restore homeostasis. In order to change the physiological response to a stressor or 
situation, intervening on the level of individual resources may prove rewarding to shift the 
balance between demands and resources. We specifically designed a short-term stress 
management training of four individual sessions during two consecutive weeks with a 
trained therapist, in which different protocols to deal with stress were put forward. The 
first focus of the brief intervention was on psycho-education; patients were informed on 
how stress and tension may exacerbate physical symptoms and disease severity. Secondly, 
the principles of applied relaxation were taught, including progressive, cue-controlled, 
and differential relaxation. Breathing exercises and visualization exercises were also added 
to the repertoire of relaxation exercises. Homework assignments and relaxation exercises 
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were regularly practiced during the two weeks of the intervention. Home work 
assignments included the assessment of stress-relevant situations and behaviors in daily 
life. During the two-month follow-up period, participants were encouraged to keep 
practicing their exercises and assignments, as well as to stick to a relapse-prevention 
program and focus on long-term goals in order to consolidate what they had learnt. Most 
patients (87 percent) in the intervention group reported improvement in their stress and 
tension levels after the training; 45 percent of patients even reported moderate to strong 
improvements. In addition, patients in the intervention group had significantly lower 
anxiety scores and scored higher on positive mood after the training than patients in the 
control group, demonstrating that the intervention positively affected distress levels.
 With a relatively small number of intervention studies investigating the physiological 
effects of psychological treatment in patients with RA, the study in this thesis aimed to 
add knowledge on this topic. Importantly, and as we hypothesized, the stress management 
training did not alter parameters of basal physiological activity, but only diminished 
stress-induced physiological reactivity. Although we did not see alterations in the psycho-
physiological stress response immediately after treatment, patients in the intervention 
group were significantly less tense and had a lower cortisol response to stress at follow-up. 
In line with this, stress-induced IL-8 levels were lower in these patients at the follow-up. 
The delayed effect at the follow-up on stress physiology observed in our study may have 
occurred because patients were encouraged to keep practicing their exercises and stick 
to a relapse-prevention program during the two months prior to the last assessment; this 
time could have been necessary to integrate all that was learnt in daily life and to 
consistently and substantially change the way of coping with stressful situations. 
 With the design presented in this thesis, we were able to demonstrate that a brief 
stress management intervention was able to alter both subjective and neuroendocrine 
parameters of acute stress, namely tension and cortisol levels, as well as change 
stress-induced immune parameters, namely circulating IL-8 levels. To our knowledge, the 
application of a Trier Social Stress Test after a psychological intervention has rarely been 
investigated [45, 46]. The combination of stress management training followed by stress 
exposure enables investigating the effects of a psychological intervention on the stress 
response when patients are challenged to cope with a real-life stressful situation; this 
study design offers the opportunity for new insights into the link between stress and 
disease. In the few studies that used this design, healthy students were randomized to 
receive a two-day group-based stress inoculation training before or after a TSST. 
Participants of the training reported having a lower stress appraisal and lower cortisol 
levels in response to the stress task; an effect that was also observed when the stress test 
was performed four months after the training. Results of these and our studies suggest 
that cortisol responses to stress can be altered through training in stress management, 
both in healthy subjects and in patients. Moreover, to our knowledge our study was the 
first to investigate and show potential intervention-related changes in immune function.
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Stress-induced tension and cortisol levels were reduced by the training, but not the 
α-amylase response to stress. This is unexpected, because the stress management training 
was aimed at reducing overall arousal and sympathetic activity. Previously, no significant 
association between cortisol and α-amylase reactivity to stress was reported [47, 48], 
suggesting that (different types of) stress not necessarily activate(s) parameters of stress in 
a similar way. The training may have specifically lowered the cortisol response to stress by 
changing negative emotions and/or cognitions that are associated with social threats, 
such as fear of losing social approval [16]. Future studies of stress should experiment with 
modulating negative as well as positive emotions and cognitions to establish more 
pronounced autonomic and neuroendocrine changes in the psychophysiological response 
to stress. 
 The implication of the decrease in IL-8 levels is as yet unknown. IL-8 acts as an acute 
player in exacerbation of inflammation and is related to perceived levels of stress attributed 
by negative affect [49, 50]. Although cortisol and IL-8 levels were not significantly related, 
the decrease in levels of IL-8 could indicate that it is a general marker of stress reactivity, 
and not necessarily a disease-specific marker of RA. This is supported by results of our first 
study that showed that patients with RA, patients with psoriasis, and healthy controls did 
not differ in basal IL-8 levels and in the IL-8 response to stress (Chapter 4), which suggests 
that IL-8 may respond in a similar fashion across different (healthy and medical) populations.
Proof of principle vs. clinical relevance
Our findings evoke the question of the clinical relevance of the observed alterations in stress 
physiology, especially since disease activity did not significantly change during the course of 
the study in both groups. In fact, so far, there has been ample evidence of psychological 
interventions that change clinical measures, such as overall disease activity [41, 51], disease 
flare-ups [30] and joint tenderness [52]. With four 1-hour sessions during two consecutive 
weeks, our intervention was very limited in time and content, but even with this brief training 
we were able to induce psychological and physiological changes in patients with RA. Since 
there are many reports of a temporal relationship between elevated levels of pro-inflamma-
tory cytokines and symptoms of RA, such as morning stiffness and radiographic progression 
[53, 54], it seems likely that changes in psychophysiological stress reactivity (e.g., cortisol and 
cytokines) can eventually affect the course of disease activity in these patient groups. 
However, this study was meant as a proof of principle to see whether it would be possible to 
influence various physiological parameters of stress and disease by means of psychological 
intervention. Treatment effects could have easily been masked by biological forces, such as 
disease flare-ups and pharmacological treatments that affect the neuroendocrine and 
immune system, although we tried to limit these effects through randomization and by 
taking into account several possible confounders, including the patient’s disease status. 
Most likely, longer and more intense interventions will produce more pronounced effects on 
stress physiology and possibly also on disease progression. 
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Risk groups
The stress management training had more pronounced effects in patients with a 
psychological risk profile showing with heightened levels of distress, than in patients 
without this profile. These effects were found on general psychological functioning 
(anxiety and negative mood) and physiological stress reactivity at a follow-up assessment; 
levels of stress-induced subjective tension, α-amylase and cortisol decreased more in 
high-risk patients than in low-risk patients in the intervention group. There also tended to 
be a risk group effect for the response of IL-8 at follow-up; stress-induced IL-8 levels had 
decreased more in high-risk patients than in low-risk patients in the intervention group. 
Thus, stress management training may be particularly beneficial for patients psychologi-
cally at risk. Previous research already indicated the importance of evaluating psychological 
risk factors when evaluating treatment outcome [55-58]. Prospective studies with patients 
with RA or with another chronic inflammatory condition, such as psoriasis, revealed that 
patients with high levels of worrying were most vulnerable to the impact of stressors on 
their disease severity, especially in highly stressful circumstances [15, 59, 60]. If patients 
with psoriasis reported their disease to be stress-reactive, they scored higher on disease 
activity than patients who did not consider themselves reactive to stress [7, 61]. Moreover, 
psychological risk factors, such as depression, influenced immune function in patients 
with RA when they felt stressed [56]. Overall, these studies, including our own, suggest 
that especially patients vulnerable to psychological stress factors may particularly benefit 
from psychological treatment and its effects on psychophysiological stress reactivity.
Methodological considerations
The studies presented in this thesis were subject to a number of limitations and 
methodological considerations.
Threats to external validity: generalization across types of stressors
In this thesis we used the TSST, an acute time-limited psychosocial experimental stressor 
that activates the ANS, HPA axis and immune system [14], to investigate acute physiological 
responses to stress. The most obvious critical note that can be put forward is to what 
extent the effects of acute stress are comparable to the wide variety of stressors 
encountered in daily life, including major life events (for example, death or divorce), 
chronic stressors (for example, living with a disabling disease) or minor or more acute daily 
stressors, such as daily hassles (for example, losing your keys). Stress research can take 
different conceptual and measurement approaches, which include a wide range of 
psychosocial stressors varying on important dimensions such as major or minor events, 
acute or chronic stressors, or a sudden or gradual onset [14, 62]. In the case of major events, 
intense release of stress mediators over a large time interval will occur, while in the case of 
minor events, only short-lived surges of neurotransmitters and hormones are expected 
[2]. Consequently, different types of stressors are associated with specific stress physiology 
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profiles, which may have different or even opposite effects on health status in patients 
with chronic inflammatory conditions. Although laboratory stressors allow control of key 
factors in the delivery of stress and observation of its effects, they have their limitations. 
Those limitations can be reduced by choosing a stress paradigm that simulates a real-life 
stressful situation, such as the psychosocial evaluation that is part of the Trier Social Stress 
Test.
Threats to external validity: generalization across patient samples
Patients in our studies were recruited from the participating departments of two regional 
hospitals. Participating patients had longstanding and relatively mild disease activity 
compared to the general population of outpatients with RA or psoriasis. Patients in this 
study were monitored by specialists of hospitals who aim to stabilize the disease or bring 
it into remission. In addition, all participants were self-selected volunteers of a study that 
was quite demanding in terms of repeated visits (especially for RA patients in the stress 
management condition), time spent at the hospital, medical assessment, blood drawings, 
saliva collection, and stress tasks. Moreover, we applied rather strict exclusion criteria with 
regard to physical and psychological co-morbidity. All in, this may have resulted in a bias 
of relatively mobile patients with well-managed disease activity or severity. Consequently, 
the patient samples of our study are not representative of regular outpatients with RA or 
psoriasis and therefore results may not be generalizable to patients with more severe 
disease activity. Patients with severe disease activity will have more inflammatory activity, 
local and/or systemic, which may be associated with altered ANS and HPA axis function 
[63, 64] and altered psychophysiological responses to stress [65-67]. In addition, because 
patients with recently diagnosed RA may show basal HPA axis function different from 
patients with longer-standing RA [64, 68], differences in the physiological response to 
stress can be expected. In order to fully comprehend psychophysiological stress responses 
in patients with chronic inflammatory diseases, including RA and psoriasis, patients with a 
wider range of disease activity and other characteristics of representative patient groups 
should be investigated. 
Threats to internal validity: confounding factors and pre-test differences 
When studying a population or comparing groups of patients, there is the following 
dilemma: if homogenous and comparable groups are created in order to rule out possible 
confounders, for example by using strict exclusion criteria, this will result in a study 
population that is not representative. Alternatively, when aiming for a representative and 
ecologically valid study sample, groups will be highly heterogeneous and differ on a wide 
range of possible confounders. In our studies, there were some significant pre-test 
differences between groups. In our study investigating the stress response of patients 
with RA, patients with psoriasis and healthy controls, there was a significant difference in 
the female-to-male ratio and the BMI across the three groups. Moreover, patients with RA 
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or psoriasis used different types of treatment medication that are designed to influence 
the immune system. For example, many more patients with RA than patients with psoriasis 
used biologics, DMARDs, and NSAIDs. Half of the patients with psoriasis used topical cor-
ticosteroids, which probably influence systemic physiological processes to a lesser extent 
than systemically administered corticosteroids, as used in RA. In addition, there were 
some small differences between groups in our stress management study; the 
female-to-male ratio, basal levels of anxiety, and the use of hormonal contraceptives 
tended to be different between the two groups, and there was a significant difference in 
the use of NSAIDs. It is well-known that all these factors can influence neuroendocrine 
and/or immune function [17]. In order to control for the possible influence of pre-existing 
differences between groups on outcome measures we used the following strategies. In 
our study investigating disease-specific differences in physiological stress reactivity, we 
tested all possible confounders that could affect an outcome measure by introducing 
them one-by-one as a covariate into the statistical models. Those confounders included 
all types of medications, sex, age, BMI, smoking status, menopausal status, and different 
indicators of psychological well-being. Results of the covariate analyses were reported 
when a confounder was significantly related to the outcome variable. In addition, the 
randomized nature of our stress management study made us decide to include all 
confounders that tended to differ or differed significantly between the two groups as 
covariates in the statistical model. The results of both studies indicate that, despite some 
pre-existing differences between groups and some significant correlations between 
these particular confounders and outcome measures, controlling for the confounders did 
not change our main findings. Although results of our studies suggest no or limited 
effects of confounders, it should be considered to use a matching strategy or a stratified 
randomization procedure in future studies of stress in order to yield more homogeneous 
groups with regard to known confounding factors and eliminate as much bias as possible. 
 
Statistical analyses
In our studies, we separately investigated group effects on basal physiological activity and 
stress-induced physiological reactivity. First, we analyzed whether there were possible 
differences in basal levels of physiological outcome parameters (i.e., did patients and 
controls differ in basal physiological activity (Chapter 3 and 4) or did the stress management 
training result in altered basal physiological activity (Chapter 5 and 6)). Second, we 
specifically compared groups with regard to their physiological reactivity to a stress task. 
For example, in our stress management study we hypothesized that the benefits of the 
training would become particularly evident when participants were challenged to cope 
with a stressful situation, with subsequent changes in physiological reactivity. Depending 
on the specific characteristics and assessment methods of the outcome measures, we 
tested whether groups differed on the combined post-stress measurement points 
(immune measures) or with regard to the response over time (other psychophysiological 
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measures), with basal levels as a covariate in the statistical model. With this model we 
compared the level of the response after stress, while controlling for possible differences 
in baseline values. 
 In addition, the sample size of our studies was relatively small to perform statistical 
subgroup analyses, particularly considering multiple testing. Prompted by the small 
sample size and the high intercorrelation of most cytokines, corrections for multiple 
testing, such as Bonferroni, were not applied in our explorative cytokine analyses. Overall, 
the studies in this thesis, especially those investigating cytokine responses, were 
explorative in nature and -clearly - results should be interpreted with caution and need 
replication in larger-sized samples.
Study design
In our stress management study, we applied the TSST two times in the same patient 
population. Because repeated exposure to the TSST leads to habituation of the 
neuroendocrine response to stress in the majority of people [69, 70], we decided against 
assessment of stress reactivity prior to the stress management training. Nevertheless, the 
effect of the stress management on cortisol and IL-8 levels were relatively small. 
Considering that the benefits of the training seem to become visible over time, future 
studies may need to apply stress induction paradigms such as the TSST only once, at a 
follow-up assessment, in order to capture the effects of the training most effectively [46]. 
In addition, we were unable to blind patients and researchers for the treatment status 
(control or intervention group) of participants. We could only blind the research members 
that conducted the stress test for the treatment status of the participant. Furthermore, our 
stress management training was relatively short in duration and limited in content. 
Although even this brief intervention was able to alter physiological parameters of stress, 
physiological changes of a sufficient magnitude may be established by interventions with 
a larger content and number of sessions.
Future directions 
Our studies aimed to further elucidate how stress may be linked to chronic inflammatory 
diseases. They suggest that patients with a chronic inflammatory condition, such as RA 
and psoriasis, may show specific neuroendocrine and immune responses to stress. In 
addition, we showed that short-term training in stress management not only improves 
psychological functioning in patients with RA, but is also able to alter the acute psycho-
physiological response to a stressor. Based on the results of our studies, future studies may 
clarify this relationship in more detail.
Stress test measures and design
First of all, future studies of experimental stress should replicate findings in larger cohorts 
of patients in order to disentangle the role of specific pharmacotherapy regimens, sex 
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(hormone)-related factors, and psychological risk profiles on physiological stress reactivity. 
Those larger studies would also allow correction for multiple testing. In addition, a wider 
variety of outcome measures should be assessed within a larger time window to measure 
stress responses that include a return-to-baseline.    
 With regard to physiological parameters, studies should include not only measures of 
both the sympathetic and parasympathetic branches of the nervous system, such as 
pre-ejection period (PEP), total peripheral resistance (TPR), and HF-HRV, but also 
neuroendocrine measures other than those of the HPA axis, such as prolactin, growth 
hormone (GH), or parameters representing communication between the neuroendo-
crine-immune system or the ANS-immune system, such as the number or sensitivity of 
corticosteroid or β-adrenergic receptors. The selection of immune measures should 
largely depend on the subject population being studied, with measures being relevant 
for disease progression [71]. It may prove fruitful to broaden the scope beyond measuring 
the major and well-known cytokines involved in many immune processes, such as IL-1 and 
TNFα, and integrate recent immunological insights. For example, IL-17A and IL-23 are two 
important cytokines involved in the disease process of psoriasis and RA, but these more 
recently discovered cytokines have remained largely unexplored in psychological stress 
research so far [72, 73]. Furthermore, immune system function can be measured by means 
of in vitro techniques and/or local measurements, in addition to more systemic approaches. 
For example, synovial cytokine levels or production by in vitro stimulated immune cells 
collected from the synovium and synovial fluid after stress induction may give insight into 
the effects of stress on local physiology. In vitro cell stimulation may especially be 
appropriate for parameters that are difficult to measure in the circulation, such as levels of 
IL-1 in healthy participants. 
 With the growing interest in the physiological effects of psychological interventions 
for all kinds of patients, the large heterogeneity of studies -mainly in terms of composition 
of the study groups, outcome measures and assay methods, timing of samples, type of 
stress paradigm, and type of intervention used - require reviews and meta-analyses that 
summarize and string together data to help us decide which steps to take next.
Psychophysiological effects of stress management and its clinical relevance
The effects of our brief intervention on psychophysiological stress reactivity may be 
amplified in full-blown interventions of longer duration and larger content. These more 
extensive interventions may not only have increased effects on ANS and HPA axis 
measures, but may also affect the immune system more effectively, for example, by 
producing changes in cytokine levels or other immunological parameters beyond their 
broad normal range. Moreover, selecting parameters of physiological processes that 
unfold over a longer period of time and are not susceptible to short-term perturbations 
may prove fruitful specifically for training in stress management [71]. Longer follow-ups 
may be needed to discern possible changes in disease activity in the long run.
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Various cortical and limbic regions are involved in the processing of potentially threatening 
stimuli, such as psychosocial stressors. Modifying these processes may therefore affect the 
psychophysiological response to a potentially stressful situation [45]. For example, 
meta-analyses have demonstrated that cortisol and immune alterations particularly 
emerge when people show relevant changes in specific cognitions and emotions that are 
associated with imminent stressors [16]. Future research should use this information to 
build specific intervention modules that will produce clinically relevant and significant 
changes in psychophysiological stress reactivity. In line with this, acute physiological 
stress responses have also been related to individual differences in psychological distress, 
coping styles, and cognitive appraisal [70, 74-77]. Future research needs to disentangle 
which factors are most relevant to identify subgroups of patients at risk for heightened 
stress reactivity, who are most likely to benefit most from stress management interventions. 
An important new step in stress research will be to determine the clinical relevance of 
alterations in physiological stress reactivity among patients with chronic inflammatory 
diseases and after psychological intervention. This is best determined in longitudinal 
prospective studies that can test whether patients with specific psychophysiological 
responses are at a higher risk for future disease exacerbations and whether interventions 
are able to limit these effects on the disease status. Moreover, a greater insight into which 
specific subgroups of patients are most at risk and may benefit most from psychological 
interventions could eventually lead to the development of screening tools for these 
patients and the implementation of this approach in clinical guidelines. All in, new and 
challenging steps have to be taken to increase our knowledge on how stress affects 
chronic inflammation and whether and how this process can be counteracted. 
Pathways to influence psychophysiological stress reactivity
In this thesis, we aimed to influence the psychophysiological stress response in patients 
with a chronic inflammatory condition through training in stress management. This 
training helped to reduce the perception of stress and diminish the activation of markers 
of the physiological stress response system. Another entrance to influence the psycho-
physiological stress response could be to tackle the possible inadequate release of 
hormones, for example stress-induced cortisol output. The aim subsequently shifts from 
reducing the perception of a stimulus as being stressful -and thereby indirectly reducing 
a physiological response to stress - to directly influencing the physiological stress response. 
For example, single high cortisol administration in humans is suggested to facilitate 
coping with stress through adaptive regulation of automatic cognitive processing [78]. 
Future studies of stress may focus on directly altering the physiological stress response in 
patients with chronic inflammatory conditions. This could, for example, be tested in an 
experimental setting by administering cortisol prior to a challenging situation, such as the 
TSST. In clinical studies, however, it has to be taken into account that patients with chronic 
inflammatory conditions may show disturbances in HPA axis function or neuroendo-
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crine-immune interactions, and that exogenous cortisol administration prior to stress may 
not necessarily have beneficial effects on the disease process, especially since both too 
much and too little HPA axis (re)activity is linked to disease and health complaints [79]. 
 Since preliminary evidence also suggests that endocrine and immune function are 
subject to the effects of conditioning [80], future studies of stress may eventually 
investigate whether conditioning paradigms can help in modulating psychophysiological 
stress reactivity in patients. Altogether, combining pharmacological treatment with 
psychological intervention seems a promising line of future research that may help to 
elucidate the complex puzzle of psychophysiological stress reactivity and disease outcome.
Concluding remarks
The goal of this thesis was to further elucidate the nature of the psychophysiological 
stress response system of patients with chronic inflammatory diseases. First, we aimed to 
increase knowledge on possible disease-specific patterns in the psychophysiological 
response to stress of patients with the prototypic chronic inflammatory diseases RA and 
psoriasis; patterns that may add to an aggravation of disease symptoms in times of stress. 
We reported that patients with psoriasis showed an increased cortisol response to a 
psychosocial stress task compared to patients with RA and controls, whereas patients 
with RA showed higher stress-induced IL-1β and IL-2 levels compared to the other groups 
when controlling for basal cytokine levels. Disease-specific immune reactivity to stress 
was also reported in our review on patients with inflammatory arthritis. Second, we aimed 
to gain a greater insight into the psychophysiological effects of stress management 
interventions. A stress management intervention was overall able to decrease psychological 
distress in patients with RA, and decrease the psychophysiological response to a 
psychosocial stress task at follow-up; stress-induced tension, cortisol, and IL-8 levels were 
lower in the intervention than in the control group, with effects being particularly evident 
in patients with RA who are psychologically at risk. Results suggest that patients with a 
chronic inflammatory condition have a disease-specific stress response profile and that a 
psychological intervention is capable of altering the psychophysiological response to 
stress in patients. The findings reported in this thesis may be substantiated by further 
research into the psychophysiological effects of stress on chronic inflammatory conditions 
and how to counteract these effects with psychological stress-reducing treatments. In the 
future, this may lead to the development of psychological interventions that are a valuable 
adjunct to regular medical treatment to control the effects of stress on chronic inflammation 
for patients psychologically at risk.  
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(s-)AA (Salivary) alpha amylase
ACh Acetylcholine
ACTH Adrenocorticotropin hormone
AIMS Arthritis impact measurement scales
AN(C)OVA Analyses of (co-)variance
ANS Autonomic nervous system
AR Adrenergic receptor
AUCG Area under the curve with respect to ground
BP Blood pressure
CA Catecholamines
CBT Cognitive-behavioral therapy
CC Control condition
CNS Central nervous system
CRH Corticotropin-releasing hormone
CRP C-reactive protein
CV Coefficients of variation
DAS28 Disease activity score 28
DHEA(-S) Dehydroepiandosterone (sulfate)
DM Diabetes mellitus
DMARDs Disease-modifying antirheumatic drugs
EMM Estimated marginal means
EPI Epinephrine
ESR Erythrocyte sedimentation rate
GH Growth hormone
HC Healthy controls
HF-HRV High-frequency heart rate variability
HPA axis Hypothalamus-pituitary-adrenal axis
HR Heart rate
IC Intervention condition
IFNγ Interferon gamma
IGF-I Insulin-like growth factor 1
(s-)IL (Soluble) interleukin
IRGL Impact of rheumatic diseases on general health and lifestyle
JIA Juvenile idiopathic arthritis
LMM Linear mixed model
MTX Methotrexate
NE Norepinephrine
NK cell Natural killer cell
NPY Neuropeptide Y
NSAIDs Nonsteroidal anti-inflammatory drugs
NTR Netherlands trial register
OA Osteoarthritis
PASI Psoriasis area and severity index
PEP Pre-ejection period
PRL Prolactin
PS Psoriasis
PSNS Parasympathetic nervous system
RA Rheumatoid arthritis
SAM axis Sympathetic-adrenal-medullary axis
SC Skin conductance
SD Standard deviation
SEM Standard error of the mean
SLE Systemic lupus erythematosus
SNS Sympathetic nervous system
SUD Subjective unit of distress
SVR Systemic vascular resistance
TNFα Tumor necrosis factor alpha
TPR Total peripheral resistance
TSST Trier Social Stress Test
VAS Visual analogue scale
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Samenvatting
Chronische ontstekingsziekten, zoals reumatoїde artritis (RA) en psoriasis, gaan gepaard 
met met langdurige ontstekingsprocessen in het lichaam. RA is een chronische ont-
stekingsziekte van de gewrichten. Deze gewrichtsontstekingen leiden vaak tot schade 
aan kraakbeen en botweefsel en de ziekte gaat dan ook vaak gepaard met lichamelijke, 
psychische en sociale klachten, zoals pijn, moeheid, functionele beperkingen, angst en 
depressieve klachten. Psoriasis is een chronische ontstekingsziekte van de huid. De ziekte 
kenmerkt zich door afgebakende rode plaques met witte huidschilfers. Patiënten met 
psoriasis hebben vaak lichamelijke symptomen, zoals jeuk en moeheid, maar ook andere 
beperkingen in het dagelijks functioneren, waaronder psychische klachten, zoals angst en 
depressieve stemming. Een van de factoren die een rol speelt bij het instandhouden en 
verergeren van chronische onstekingsziekten zoals RA en psoriasis is stress. Wanneer iemand 
stress ervaart, wordt het psychofysiologische stresssysteem geactiveerd. Dit systeem 
bestaat uit twee takken: het autonome zenuwstelsel wordt geactiveerd (de hartslag 
versnelt, je gaat transpireren, etc.) en de afgifte van stresshormonen wordt gestimuleerd. 
De beide takken van het psychofysiologische stresssysteem communiceren met het immuun - 
stelsel en kunnen op deze manier de relatie tussen stress en chronische ontstekingsziekten 
verklaren. 
 Het is nog niet precies duidelijk hoe stress het psychofysiologische stresssysteem 
activeert in patiënten met chronische ontstekingsziekten en in hoeverre dit stresssysteem 
-wellicht ziektespecifiek- is veranderd in patiënten met een chronische ontstekingsziekte 
en ten opzichte van mensen zonder deze aandoening. In deze thesis werd een bijdrage 
geleverd aan de beantwoording van deze vragen. Bovendien werd er onderzocht in 
hoeverre het mogelijk is om de psychofysiologische effecten van stress te verminderen 
door patїenten met een chronische onstekingsziekte een interventie te geven die gericht 
is op het verminderen van stress. De belangrijkste bevindingen uit deze thesis worden 
hieronder beschreven en bediscussieerd. 
Na een inleidend hoofdstuk (Hoofdstuk 1) werd in deel 1 van deze thesis (Hoofdstuk 2, 3 
en 4) ingegaan op de vraag hoe de psychofysiologische stressreactie eruit ziet van 
patiënten met verschillende chronische ontstekingsziekten. In Hoofdstuk 2 vatten we de 
literatuur over stressreacties van patiënten met reumatische ontstekingsziekten samen. 
We keken naar de autonome, neuroendocriene en immuunreacties op verschillende 
typen kortdurende fysieke en psychologische stresstaken patiënten met RA, systemische 
lupus erythematodes (SLE) en patiënten met juveniele ideopathische artritis (JIA).  De 16 
studie die voldeden aan onze inclusiecriteria lieten zien dat er weinig bewijs was voor 
veranderde basale of stress-gerelateerde autonome en neuroendocriene waarden. Echter, 
patiënten lieten wel ziekte-specifieke veranderingen zien in de immuunreactie op stress 
vergeleken met controles. De vergelijking tussen de verschillende studies werd echter 
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bemoeilijkt door de grote heterogeniteit van de studies, onder meer qua uitkomstmaten, 
stresstesten, meetpunten en patiëntengroepen. 
 In Hoofdstuk 3 en 4 werd de psychofysiologische stressreactie onderzocht van 
patiënten met de prototypische chronische ontstekingsziekten RA en psoriasis en van 
gezonde controles. Vóór, gedurende en na een psychosociale stresstaak (de Trier Social 
Stress Test; TSST) werden zelf-gerapporteerde spanning en maten voor autonome 
(speeksel α-amylase), neuroendocriene (speekselcortisol) en immuunactiviteit (cytokines 
in het bloed) afgenomen. In Hoofdstuk 3 rapporteerden we de resultaten van de 
autonome en endocriene reacties en vonden we een significant verhoogde cortisolreac-
tie op de stresstaak in patiënten met psoriasis, terwijl de andere parameters niet 
verschilden tussen de drie groepen. De resultaten veranderden niet als er gecontroleerd 
werd voor verschilllende farmacotherapieën, leeftijd, sexe, BMI, roken en menopauze. In 
Hoofdstuk 4 rapporteerden we de immuunreacties en vonden we als belangrijkste 
resultaat dat de IL-1ß en IL-2 waarden na stress verhoogd waren in patiënten met RA 
vergeleken met de andere twee groepen. Ook hier veranderden de resultaten niet nadat 
we hadden gecontroleerd voor farmacotherapieën, leeftijd, sexe of menopauze. De 
resultaten van hoofdstuk 3 en 4 suggereren dat patiënten met psoriasis een specifieke 
cortisolreactie op stress laten zien, terwijl patiënten met RA een specifieke cytokinereactie 
na stress laten zien vergeleken met de andere groepen. Terughoudendheid in de 
interpretatie van deze resultaten is echter gewenst, gezien het exploratieve karakter van 
deze studie. 
Het tweede doel van deze thesis (Hoofdstuk 5 en 6) was te onderzoeken in hoeverre 
een stressmanagement training in staat is om de psychofysiologische stressreactie te 
beїnvloeden in patiënten met RA. Patiënten met RA werden gerandomiseerd naar de 
 interventiegroep of de controlegroep. Er werd gekeken naar de algemene effecten van 
een individuele korte stressmanagement training voor RA patiënten door het algemeen 
psychologisch en lichamelijk functioneren te meten vóór de stressmanagement training, 
direct na de training en negen weken later. Ook werd de psychofysiologische reactie op 
een stresstaak (TSST) bepaald direct na de training en negen weken later. Maten voor 
autonome, neuroendocriene en immuunactiviteit (speeksel α-amylase, speekselcortisol 
en cytokines in het bloed) werden afgenomen vóór, tijdens en na de stresstaak. Na de 
eerste algemene meting nam de helft van de participanten deel aan de training. 
Patiënten in de interventiegroep kregen vier individuele trainingen in stressmanagement 
gedurende twee weken. De sessies bevatten modules psycho-educatie en ademhalings-, 
ontspannings- en visualisatieoefeningen. Tijdens de training werden participanten aan- 
gemoedigd dagelijks huiswerkoefeningen te maken en dit voort te zetten na de training. 
 De effecten van de stressmanagement training worden beschreven in Hoofdstuk 5 
en 6. De resultaten laten zien dat een korte individuele stressmanagement training het 
psychologisch functioneren van patiënten met RA verbeterde. Angstklachten namen af 
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en de positieve stemming verbeterde. Ook rapporteerden patiënten die de training 
hadden gevolgd minder spanning en hadden ze lagere cortisolspiegels en lagere IL-8 
waarden bij het uitvoeren van de stresstaak negen weken na de training, maar niet bij de 
stresstaak direct na de training. De effecten op de stressreactie waren het sterkst in de 
subgroep patiënten met verhoogde basale zelfgerapporteerde stresswaarden. De resultaten 
van deze studie laten zien dat een korte stressmanagement interventie invloed kan hebben 
op psychofysiologische maten van het endocriene en immuunsysteem. Vooral risico -
patiënten die meer stress rapporteren lijken baat te hebben bij een dergelijke interventie. 
Uitgebreidere interventies zullen naar verwachting nodig zijn om de hiergenoemde 
effecten te versterken, uitspraken te doen over mogelijke klinische relevantie en wellicht 
op termijn ook veranderingen in ziekteactiviteit zichtbaar te kunnen maken. 
Uit de studies van dit proefschrift kan geconcludeerd worden dat patiënten met 
verschillende chronische ontstekingsziekten zich kenmerken door een specifieke psycho-
fysiologische stressreactie en dat een korte stressmanagement training deze psycho-
fysiologische stressreactie kan beïnvloeden. Meer onderzoek op dit terrein kan op de 
lange termijn wellicht leiden tot de ontwikkeling van psychologische interventies als 
additionele therapie op de reguliere medische zorg voor patiënten met een chronische 
 ontstekingsziekte, om zodoende de effecten van stress op chronische ontsteking te 
verminderen, vooral in patiënten met een psychologisch risico-profiel.
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